Page last updated: 2024-11-03

pyrimethamine and Parasitemia

pyrimethamine has been researched along with Parasitemia in 185 studies

Maloprim: contains above 2 cpds

Parasitemia: The presence of parasites (especially malarial parasites) in the blood. (Dorland, 27th ed)

Research Excerpts

ExcerptRelevanceReference
"To compare the effectiveness of mefloquine and sulphadoxine-pyrimethamine as intermittent preventive therapy for malaria among pregnant women with HIV."9.27Comparative study of mefloquine and sulphadoxine-pyrimethamine for malaria prevention among pregnant women with HIV in southwest Nigeria. ( Abdus-Salam, R; Akinyotu, O; Arowojolu, A; Bello, F, 2018)
"The spread of SP resistance may compromise the effectiveness of intermittent preventive treatment of malaria in pregnancy (MiP) with sulfadoxine-pyrimethamine (IPTp-SP) across Africa."9.27Intermittent screening and treatment with artemether-lumefantrine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in pregnancy: a facility-based, open-label, non-inferiority trial in Nigeria. ( Berens-Riha, N; Esu, E; Loescher, T; Meremikwu, M; Nwachuku, N; Pritsch, M, 2018)
"Intermittent treatment with sulfadoxine-pyrimethamine is widely recommended for the prevention of malaria in pregnant women in Africa."9.22Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy. ( Ategeka, J; Awori, P; Charlebois, ED; Clark, TD; Dorsey, G; Feeney, ME; Havlir, DV; Jagannathan, P; Kakuru, A; Kamya, MR; Muehlenbachs, A; Muhindo, MK; Nakalembe, M; Natureeba, P; Nayebare, P; Olwoch, P; Opira, B; Rizzuto, G, 2016)
"To compare the efficacy of monthly SP presumptive treatment, versus weekly chloroquine for malaria prophylaxis in children attending the Sickle Cell Clinic, Mulago Hospital."9.14Presumptive treatment with sulphadoxine-pyrimethamine versus weekly chloroquine for malaria prophylaxis in children with sickle cell anaemia in Uganda: a randomized controlled trial. ( Nakiboneka, D; Nakibuuka, V; Ndeezi, G; Ndugwa, CM; Tumwine, JK, 2009)
"Whether administration of folic acid to children with malaria anemia is helpful is controversial."9.12Folic acid treatment of Zambian children with moderate to severe malaria anemia. ( Bennett, S; Fielding, K; Greenwood, B; Malunga, P; Mulenga, M; Shulman, C; Thuma, P, 2006)
"Intermittent preventive treatment with sulphadoxine-pyrimethamine (IPT-SP) is currently the recommended regimen for prevention of malaria in pregnancy in endemic areas."9.12Intermittent preventive treatment with sulphadoxine-pyrimethamine is effective in preventing maternal and placental malaria in Ibadan, south-western Nigeria. ( Fadero, FF; Falade, CO; Hamer, DH; Mokuolu, OA; Salako, LA; Yusuf, BO, 2007)
"The treatment efficacy and effects of artemether-lumefantrine (AL) and amodiaquine-sulfalene-pyrimethamine (ASP) on gametocyte carriage were evaluated in 181 children < or = 10 years of age with uncomplicated Plasmodium falciparum malaria randomized to receive either drug combination."9.12Therapeutic efficacy and effects of artemether-lumefantrine and amodiaquine-sulfalene-pyrimethamine on gametocyte carriage in children with uncomplicated Plasmodium falciparum malaria in southwestern Nigeria. ( Adedeji, AA; Fateye, BA; Fehintola, FA; Folarin, OA; Gbotosho, GO; Happi, CT; Sowunmi, A; Tambo, E, 2007)
"The World Health Organization advocates 2-3 doses of sulfadoxine-pyrimethamine (SP) for intermittent preventive treatment of malaria (SP IPTp)."9.12Inferiority of single-dose sulfadoxine-pyrimethamine intermittent preventive therapy for malaria during pregnancy among HIV-positive Zambian women. ( Chalwe, V; Champo, D; Chilengi, R; Gill, CJ; Hamer, DH; Macleod, WB; Mukwamataba, D; Mwanakasale, V; Mwananyanda, L; Thea, DM, 2007)
"In an open, randomized, clinical trial, conducted in New Halfa, eastern Sudan, in September-October 2004, the efficacies and adverse effects of artesunate plus sulfadoxine-pyrimethamine (SP), in the treatment of uncomplicated, Plasmodium falciparum malaria, were compared with those of SP alone."9.11A comparison of the efficacy of artesunate plus sulfadoxine-pyrimethamine with that of sulfadoxine-pyrimethamine alone, in the treatment of uncomplicated, Plasmodium falciparum malaria in eastern Sudan. ( A-Elbasit, IE; Adam, I; Elbashir, MI; Idris, SM; Malik, EM, 2005)
"The efficacy and kinetics of the combination chloroquine plus sulfadoxine-pyrimethamine (CQ + SP), given sequentially and simultaneously, were investigated in 32 patients with acute uncomplicated Plasmodium falciparum malaria in Palawan Island, the Philippines."9.10Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ( Bustos, DG; Diquet, B; Gay, F; Laracas, CJ; Lazaro, JE; Pottier, A; Traore, B, 2002)
", Basel Switzerland) (pyrimethamine and sulfadoxine), primaquine in a high dose, and artesunate for treating acute Plasmodium vivax malaria, we conducted a comparative clinical trial of these 3 drugs in an open-label study."9.09Efficacy of primaquine regimens for primaquine-resistant Plasmodium vivax malaria in Thailand. ( Bussaratid, V; Krudsood, S; Looareesuwan, S; Phumratanaprapin, W; Silachamroon, U; Singhasivanon, P; Srivilirit, S; Treeprasertsuk, S; Wilairatana, P, 1999)
"Intermittent preventive treatment (IPT) with sulphadoxine-pyrimethamine (SP) is recommended for preventing maternal and fetal effects of malaria in pregnancy."9.01A systematic review and meta-analysis of dihydroartemisinin-piperaquine versus sulphadoxine-pyrimethamine for malaria prevention in pregnancy. ( Esu, E; Meremikwu, M; Oduwole, O; Okusanya, BO; Olaleye, A, 2019)
"The World Health Organization recommends intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine for malaria for all women who live in moderate to high malaria transmission areas in Africa."8.98Mefloquine for preventing malaria in pregnant women. ( Aponte, JJ; González, R; Menéndez, C; Piqueras, M; Pons-Duran, C; Ter Kuile, FO, 2018)
"Mefloquine was more efficacious than sulfadoxine-pyrimethamine in HIV-uninfected women or daily cotrimoxazole prophylaxis in HIV-infected pregnant women for prevention of malaria infection and was associated with lower risk of maternal anaemia, no adverse effects on pregnancy outcomes (such as stillbirths and abortions), and no effects on low birth weight and prematurity."8.98Mefloquine for preventing malaria in pregnant women. ( Aponte, JJ; González, R; Menéndez, C; Piqueras, M; Pons-Duran, C; Ter Kuile, FO, 2018)
" falciparum malaria is treated using Artemisinin-based Combination Therapy (ACT)."8.85Artemisinin-based combination therapy for treating uncomplicated malaria. ( Donegan, S; Garner, P; Olliaro, P; Sinclair, D; Zani, B, 2009)
"In 2012 the World Health Organisation (WHO) revised the policy on Intermittent Preventive Treatment with Sulphadoxine Pyrimethamine (IPTp-SP) to at least three doses for improved protection against malaria parasitaemia and its associated effects such as anaemia during pregnancy."8.02Intermittent preventive treatment comparing two versus three doses of sulphadoxine pyrimethamine (IPTp-SP) in the prevention of anaemia in pregnancy in Ghana: A cross-sectional study. ( Agyeman, YN; Annor, RB; Newton, S; Owusu-Dabo, E, 2021)
"Despite widespread parasite resistance to sulphadoxine-pyrimethamine (SP) its use for intermittent preventative treatment during pregnancy remains the policy in Benin and throughout most of sub-Saharan Africa."7.79High rates of parasite recrudescence following intermittent preventive treatment with sulphadoxine-pyrimethamine during pregnancy in Benin. ( Alifrangis, M; De Tove, YS; Deloron, P; Doritchamou, J; Luty, AJ; Massougbodji, A; Moussiliou, A; Ndam, NT, 2013)
"Antenatal intermittent preventive therapy with 2 doses of sulfadoxine-pyrimethamine (IPTp-SP) is the mainstay of efforts in sub-Saharan Africa to prevent pregnancy-associated malaria (PAM)."7.78Antenatal receipt of sulfadoxine-pyrimethamine does not exacerbate pregnancy-associated malaria despite the expansion of drug-resistant Plasmodium falciparum: clinical outcomes from the QuEERPAM study. ( Antonia, AL; Chaluluka, E; Feng, G; Meshnick, SR; Molyneux, ME; Mwapasa, V; Rogerson, SJ; Taylor, SM; ter Kuile, FO, 2012)
"To assess the effect of intermittent preventive treatment with sulfadoxine and pyrimethamine (IPT-SP) on placental parasitemia and maternal and perinatal outcome."7.77Efficacy of intermittent preventive treatment with sulfadoxine-pyrimethamine on placental parasitemia in pregnant women in midwestern Nigeria. ( Akubuo, KK; Aziken, ME; Gharoro, EP, 2011)
"Effectiveness of cotrimoxazole (CTX) compared with sulfadoxine-pyrimethamine (SP) intermittent-preventive-therapy (IPTp) for malaria in HIV-infected pregnant women is unknown."7.77Marked reduction in prevalence of malaria parasitemia and anemia in HIV-infected pregnant women taking cotrimoxazole with or without sulfadoxine-pyrimethamine intermittent preventive therapy during pregnancy in Malawi. ( Fitzgerald, M; Kapito-Tembo, A; Meshnick, SR; Mwapasa, V; Phiri, K; van Hensbroek, MB, 2011)
"The World Health Organization (WHO) recommends using insecticide-treated mosquito nets (ITNs) and intermittent preventive treatment with sulphadoxine-pyrimethamine (IPT-SP) to prevent malaria in sub-Saharan Africa."7.77Coverage of intermittent prevention treatment with sulphadoxine-pyrimethamine among pregnant women and congenital malaria in Côte d'Ivoire. ( Coffie, PA; Dabis, F; Eholie, SP; Ekouevi, DK; Kanhon, S; Kone, M; Kouakou, F; Menan, H; Sloan, C; Vanga-Bosson, HA, 2011)
"To evaluate the impact of a 2-year programme for community-based delivery of sulfadoxine-pyrimethamine (SP) on intermittent preventive treatment during pregnancy coverage, antenatal clinic attendance and pregnancy outcome."7.75Community-based distribution of sulfadoxine-pyrimethamine for intermittent preventive treatment of malaria during pregnancy improved coverage but reduced antenatal attendance in southern Malawi. ( Brabin, BJ; D'Alessandro, U; Gies, S; Kalanda, G; Kazembe, PN; Msyamboza, KP; Savage, EJ, 2009)
"Intermittent preventive treatment with sulphadoxine-pyrimethamine (SP) is recommended for reducing the risk of malaria in pregnancy and its consequences on mothers and babies (IPTp-SP)."7.74Implementation of intermittent preventive treatment in pregnancy with sulphadoxine/pyrimethamine (IPTp-SP) at a district health centre in rural Senegal. ( Badiane, M; Brasseur, P; Cisse, M; Delenne, H; Olliaro, A; Olliaro, PL; Vaillant, M, 2008)
"The prevalence of infection with malarial parasites and the incidence of anaemia and delivery of infants with low birthweight (LBW) were investigated in 575 Malawian mothers who received one, two or three doses of sulfadoxine-pyrimethamine (SP) during pregnancy."7.70An evaluation of the effects of intermittent sulfadoxine-pyrimethamine treatment in pregnancy on parasite clearance and risk of low birthweight in rural Malawi. ( Brabin, BJ; Broadhead, RL; Chimsuku, L; Kazembe, P; Russell, WB; Verhoeff, FH, 1998)
"In 1993, Malawi introduced sulphadoxine-pyrimethamine (SP) for the treatment of uncomplicated, Plasmodium falciparum malaria and became the first country in Africa to abandon chloroquine for first-time therapy."7.69Parasitological and haematological responses to treatment of Plasmodium falciparum malaria with sulphadoxine-pyrimethamine in southern Malawi. ( Brabin, BJ; Kachale, B; Kazembe, P; Masache, P; Van der Kaay, HJ; Verhoeff, FH, 1997)
"We assessed the impact of preventive treatment in pregnancy on maternal malaria and fetal growth."7.30The Impact of Antenatal Azithromycin and Monthly Sulfadoxine-Pyrimethamine on Maternal Malaria during Pregnancy and Fetal Growth: A Randomized Controlled Trial. ( Ashorn, P; Ashorn, U; Cheung, YB; Fan, YM; Hallamaa, L; Kulmala, T; Luntamo, M; Maleta, K; Mangani, C, 2023)
"Intermittent preventive treatment of malaria during pregnancy (IPTp) with dihydroartemisinin-piperaquine (DP) provides greater protection from placental malaria than sulfadoxine-pyrimethamine (SP)."5.51The Effect of Intermittent Preventive Treatment of Malaria During Pregnancy and Placental Malaria on Infant Risk of Malaria. ( Andronescu, LR; Chinkhumba, J; Gutman, JR; Kachepa, W; Kachingwe, M; Laufer, MK; Liang, Y; Mathanga, DP; Peterson, I; Sharma, A, 2022)
"Chloroquine failure rate was high which was well above the WHO recommended cut off threshold for drug policy change (> 10%), Sulfadoxine- Pyrimethamine can be used in place of Chloroquine as the first line drug in uncomplicated P."5.42Comparative Study of Effectiveness and Resistance Profile of Chloroquine and Sulfadoxine-Pyrimethamine in Uncomplicated Plasmodium falciparum Malaria in Kolkata. ( Basu, A; Guha, SK; Saha, S, 2015)
" There was significant association between gravidity and SP dosage taken (Pearson χ2 = 18."5.37The effectiveness and perception of the use of sulphadoxine-pyrimethamine in intermittent preventive treatment of malaria in pregnancy programme in Offinso district of Ashanti region, Ghana. ( Browne, E; Lawson, B; Tutu, EO, 2011)
"Emerging malaria parasite sulfadoxine-pyrimethamine (SP) resistance has prompted assessment of alternatives for intermittent preventive treatment in pregnancy (IPTp)."5.30A Randomized Open-Label Evaluation of the Antimalarial Prophylactic Efficacy of Azithromycin-Piperaquine versus Sulfadoxine-Pyrimethamine in Pregnant Papua New Guinean Women. ( Benjamin, JM; Davis, TME; Kasian, B; Kong, C; Laman, M; Moore, BR; Mueller, I; Ome-Kaius, M; Robinson, LJ; Rogerson, S; Tobe, R; Yadi, G, 2019)
"To compare the effectiveness of mefloquine and sulphadoxine-pyrimethamine as intermittent preventive therapy for malaria among pregnant women with HIV."5.27Comparative study of mefloquine and sulphadoxine-pyrimethamine for malaria prevention among pregnant women with HIV in southwest Nigeria. ( Abdus-Salam, R; Akinyotu, O; Arowojolu, A; Bello, F, 2018)
"The spread of SP resistance may compromise the effectiveness of intermittent preventive treatment of malaria in pregnancy (MiP) with sulfadoxine-pyrimethamine (IPTp-SP) across Africa."5.27Intermittent screening and treatment with artemether-lumefantrine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in pregnancy: a facility-based, open-label, non-inferiority trial in Nigeria. ( Berens-Riha, N; Esu, E; Loescher, T; Meremikwu, M; Nwachuku, N; Pritsch, M, 2018)
"Intermittent treatment with sulfadoxine-pyrimethamine is widely recommended for the prevention of malaria in pregnant women in Africa."5.22Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy. ( Ategeka, J; Awori, P; Charlebois, ED; Clark, TD; Dorsey, G; Feeney, ME; Havlir, DV; Jagannathan, P; Kakuru, A; Kamya, MR; Muehlenbachs, A; Muhindo, MK; Nakalembe, M; Natureeba, P; Nayebare, P; Olwoch, P; Opira, B; Rizzuto, G, 2016)
"The effectiveness of sulphadoxine-pyrimethamine (SP) intermittent preventive treatment of malaria in pregnancy (IPTp) might be compromised by high prevalence of resistance-associated Plasmodium falciparum dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps) mutations."5.20In vivo efficacy of sulphadoxine-pyrimethamine for the treatment of asymptomatic parasitaemia in pregnant women in Machinga District, Malawi. ( Abdallah, J; Gutman, J; Iriemenam, NC; Mathanga, DP; Mwandama, D; Shi, YP; Skarbinski, J; Wiegand, RE, 2015)
"To compare the efficacy of monthly SP presumptive treatment, versus weekly chloroquine for malaria prophylaxis in children attending the Sickle Cell Clinic, Mulago Hospital."5.14Presumptive treatment with sulphadoxine-pyrimethamine versus weekly chloroquine for malaria prophylaxis in children with sickle cell anaemia in Uganda: a randomized controlled trial. ( Nakiboneka, D; Nakibuuka, V; Ndeezi, G; Ndugwa, CM; Tumwine, JK, 2009)
"The use of sulfadoxine-pyrimethamine (SP) for intermittent preventive treatment in pregnancy (IPTp) is threatened by the spread of resistance to SP."5.13A randomized, controlled trial of intermittent preventive treatment with sulfadoxine-pyrimethamine, amodiaquine, or the combination in pregnant women in Ghana. ( Affipunguh, PK; Bruce, J; Chandramohan, D; Clerk, CA; Greenwood, B; Hodgson, A; Mensah, N, 2008)
"The main objective of the study was to assess the impact of a community-based delivery system of intermittent preventive treatment (IPT) for malaria in pregnancy with sulfadoxine-pyrimethamine (SP) on access, parasitemia, anemia and low birth weight as primary outcome measures."5.13Intermittent preventive treatment of malaria in pregnancy: a community-based delivery system and its effect on parasitemia, anemia and low birth weight in Uganda. ( Bygbjerg, I; Magnussen, P; Mbonye, AK, 2008)
"Whether administration of folic acid to children with malaria anemia is helpful is controversial."5.12Folic acid treatment of Zambian children with moderate to severe malaria anemia. ( Bennett, S; Fielding, K; Greenwood, B; Malunga, P; Mulenga, M; Shulman, C; Thuma, P, 2006)
"We investigated the ability of intermittent preventive treatment in pregnancy (IPTp) with sulphadoxine/pyrimethamine to prevent anaemia and low birthweight in Gambian multigravidae."5.12A randomized, placebo-controlled trial of intermittent preventive treatment with sulphadoxine-pyrimethamine in Gambian multigravidae. ( Balajo, B; Dunyo, S; Greenwood, B; Mbaye, A; Milligan, P; Richardson, K; Shulman, C; Walraven, G, 2006)
"Few studies have documented the effectiveness in west Africa of intermittent preventive treatment of malaria with sulfadoxine-pyrimethamine (SP) in pregnancy."5.12A comparison of sulfadoxine-pyrimethamine with chloroquine and pyrimethamine for prevention of malaria in pregnant Nigerian women. ( Madaki, JK; Sagay, AS; Thacher, TD; Tukur, IU, 2007)
"Intermittent preventive treatment with sulphadoxine-pyrimethamine (IPT-SP) is currently the recommended regimen for prevention of malaria in pregnancy in endemic areas."5.12Intermittent preventive treatment with sulphadoxine-pyrimethamine is effective in preventing maternal and placental malaria in Ibadan, south-western Nigeria. ( Fadero, FF; Falade, CO; Hamer, DH; Mokuolu, OA; Salako, LA; Yusuf, BO, 2007)
"The treatment efficacy and effects of artemether-lumefantrine (AL) and amodiaquine-sulfalene-pyrimethamine (ASP) on gametocyte carriage were evaluated in 181 children < or = 10 years of age with uncomplicated Plasmodium falciparum malaria randomized to receive either drug combination."5.12Therapeutic efficacy and effects of artemether-lumefantrine and amodiaquine-sulfalene-pyrimethamine on gametocyte carriage in children with uncomplicated Plasmodium falciparum malaria in southwestern Nigeria. ( Adedeji, AA; Fateye, BA; Fehintola, FA; Folarin, OA; Gbotosho, GO; Happi, CT; Sowunmi, A; Tambo, E, 2007)
"The World Health Organization advocates 2-3 doses of sulfadoxine-pyrimethamine (SP) for intermittent preventive treatment of malaria (SP IPTp)."5.12Inferiority of single-dose sulfadoxine-pyrimethamine intermittent preventive therapy for malaria during pregnancy among HIV-positive Zambian women. ( Chalwe, V; Champo, D; Chilengi, R; Gill, CJ; Hamer, DH; Macleod, WB; Mukwamataba, D; Mwanakasale, V; Mwananyanda, L; Thea, DM, 2007)
"In Mali, IPT with SP appears more efficacious than weekly chloroquine chemoprophylaxis in preventing malaria during pregnancy."5.11Comparison of intermittent preventive treatment with chemoprophylaxis for the prevention of malaria during pregnancy in Mali. ( Coulibaly, D; Doumbo, O; Doumtabe, D; Kayentao, K; Keita, AS; Kodio, M; Maiga, B; Maiga, H; Mungai, M; Newman, RD; Ongoiba, A; Parise, ME, 2005)
"The study examined the efficacy of chloroquine (CQ), amodiaquine (AQ) and sulphadoxine-pyrimethamine (SP) for the treatment of uncomplicated Plasmodium falciparum malaria in Ghana."5.11A randomized comparative study of chloroquine, amodiaquine and sulphadoxine-pyrimethamine for the treatment of uncomplicated malaria in Ghana. ( Amankwa, J; Ansah, NA; Ansah, P; Anto, F; Anyorigiya, T; Atuguba, F; Hodgson, A; Mumuni, G; Oduro, AR, 2005)
"In an open, randomized, clinical trial, conducted in New Halfa, eastern Sudan, in September-October 2004, the efficacies and adverse effects of artesunate plus sulfadoxine-pyrimethamine (SP), in the treatment of uncomplicated, Plasmodium falciparum malaria, were compared with those of SP alone."5.11A comparison of the efficacy of artesunate plus sulfadoxine-pyrimethamine with that of sulfadoxine-pyrimethamine alone, in the treatment of uncomplicated, Plasmodium falciparum malaria in eastern Sudan. ( A-Elbasit, IE; Adam, I; Elbashir, MI; Idris, SM; Malik, EM, 2005)
"To evaluate the effects of intermittent preventive treatment for malaria in infants (IPTi) with sulfadoxine-pyrimethamine in an area of intense, seasonal transmission."5.11Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana. ( Amponsa-Achiano, K; Awine, T; Baiden, R; Binka, F; Carneiro, I; Chandramohan, D; Greenwood, B; Hodgson, A; Jaffar, S; Mensah, N; Owusu-Agyei, S, 2005)
" The authors recommend that the treatment to be used in Abie must be firstly amodiaquine followed by sulfadoxine-pyrimethamine in cases where there is persistent asymptomatic parasitemia."5.11[Evaluation of the therapeutic efficacy of amodiaquine versus chloroquine in the treatment of uncomplicated malaria in Abie, Côte-d'Ivoire]. ( Adjetey, TA; Affoumou, GB; Barro-Kiki, P; Kone, M; Loukou, DD; Menan, EI; Nebavi, NG; Yavo, W, 2005)
"We evaluated gametocyte carriage and intensities of gametocytaemia in 710 children presenting with acute, symptomatic, uncomplicated Plasmodium falciparum malaria who were treated with various antimalarial drug regimens: chloroquine (CQ); chloroquine plus chlorpheniramine, a histamine H1 receptor antagonist that reverses CQ resistance in P."5.10Plasmodium falciparum gametocytaemia in Nigerian children: before, during and after treatment with antimalarial drugs. ( Fateye, BA; Sowunmi, A, 2003)
"The efficacy and kinetics of the combination chloroquine plus sulfadoxine-pyrimethamine (CQ + SP), given sequentially and simultaneously, were investigated in 32 patients with acute uncomplicated Plasmodium falciparum malaria in Palawan Island, the Philippines."5.10Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ( Bustos, DG; Diquet, B; Gay, F; Laracas, CJ; Lazaro, JE; Pottier, A; Traore, B, 2002)
" 600 children with acute uncomplicated Plasmodium falciparum malaria, aged 6 months to 10 years, at five health centres were randomly assigned pyrimethaminesulphadoxine (25 mg/500 mg) with placebo; pyrimethamine-sulphadoxine plus one dose of artesunate (4mg/kg bodyweight); or pyrimethamine-sulphadoxine plus one dose 4 mg/kg bodyweight artesunate daily for 3 days."5.09Efficacy of artesunate plus pyrimethamine-sulphadoxine for uncomplicated malaria in Gambian children: a double-blind, randomised, controlled trial. ( Alloueche, A; Anyalebechi, C; Bojang, K; Coleman, R; Doherty, T; Duraisingh, M; Gosling, R; Greenwood, B; McAdam, K; Milligan, P; Olliaro, P; Pinder, M; Sadiq, A; Targett, G; Ude, JI; von Seidlein, L; Walraven, G; Warhurst, D, 2000)
", Basel Switzerland) (pyrimethamine and sulfadoxine), primaquine in a high dose, and artesunate for treating acute Plasmodium vivax malaria, we conducted a comparative clinical trial of these 3 drugs in an open-label study."5.09Efficacy of primaquine regimens for primaquine-resistant Plasmodium vivax malaria in Thailand. ( Bussaratid, V; Krudsood, S; Looareesuwan, S; Phumratanaprapin, W; Silachamroon, U; Singhasivanon, P; Srivilirit, S; Treeprasertsuk, S; Wilairatana, P, 1999)
"We conducted two randomized clinical trials to determine the in vivo efficacy of amodiaquine and sulfadoxine/pyrimethamine in treating Plasmodium falciparum malaria."5.09In vivo efficacy study of amodiaquine and sulfadoxine/ pyrimethamine in Kibwezi, Kenya and Kigoma, Tanzania. ( Ashruf, G; Bennebroek, J; Gikunda, S; Gorissen, E; Kager, PA; Lamboo, M; Mbaruku, G, 2000)
"In a randomized trial, a high dosage chloroquine monotherapy (45 mg/kg over 3 days) was compared with combination regimens of sulfadoxine/pyrimethamine and chloroquine/clindamycin for treating Gabonese school children with Plasmodium falciparum malaria."5.08Sulfadoxine/pyrimethamine or chloroquine/clindamycin treatment of Gabonese school children infected with chloroquine resistant malaria. ( Bienzle, U; Graninger, W; Kremsner, PG; Metzger, W; Mordmüller, B, 1995)
"To define an effective and deliverable antimalarial regimen for use during pregnancy, pregnant women at highest risk of malaria (those in their first or second pregnancy) in an area of Malawi with high transmission of chloroquine (CQ)-resistant Plasmodium falciparum were placed on CQ and/or sulfadoxine-pyrimethamine (SP)."5.07The efficacy of antimalarial regimens containing sulfadoxine-pyrimethamine and/or chloroquine in preventing peripheral and placental Plasmodium falciparum infection among pregnant women in Malawi. ( Chitsulo, L; Kazembe, P; Macheso, A; Schultz, LJ; Steketee, RW; Wirima, JJ, 1994)
"Intermittent preventive treatment (IPT) with sulphadoxine-pyrimethamine (SP) is recommended for preventing maternal and fetal effects of malaria in pregnancy."5.01A systematic review and meta-analysis of dihydroartemisinin-piperaquine versus sulphadoxine-pyrimethamine for malaria prevention in pregnancy. ( Esu, E; Meremikwu, M; Oduwole, O; Okusanya, BO; Olaleye, A, 2019)
"The World Health Organization recommends intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine for malaria for all women who live in moderate to high malaria transmission areas in Africa."4.98Mefloquine for preventing malaria in pregnant women. ( Aponte, JJ; González, R; Menéndez, C; Piqueras, M; Pons-Duran, C; Ter Kuile, FO, 2018)
"Mefloquine was more efficacious than sulfadoxine-pyrimethamine in HIV-uninfected women or daily cotrimoxazole prophylaxis in HIV-infected pregnant women for prevention of malaria infection and was associated with lower risk of maternal anaemia, no adverse effects on pregnancy outcomes (such as stillbirths and abortions), and no effects on low birth weight and prematurity."4.98Mefloquine for preventing malaria in pregnant women. ( Aponte, JJ; González, R; Menéndez, C; Piqueras, M; Pons-Duran, C; Ter Kuile, FO, 2018)
" falciparum malaria is treated using Artemisinin-based Combination Therapy (ACT)."4.85Artemisinin-based combination therapy for treating uncomplicated malaria. ( Donegan, S; Garner, P; Olliaro, P; Sinclair, D; Zani, B, 2009)
"The World Health Organization recommends the provision of intermittent preventive treatment during pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) at 4-week intervals from gestational week 13 to delivery in areas of moderate to high malaria transmission intensity."4.02Sulfadoxine-pyrimethamine parasitological efficacy against Plasmodium falciparum among pregnant women and molecular markers of resistance in Zambia: an observational cohort study. ( Bruce, J; Chandramoha, D; Chaponda, EB; Matthew Chico, R; Mharakurwa, S; Michelo, C, 2021)
"In 2012 the World Health Organisation (WHO) revised the policy on Intermittent Preventive Treatment with Sulphadoxine Pyrimethamine (IPTp-SP) to at least three doses for improved protection against malaria parasitaemia and its associated effects such as anaemia during pregnancy."4.02Intermittent preventive treatment comparing two versus three doses of sulphadoxine pyrimethamine (IPTp-SP) in the prevention of anaemia in pregnancy in Ghana: A cross-sectional study. ( Agyeman, YN; Annor, RB; Newton, S; Owusu-Dabo, E, 2021)
"Hence, this study was therefore aimed at evaluating the antimalarial activity of a probiotic bacterium Lactobacillus sakei isolated from traditionally fermented milk in mice infected with chloroquine sensitive Plasmodium berghei ANKA."4.02In vivo antimalarial activity of a probiotic bacterium Lactobacillus sakei isolated from traditionally fermented milk in BALB/c mice infected with Plasmodium berghei ANKA. ( Achidi, EA; Bila, RB; Feugaing Sofeu, DD; Ivo, EP; Taiwe, GS; Tatsinkou Fossi, B; Toukam, LL, 2021)
"Pyrimethamine-loaded nanomicelles showed potent antimalarial activity and can be considered as a potential candidate for further examination of their suitability as an antimalarial drug."3.96A new effective antiplasmodial compound: Nanoformulated pyrimethamine. ( Bide, VZ; Kalani, H; Nematolahy, P; Pestehchian, N; Vafaei, MR; Varshosaz, J; Yousefi, HA, 2020)
"A cross-sectional study was conducted of 426 pregnant mothers on IPTp with sulphadoxine-pyrimethamine against malaria who presented in labor, at National Hospital Abuja, Nigeria between January and June 2017."3.96The efficacy of intermittent preventive therapy in the eradication of peripheral and placental parasitemia in a malaria-endemic environment, as seen in a tertiary hospital in Abuja, Nigeria. ( Agboghoroma, CO; Iregbu, KC; Umemmuo, MU, 2020)
" Whether the addition of azithromycin to the monthly sulfadoxine-pyrimethamine plus amodiaquine used for seasonal malaria chemoprevention could reduce mortality and morbidity among African children was unclear."3.91Effect of Adding Azithromycin to Seasonal Malaria Chemoprevention. ( Barry, A; Cairns, M; Chandramohan, D; Coumare, S; Diarra, M; Dicko, A; Doumbo, O; Greenwood, B; Kuepfer, I; Milligan, P; Nikiema, F; Ouedraogo, JB; Sagara, I; Tapily, A; Thera, I; Tinto, H; Traore, A; Yerbanga, S; Zongo, I, 2019)
"Six years after the implementation of intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) in Gabon, its impact on placental malaria and pregnancy outcomes remains unknown."3.83Decrease of microscopic Plasmodium falciparum infection prevalence during pregnancy following IPTp-SP implementation in urban cities of Gabon. ( Ambounda, N; Bouyou-Akotet, MK; Kendjo, E; Kombila, M; Mawili-Mboumba, DP; Moutandou Chiesa, S; Tshibola Mbuyi, ML; Tsoumbou-Bakana, G; Zong, J, 2016)
"Despite widespread parasite resistance to sulphadoxine-pyrimethamine (SP) its use for intermittent preventative treatment during pregnancy remains the policy in Benin and throughout most of sub-Saharan Africa."3.79High rates of parasite recrudescence following intermittent preventive treatment with sulphadoxine-pyrimethamine during pregnancy in Benin. ( Alifrangis, M; De Tove, YS; Deloron, P; Doritchamou, J; Luty, AJ; Massougbodji, A; Moussiliou, A; Ndam, NT, 2013)
"Antenatal intermittent preventive therapy with 2 doses of sulfadoxine-pyrimethamine (IPTp-SP) is the mainstay of efforts in sub-Saharan Africa to prevent pregnancy-associated malaria (PAM)."3.78Antenatal receipt of sulfadoxine-pyrimethamine does not exacerbate pregnancy-associated malaria despite the expansion of drug-resistant Plasmodium falciparum: clinical outcomes from the QuEERPAM study. ( Antonia, AL; Chaluluka, E; Feng, G; Meshnick, SR; Molyneux, ME; Mwapasa, V; Rogerson, SJ; Taylor, SM; ter Kuile, FO, 2012)
"To assess the effect of intermittent preventive treatment with sulfadoxine and pyrimethamine (IPT-SP) on placental parasitemia and maternal and perinatal outcome."3.77Efficacy of intermittent preventive treatment with sulfadoxine-pyrimethamine on placental parasitemia in pregnant women in midwestern Nigeria. ( Akubuo, KK; Aziken, ME; Gharoro, EP, 2011)
"Effectiveness of cotrimoxazole (CTX) compared with sulfadoxine-pyrimethamine (SP) intermittent-preventive-therapy (IPTp) for malaria in HIV-infected pregnant women is unknown."3.77Marked reduction in prevalence of malaria parasitemia and anemia in HIV-infected pregnant women taking cotrimoxazole with or without sulfadoxine-pyrimethamine intermittent preventive therapy during pregnancy in Malawi. ( Fitzgerald, M; Kapito-Tembo, A; Meshnick, SR; Mwapasa, V; Phiri, K; van Hensbroek, MB, 2011)
"The World Health Organization (WHO) recommends using insecticide-treated mosquito nets (ITNs) and intermittent preventive treatment with sulphadoxine-pyrimethamine (IPT-SP) to prevent malaria in sub-Saharan Africa."3.77Coverage of intermittent prevention treatment with sulphadoxine-pyrimethamine among pregnant women and congenital malaria in Côte d'Ivoire. ( Coffie, PA; Dabis, F; Eholie, SP; Ekouevi, DK; Kanhon, S; Kone, M; Kouakou, F; Menan, H; Sloan, C; Vanga-Bosson, HA, 2011)
" They were monitored for development of Plasmodium falciparum malaria, which was treated with chloroquine (CQ) + sulfadoxine-pyrimethamine (SP) and the children followed up for 28 days."3.76Prolonged elevation of viral loads in HIV-1-infected children in a region of intense malaria transmission in Northern Uganda: a prospective cohort study. ( Egwang, TG; Kiyingi, HS; Nannyonga, M, 2010)
"To evaluate the impact of a 2-year programme for community-based delivery of sulfadoxine-pyrimethamine (SP) on intermittent preventive treatment during pregnancy coverage, antenatal clinic attendance and pregnancy outcome."3.75Community-based distribution of sulfadoxine-pyrimethamine for intermittent preventive treatment of malaria during pregnancy improved coverage but reduced antenatal attendance in southern Malawi. ( Brabin, BJ; D'Alessandro, U; Gies, S; Kalanda, G; Kazembe, PN; Msyamboza, KP; Savage, EJ, 2009)
"Intermittent preventive treatment with sulphadoxine-pyrimethamine (SP) is recommended for reducing the risk of malaria in pregnancy and its consequences on mothers and babies (IPTp-SP)."3.74Implementation of intermittent preventive treatment in pregnancy with sulphadoxine/pyrimethamine (IPTp-SP) at a district health centre in rural Senegal. ( Badiane, M; Brasseur, P; Cisse, M; Delenne, H; Olliaro, A; Olliaro, PL; Vaillant, M, 2008)
"RBx11160 (OZ277) is a promising antimalarial drug candidate that Ranbaxy Laboratories Limited and Medicines for Malaria Venture (MMV) are currently developing as a fixed combination with piperaquine."3.74In vitro and in vivo interaction of synthetic peroxide RBx11160 (OZ277) with piperaquine in Plasmodium models. ( Chollet, J; Santo-Tomas, J; Scheurer, C; Snyder, C; Wittlin, S, 2007)
"The World Health Organization recommends that pregnant women in malaria-endemic areas receive >or= 2 doses of intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp/SP) in the second and third trimesters of pregnancy to prevent maternal anemia, placental parasitemia, and low birth weight (LBW)."3.73Malaria prevention during pregnancy: assessing the disease burden one year after implementing a program of intermittent preventive treatment in Koupela District, Burkina Faso. ( Asamoa, K; Bougouma, EC; Cotte, AH; Diarra, A; Konaté, A; Moran, AC; Newman, RD; Ouédraogo, A; Parise, ME; Sirima, SB, 2006)
"We have previously shown that both chloroquine and paracetamol (acetaminophen) have antipyretic activity during treatment of acute uncomplicated Plasmodium falciparum malaria in children 1-4 years old."3.73Relationship between antipyretic effects and cytokine levels in uncomplicated falciparum malaria during different treatment regimes. ( Björkman, A; Hugosson, E; Montgomery, SM; Premji, Z; Troye-Blomberg, M, 2006)
"Febrile adults with Plasmodium falciparum parasitemia were treated with sulfadoxine-pyrimethamine and were monitored for 28 days."3.73HIV immunosuppression and antimalarial efficacy: sulfadoxine-pyrimethamine for the treatment of uncomplicated malaria in HIV-infected adults in Siaya, Kenya. ( Bloland, PB; Hamel, MJ; Kain, KC; Obonyo, CO; Shah, SN; Slutsker, L; Smith, EE, 2006)
"The prevalence of infection with malarial parasites and the incidence of anaemia and delivery of infants with low birthweight (LBW) were investigated in 575 Malawian mothers who received one, two or three doses of sulfadoxine-pyrimethamine (SP) during pregnancy."3.70An evaluation of the effects of intermittent sulfadoxine-pyrimethamine treatment in pregnancy on parasite clearance and risk of low birthweight in rural Malawi. ( Brabin, BJ; Broadhead, RL; Chimsuku, L; Kazembe, P; Russell, WB; Verhoeff, FH, 1998)
" Seventy patients with Plasmodium falciparum malaria were included in a study of resistance to chloroquine and sulfadoxine-pyrimethamine therapy."3.70Chemotherapy of malaria and resistance to antimalarial drugs in Guayana area, Venezuela. ( Caraballo, A; Rodriguez-Acosta, A, 1999)
"The spectrum of antimalarial activity of the new macrolide antibiotic azithromycin was evaluated against blood- and sporozoite-induced infections with a chloroquine-resistant strain of Plasmodium yoelii nigeriensis (N-67) in Swiss mice and with simian parasite Plasmodium cynomolgi B in rhesus monkeys."3.70Azithromycin: antimalarial profile against blood- and sporozoite-induced infections in mice and monkeys. ( Puri, SK; Singh, N, 2000)
"As chloroquine resistance spreads across Africa, the dihydrofolate reductase (DHFR) inhibitors pyrimethamine and proguanil are being used as alternative first-line drugs for the treatment and prevention of Plasmodium falciparum malaria."3.69Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. ( Bouare, M; Djimde, A; Doumbo, O; Plowe, CV; Wellems, TE, 1995)
"In 1993, Malawi introduced sulphadoxine-pyrimethamine (SP) for the treatment of uncomplicated, Plasmodium falciparum malaria and became the first country in Africa to abandon chloroquine for first-time therapy."3.69Parasitological and haematological responses to treatment of Plasmodium falciparum malaria with sulphadoxine-pyrimethamine in southern Malawi. ( Brabin, BJ; Kachale, B; Kazembe, P; Masache, P; Van der Kaay, HJ; Verhoeff, FH, 1997)
"We assessed the impact of preventive treatment in pregnancy on maternal malaria and fetal growth."3.30The Impact of Antenatal Azithromycin and Monthly Sulfadoxine-Pyrimethamine on Maternal Malaria during Pregnancy and Fetal Growth: A Randomized Controlled Trial. ( Ashorn, P; Ashorn, U; Cheung, YB; Fan, YM; Hallamaa, L; Kulmala, T; Luntamo, M; Maleta, K; Mangani, C, 2023)
"In endemic areas, malaria and its adverse effects in schoolchildren may be prevented by intermittent preventive treatment (IPTsc)."2.84Efficacy and safety of intermittent preventive treatment in schoolchildren with sulfadoxine/pyrimethamine (SP) and SP plus piperaquine in Democratic Republic of the Congo: a randomised controlled trial. ( da Luz, RI; Doua, JY; Lutumba, P; Matangila, JR; Mitashi, P; Van Geertruyden, JP, 2017)
"The ongoing development of new antimalarial drugs and the increasing use of controlled human malaria infection (CHMI) studies to investigate their activity in early-stage clinical trials require the development of methods to analyze their pharmacodynamic effect."2.80Evaluating the pharmacodynamic effect of antimalarial drugs in clinical trials by quantitative PCR. ( Baker, M; Marquart, L; McCarthy, JS; O'Rourke, P, 2015)
"Primaquine was well tolerated and could be administered along with an artemisinin combination therapy as the first-line therapy."2.78Nonrandomized controlled trial of artesunate plus sulfadoxine-pyrimethamine with or without primaquine for preventing posttreatment circulation of Plasmodium falciparum gametocytes. ( Anvikar, A; Juliano, JJ; MacDonald, PD; Meshnick, SR; Mishra, N; Poole, C; Schapira, A; Shah, NK; Srivastava, B; Valecha, N, 2013)
" The impact of MDA with the gametocytocidal drug combination sulphadoxine-pyrimethamine (SP) plus artesunate (AS) plus primaquine (PQ, single dose 0."2.76A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania. ( Bousema, T; Drakeley, C; Gosling, R; Hermsen, R; Masokoto, A; Mosha, F; Mwanziva, C; Okell, L; Sauerwein, R; Semvua, S; Shekalaghe, SA; Teelen, K; ter Braak, R; van den Bijllaardt, W; van den Bosch, S, 2011)
" The main outcome measures for safety were incidences of post-treatment clinical and laboratory adverse events."2.74Artemisinin-naphthoquine combination (ARCO) therapy for uncomplicated falciparum malaria in adults of Papua New Guinea: a preliminary report on safety and efficacy. ( Geita, J; Hiawalyer, G; Hombhanje, FW; Jones, R; Kevau, I; Kuanch, C; Linge, D; Masta, A; Sapuri, M; Saweri, A; Toraso, S, 2009)
" Adverse events and clinical and parasitological outcomes were recorded."2.73A randomised trial to assess the safety and efficacy of artemether-lumefantrine (Coartem) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwanda. ( D'Alessandro, U; Fanello, CI; Karema, C; Ngamije, D; van Doren, W; Van Overmeir, C, 2007)
"Nearly all recurrences were due to new infections."2.73Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial. ( Dokomajilar, C; Dorsey, G; Guiguemde, RT; Ouedraogo, JB; Rosenthal, PJ; Rouamba, N; Tinto, H; Zongo, I, 2007)
" However, the optimal dosing regimen in settings in which human immunodeficiency virus (HIV) is highly prevalent among pregnant women remains controversial."2.73Two-dose versus monthly intermittent preventive treatment of malaria with sulfadoxine-pyrimethamine in HIV-seropositive pregnant Zambian women. ( Chalwe, V; Champo, D; Chilengi, R; Gill, CJ; Hamer, DH; Macleod, WB; Mubikayi, L; Mukwamataba, D; Mulele, CK; Mulenga, M; Mwanakasale, V; Mwananyanda, L; Thea, DM, 2007)
"The strategy of intermittent preventive treatment of malaria in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) was also addressed."2.72Drug treatment and prevention of malaria in pregnancy: a critical review of the guidelines. ( Al Khaja, KAJ; Sequeira, RP, 2021)
"Effective intermittent preventive treatment in pregnancy (IPTp) diminishes placental malaria (PM) and its subsequent malaria-associated morbidity."2.50Pregnancy-associated malaria and malaria in infants: an old problem with present consequences. ( Abellana, R; Cot, M; Moya-Alvarez, V, 2014)
"007) and dosage (p = 0."1.72Intermittent preventive treatment with Sulphadoxine-Pyrimethamine (IPTp-SP) is associated with protection against sub-microscopic P. falciparum infection in pregnant women during the low transmission dry season in southwestern Cameroon: A Semi - longitudi ( Achidi, EA; Amambua-Ngwa, A; Anchang-Kimbi, JK; Apinjoh, TO; Chi, HF; Dionne-Odom, J; Kwi, PN; Mayaba, JM; Moyeh, MN; Ntui, VN; Tangi, LN; Tita, ATN; Titanji, VPK; Toussi, CT, 2022)
"Chloroquine failure rate was high which was well above the WHO recommended cut off threshold for drug policy change (> 10%), Sulfadoxine- Pyrimethamine can be used in place of Chloroquine as the first line drug in uncomplicated P."1.42Comparative Study of Effectiveness and Resistance Profile of Chloroquine and Sulfadoxine-Pyrimethamine in Uncomplicated Plasmodium falciparum Malaria in Kolkata. ( Basu, A; Guha, SK; Saha, S, 2015)
"Intermittent preventive treatment during pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) is protective against malaria but may also affect hematopoiesis and contribute to fetal anemia."1.38The effects of malaria and intermittent preventive treatment during pregnancy on fetal anemia in Malawi. ( Chaluluka, E; Feng, G; Meshnick, SR; Molyneux, ME; Rogawski, ET; Rogerson, SJ, 2012)
" There was significant association between gravidity and SP dosage taken (Pearson χ2 = 18."1.37The effectiveness and perception of the use of sulphadoxine-pyrimethamine in intermittent preventive treatment of malaria in pregnancy programme in Offinso district of Ashanti region, Ghana. ( Browne, E; Lawson, B; Tutu, EO, 2011)
"Parasite recrudescences in 33 consecutive paired episodes during the same pregnancy were identified by msp1 and msp2 genotyping."1.35Sub-microscopic infections and long-term recrudescence of Plasmodium falciparum in Mozambican pregnant women. ( Alonso, PL; Aponte, JJ; Bardají, A; Cisteró, P; Mandomando, I; Mayor, A; Menéndez, C; Puyol, L; Sanz, S; Serra-Casas, E; Sigauque, B, 2009)
") was tested alone, or in a double and triple combination with a fixed oral dose of 1."1.35Plasmodium berghei: efficacy of 5-fluoroorotate in combination with commonly used antimalarial drugs in a mouse model. ( Ishih, A; Kano, S; Kino, H; Muregi, FW, 2009)
"Falciparum Malaria is hyperendemic in southern Nigeria and chloroquine resistance is an increasing problem."1.33Efficacy of amodiaquine in uncomplicated falciparum malaria in Nigeria in an area with high-level resistance to chloroquine and sulphadoxine/pyrimethamine. ( Göbels, K; Graupner, J; Grobusch, MP; Häussinger, D; Lund, A; Richter, J, 2005)
"Sulfadoxine-pyremethamine treatment alone cured 68."1.33The efficacy of sulfadoxine-pyrimethamine alone and in combination with chloroquine for malaria treatment in rural Eastern Sudan: the interrelation between resistance, age and gametocytogenesis. ( A-Elbasit, IE; Alifrangis, M; Elbashir, MI; Giha, HA; Khalil, IF, 2006)
"falciparum malaria were initially treated with chloroquine (CQ)."1.32Therapeutic efficacies of antimalarial drugs in the treatment of uncomplicated, Plasmodium falciparum malaria in Assam, north-eastern India. ( Barman, K; Dev, V; Phookan, S, 2003)
"This work shows that an early treatment of a malaria infection produced by a non-lethal parasite drives the immune response towards a loss of cross-protection to further infections, in particular with more virulent parasites."1.32Early treatment during a primary malaria infection modifies the development of cross immunity. ( Hernández-Clemente, FF; Legorreta-Herrera, M; Licona-Chávez, RN; Soto-Cruz, I; Ventura-Ayala, ML, 2004)
"Amodiaquine was 3."1.31In vitro sensitivity of Plasmodium falciparum to amodiaquine compared with other major antimalarials in Madagascar. ( Ariey, F; Duchemin, JB; Harisoa, JL; Mauclere, P; Pietra, V; Rabarijaona, LP; Raharimalala, LA; Rakotomanana, F; Ranaivo, L; Randrianarivelojosia, M; Robert, V, 2002)
" From September to December 1998, 598 children with uncomplicated malaria were treated; 135 received chloroquine (CQ) alone, 276 received pyrimethamine/sulfadoxine (Fansidar, PSD) alone, 113 received PSD with a single dose of artesunate (PSD + 1ART) and 74 received PSD combined with three doses of artesunate (PSD + 3ART)."1.31Parasitaemia and gametocytaemia after treatment with chloroquine, pyrimethamine/sulfadoxine, and pyrimethamine/sulfadoxine combined with artesunate in young Gambians with uncomplicated malaria. ( Coleman, R; Doherty, T; Jawara, M; Targett, G; von Seidlein, L; Walraven, G, 2001)
"falciparum malaria were treated with PS and monitored for 56 days."1.30Pyrimethamine-sulfadoxine efficacy and selection for mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase in Mali. ( Cortese, JF; Coulibaly, Y; Diakité, M; Diallo, M; Dicko, A; Diourté, Y; Djimdé, A; Doumbo, OK; Plowe, CV; Sagara, I, 1999)
"Chloroquine was prescribed at 25 mg/kg for 3 days in febrile patients with uncomplicated P."1.30[Chloroquine sensitivity of Plasmodium falciparum at the Gamkalley Clinic and the Nigerian armed forces PMI (Niamey, Niger)]. ( Ali, I; Bendavid, C; Condomines, P; Crassard, N; Djermakoye, F; Faugère, B; Parola, P, 1999)
"Fever was the only clinical manifestation attributable to parasitemia and only when the parasite density was > or = 5000/microL."1.29Impact of transmission intensity and age on Plasmodium falciparum density and associated fever: implications for malaria vaccine trial design. ( Bales, JD; Beadle, C; Beier, JC; Chumo, DK; Hoffman, SL; McElroy, PD; Oloo, AJ; Onyango, FK; Oster, CN; Sherwood, JA, 1995)
"Oral pyrimethamine treatment (10 mg/kg for 4 days) in infected mice (5-10%) returned the altered levels of the above enzymes to almost normal 1 week after the cessation of drug treatment."1.29Studies on ammonia-metabolizing enzymes during Plasmodium yoelii infection and pyrimethamine treatment in mice. ( Agrawal, A; Pandey, VC; Puri, SK; Tripathi, LM, 1996)

Research

Studies (185)

TimeframeStudies, this research(%)All Research%
pre-19901 (0.54)18.7374
1990's26 (14.05)18.2507
2000's95 (51.35)29.6817
2010's51 (27.57)24.3611
2020's12 (6.49)2.80

Authors

AuthorsStudies
Cohen, A1
Suzanne, P1
Lancelot, JC1
Verhaeghe, P1
Lesnard, A1
Basmaciyan, L1
Hutter, S1
Laget, M1
Dumètre, A1
Paloque, L1
Deharo, E1
Crozet, MD1
Rathelot, P1
Dallemagne, P1
Lorthiois, A1
Sibley, CH1
Vanelle, P1
Valentin, A1
Mazier, D1
Rault, S1
Azas, N1
Joste, V1
Guillochon, E1
Clain, J1
Coppée, R1
Houzé, S1
Apinjoh, TO1
Ntui, VN1
Chi, HF1
Moyeh, MN1
Toussi, CT1
Mayaba, JM1
Tangi, LN1
Kwi, PN1
Anchang-Kimbi, JK1
Dionne-Odom, J1
Tita, ATN1
Achidi, EA2
Amambua-Ngwa, A1
Titanji, VPK1
Crider, K1
Williams, J1
Qi, YP1
Gutman, J2
Yeung, L1
Mai, C1
Finkelstain, J1
Mehta, S1
Pons-Duran, C3
Menéndez, C4
Moraleda, C1
Rogers, L1
Daniels, K1
Green, P1
Hallamaa, L1
Ashorn, P1
Cheung, YB1
Luntamo, M1
Ashorn, U1
Kulmala, T1
Maleta, K1
Mangani, C1
Fan, YM1
Pestehchian, N1
Vafaei, MR1
Nematolahy, P1
Varshosaz, J1
Yousefi, HA1
Bide, VZ1
Kalani, H1
Moore, BR1
Benjamin, JM1
Tobe, R1
Ome-Kaius, M1
Yadi, G1
Kasian, B1
Kong, C1
Robinson, LJ1
Laman, M1
Mueller, I1
Rogerson, S1
Davis, TME1
Umemmuo, MU1
Agboghoroma, CO1
Iregbu, KC1
Chaponda, EB1
Mharakurwa, S1
Michelo, C1
Bruce, J2
Chandramoha, D1
Matthew Chico, R1
Al Khaja, KAJ1
Sequeira, RP1
Agyeman, YN1
Newton, S1
Annor, RB1
Owusu-Dabo, E1
Andronescu, LR1
Sharma, A1
Peterson, I1
Kachingwe, M1
Kachepa, W1
Liang, Y1
Gutman, JR2
Mathanga, DP2
Chinkhumba, J1
Laufer, MK3
Esu, EB1
Oringanje, C1
Meremikwu, MM1
Toukam, LL1
Tatsinkou Fossi, B1
Taiwe, GS1
Bila, RB1
Feugaing Sofeu, DD1
Ivo, EP1
Mohamed, AO1
Abdel Hamid, MM1
Mohamed, OS1
Elkando, NS1
Suliman, A1
Adam, MA1
Elnour, FAA1
Malik, EM4
Sandoval, E1
Lafuente-Monasterio, MJ1
Almela, MJ1
Castañeda, P1
Jiménez Díaz, MB1
Martínez-Martínez, MS1
Vidal, J1
Angulo-Barturen, Í1
Bamborough, P1
Burrows, J1
Cammack, N1
Chaparro, MJ1
Coterón, JM1
de Cozar, C1
Crespo, B1
Díaz, B1
Drewes, G1
Fernández, E1
Ferrer-Bazaga, S1
Fraile, MT1
Gamo, FJ1
Ghidelli-Disse, S1
Gómez, R1
Haselden, J1
Huss, S1
León, ML1
de Mercado, J1
Macdonald, SJF1
Martín Hernando, JI1
Prats, S1
Puente, M1
Rodríguez, A1
de la Rosa, JC1
Rueda, L1
Selenski, C1
Willis, P1
Wilson, DM1
Witty, M1
Calderón, F1
González, R2
Piqueras, M2
Aponte, JJ3
Ter Kuile, FO4
Akinyotu, O2
Bello, F2
Abdus-Salam, R2
Arowojolu, A2
Esu, E2
Berens-Riha, N1
Pritsch, M1
Nwachuku, N1
Loescher, T1
Meremikwu, M2
Chandramohan, D5
Dicko, A4
Zongo, I2
Sagara, I3
Cairns, M2
Kuepfer, I1
Diarra, M1
Barry, A2
Tapily, A1
Nikiema, F1
Yerbanga, S1
Coumare, S1
Thera, I1
Traore, A1
Milligan, P5
Tinto, H3
Doumbo, O4
Ouedraogo, JB3
Greenwood, B9
Adeoye, IA1
Fagbamigbe, AF1
Olaleye, A1
Okusanya, BO1
Oduwole, O1
Shah, NK1
Schapira, A1
Juliano, JJ1
Srivastava, B1
MacDonald, PD1
Poole, C1
Anvikar, A1
Meshnick, SR5
Valecha, N1
Mishra, N1
Moussiliou, A1
De Tove, YS1
Doritchamou, J1
Luty, AJ1
Massougbodji, A1
Alifrangis, M4
Deloron, P1
Ndam, NT1
Kikueta, CM1
Kambu, OK1
Mbenza, AP1
Mavinga, ST1
Mbamu, BM1
Cos, P1
Maes, L1
Apers, S1
Pieters, L1
Cimanga, RK1
Sharma, L1
Shukla, G1
Gogtay, N1
Kannan, S1
Thatte, UM1
Olliaro, PL3
Sinclair, D2
Valea, I1
Drabo, MK1
Huybregts, L1
Henry, MC1
Roberfroid, D1
Guiguemde, RT2
Kolsteren, P1
D'Alessandro, U4
Mosha, D1
Chilongola, J1
Ndeserua, R1
Mwingira, F1
Genton, B3
Moya-Alvarez, V1
Abellana, R1
Cot, M1
Cohee, LM1
Kalilani-Phiri, L1
Boudova, S1
Joshi, S1
Mukadam, R1
Seydel, KB1
Mawindo, P1
Thesing, P1
Kamiza, S1
Makwakwa, K1
Muehlenbachs, A2
Taylor, TE2
Mpogoro, FJ1
Matovelo, D1
Dosani, A1
Ngallaba, S1
Mugono, M1
Mazigo, HD1
Mwandama, D1
Wiegand, RE1
Abdallah, J1
Iriemenam, NC1
Shi, YP1
Skarbinski, J2
Marquart, L1
Baker, M1
O'Rourke, P1
McCarthy, JS1
Basu, A1
Saha, S1
Guha, SK1
Awine, T2
Belko, MM1
Oduro, AR2
Oyakhirome, S2
Tagbor, H1
Williams, JE1
Kakuru, A1
Jagannathan, P1
Muhindo, MK1
Natureeba, P1
Awori, P1
Nakalembe, M1
Opira, B1
Olwoch, P1
Ategeka, J1
Nayebare, P1
Clark, TD2
Feeney, ME1
Charlebois, ED1
Rizzuto, G1
Havlir, DV1
Kamya, MR2
Dorsey, G4
Bouyou-Akotet, MK1
Mawili-Mboumba, DP1
Kendjo, E1
Moutandou Chiesa, S1
Tshibola Mbuyi, ML1
Tsoumbou-Bakana, G1
Zong, J1
Ambounda, N1
Kombila, M1
Mwangi, VI1
Mumo, RM1
Kiboi, DM1
Omar, SA2
Ng'ang'a, ZW1
Ozwara, HS1
Matangila, JR1
Doua, JY1
Mitashi, P1
da Luz, RI1
Lutumba, P1
Van Geertruyden, JP1
Adam, I3
Elmardi, KA2
Carmona-Fonseca, J2
Arango, E1
Blair, S1
Clerk, CA1
Affipunguh, PK1
Mensah, N2
Hodgson, A3
Zikusooka, CM1
McIntyre, D1
Barnes, KI2
Temperley, M1
Mueller, DH1
Njagi, JK1
Akhwale, W1
Clarke, SE1
Jukes, MC1
Estambale, BB1
Brooker, S1
Delenne, H1
Cisse, M1
Badiane, M1
Olliaro, A1
Vaillant, M1
Brasseur, P1
Okokon, JE1
Nwafor, PA1
Stepniewska, K1
Price, RN1
Sutherland, CJ2
Drakeley, CJ2
von Seidlein, L3
Nosten, F1
White, NJ2
Mayor, A1
Serra-Casas, E1
Bardají, A1
Sanz, S1
Puyol, L1
Cisteró, P1
Sigauque, B1
Mandomando, I1
Alonso, PL1
Gies, S2
Coulibaly, SO1
Ouattara, FT1
Ogunfowokan, O1
Dankyau, M1
Madaki, AJ1
Thacher, TD3
Oesterholt, MJ1
Sawa, P3
Howitt, C1
Gouagna, LC3
Sauerwein, RW4
Bousema, T4
Msyamboza, KP1
Savage, EJ1
Kazembe, PN3
Kalanda, G1
Brabin, BJ3
Muregi, FW1
Kano, S1
Kino, H1
Ishih, A1
Barger, B1
Maiga, H2
Traore, OB1
Tekete, M1
Tembine, I2
Dara, A1
Traore, ZI1
Gantt, S1
Doumbo, OK4
Djimde, AA1
Zani, B1
Donegan, S1
Olliaro, P2
Garner, P1
Hombhanje, FW1
Linge, D1
Saweri, A1
Kuanch, C1
Jones, R1
Toraso, S1
Geita, J1
Masta, A1
Kevau, I1
Hiawalyer, G1
Sapuri, M1
Nakibuuka, V1
Ndeezi, G1
Nakiboneka, D1
Ndugwa, CM1
Tumwine, JK1
Whegang, SY1
Tahar, R1
Foumane, VN1
Soula, G1
Gwét, H1
Thalabard, JC1
Basco, LK1
Kinzer, MH1
Chand, K1
Basri, H1
Lederman, ER1
Susanti, AI1
Elyazar, I1
Taleo, G1
Rogers, WO1
Bangs, MJ2
Maguire, JD1
Okell, L2
Shekalaghe, S1
Griffin, JT1
Omar, S2
Sutherland, C1
Sauerwein, R3
Ghani, AC1
Drakeley, C2
Aziken, ME1
Akubuo, KK1
Gharoro, EP1
Ouédraogo, A2
Tiono, AB1
Diarra, A2
Nébié, IO1
Konaté, AT1
Sirima, SB2
Kapito-Tembo, A1
van Hensbroek, MB1
Phiri, K1
Fitzgerald, M1
Mwapasa, V2
Seboxa, T1
Mao, P1
Pinchouk, N1
Anbessie, J1
Alemu, H1
Diro, E1
Vanga-Bosson, HA1
Coffie, PA1
Kanhon, S1
Sloan, C1
Kouakou, F1
Eholie, SP1
Kone, M3
Dabis, F1
Menan, H1
Ekouevi, DK1
Tipsuwan, W1
Srichairatanakool, S1
Kamchonwongpaisan, S1
Yuthavong, Y1
Uthaipibull, C1
Dicko, M1
Diallo, AI1
Dicko, Y1
Dara, N1
Sidibe, Y1
Santara, G1
Conaré, T1
Cousens, S1
Milligan, PJ1
Diallo, DA1
Shekalaghe, SA1
van den Bosch, S1
ter Braak, R1
van den Bijllaardt, W1
Mwanziva, C1
Semvua, S1
Masokoto, A1
Mosha, F1
Teelen, K1
Hermsen, R1
Gosling, R2
Kiyingi, HS1
Egwang, TG1
Nannyonga, M1
Taylor, SM2
van Eijk, AM1
Hand, CC1
Mwandagalirwa, K1
Messina, JP1
Tshefu, AK1
Atua, B1
Emch, M1
Muwonga, J1
Tine, RC1
Faye, B1
Ndour, CT1
Ndiaye, JL1
Ndiaye, M1
Bassene, C1
Magnussen, P4
Bygbjerg, IC2
Sylla, K1
Ndour, JD1
Gaye, O1
Tutu, EO1
Lawson, B1
Browne, E1
Arango, EM1
Upegui, YA1
Umeh, UA1
Obi, SN1
Onah, HE1
Ugwu, EO1
Ajah, LO1
Umeh, CR1
Okafor, II1
Antonia, AL1
Chaluluka, E2
Feng, G2
Molyneux, ME2
Rogerson, SJ2
Khatib, RA2
Njau, JD1
Goodman, CA2
Elling, BF2
Kahigwa, E1
Roberts, JM1
MacArthur, JR1
Kabanywanyi, AM1
Smith, EE2
Somi, MF1
Lyimo, T1
Mwita, A1
Tanner, M1
Mills, A1
Mshinda, H3
Bloland, PB5
Abdulla, SM1
Kachur, SP1
Rutta, AS1
Francis, F1
Mmbando, BP1
Ishengoma, DS1
Sembuche, SH1
Malecela, EK1
Sadi, JY1
Kamugisha, ML1
Lemnge, MM1
Rogawski, ET1
Sangaré, D1
Dolo, G1
Guindo, A1
Sissoko, M1
Sogoba, M1
Niambélé, MB1
Yalcoué, D1
Kaslow, DC1
Klion, AD1
Diallo, D1
Miller, LH1
Touré, Y1
Méndez, F1
Muñoz, A1
Carrasquilla, G1
Jurado, D1
Arévalo-Herrera, M1
Cortese, JF2
Plowe, CV4
Rodríguez, MC1
Margos, G1
Compton, H1
Ku, M1
Lanz, H1
Rodríguez, MH1
Sinden, RE2
Terlouw, DJ1
Aidoo, MA1
Udhayakumar, V1
Kolczak, MS1
Oloo, AJ3
Kager, PA2
Lal, AA1
Nahlen, BL1
Kuile, FO1
Randrianarivelojosia, M2
Harisoa, JL1
Rabarijaona, LP1
Raharimalala, LA1
Ranaivo, L1
Pietra, V2
Duchemin, JB1
Rakotomanana, F1
Robert, V2
Mauclere, P1
Ariey, F1
Bousema, JT2
Meutstege, AM2
Okech, BE1
Akim, NI1
Githure, JI2
Beier, JC3
Sowunmi, A9
Fateye, BA7
JONES, SA1
Ndyomugyenyi, R2
Clarke, S1
Dev, V1
Phookan, S1
Barman, K1
Fehintola, FA6
Adedeji, AA8
Gbotosho, GO3
Falade, CO3
Tambo, E3
Happi, TC3
Oduola, AM4
Müller, O1
Traore, C1
Kouyate, B1
van den Broek, IV1
van der Wardt, S1
Talukder, L1
Chakma, S1
Brockman, A1
Nair, S1
Anderson, TC1
Legorreta-Herrera, M1
Ventura-Ayala, ML1
Licona-Chávez, RN1
Soto-Cruz, I1
Hernández-Clemente, FF1
Okech, BA1
Akim, IN1
Kengne, P1
Zampan, H1
Veas, F1
Guiguemdé, TR1
Randrianasolo, L1
Randriamanantena, A1
Ranarivelo, L1
Ratsimbasoa, A1
Domarle, O1
Challis, K1
Osman, NB1
Cotiro, M1
Nordahl, G1
Dgedge, M2
Bergström, S1
Babalola, CP1
Kayentao, K2
Kodio, M2
Newman, RD2
Doumtabe, D1
Ongoiba, A1
Coulibaly, D2
Keita, AS2
Maiga, B2
Mungai, M2
Parise, ME2
Anyorigiya, T1
Ansah, P1
Anto, F1
Ansah, NA1
Atuguba, F1
Mumuni, G1
Amankwa, J1
Pitmang, SL1
Madaki, JK2
Egah, DZ1
Fischer, PR1
Nambei, WS1
Gbagba, FE1
Ndémanga, J1
Doui-Doumgba, K1
Diallo, TO1
Ndadjimbaye, V1
Flori, P1
Perraut, R1
Garraud, O1
Graupner, J1
Göbels, K1
Grobusch, MP2
Lund, A1
Richter, J1
Häussinger, D1
A-Elbasit, IE2
Idris, SM1
Elbashir, MI2
Mockenhaupt, FP1
Teun Bousema, J1
Eggelte, TA1
Schreiber, J1
Ehrhardt, S1
Wassilew, N1
Otchwemah, RN1
Bienzle, U2
Owusu-Agyei, S1
Carneiro, I1
Amponsa-Achiano, K1
Jaffar, S1
Baiden, R1
Binka, F1
Adjetey, TA2
Affoumou, GB1
Loukou, DD1
Nebavi, NG2
Barro-Kiki, P1
Menan, EI2
Yavo, W2
Mugittu, K2
Abdulla, S2
Falk, N1
Masanja, H1
Felger, I1
Beck, HP2
Eggena, MP1
Hopkins, H1
Barugahare, B1
Okello, M1
Ssali, F1
Mugyenyi, P1
Rosenthal, PJ3
Cao, H1
Jongco, AM1
Ting, LM1
Thathy, V1
Mota, MM1
Kim, K1
Schneider, P1
Gouagna, L1
Schallig, H1
Patrick Kachur, S1
Schulden, J1
Kassala, H1
Causer, LM1
Mkikima, S1
Zurovac, D1
Midia, B1
Ochola, SA1
English, M1
Snow, RW1
Khalil, IF2
Giha, HA1
Mbaye, A2
Richardson, K2
Balajo, B2
Dunyo, S2
Shulman, C4
Walraven, G4
Mulenga, M3
Malunga, P1
Bennett, S2
Thuma, P1
Fielding, K2
Cotte, AH1
Konaté, A1
Moran, AC1
Asamoa, K1
Bougouma, EC1
Hugosson, E1
Montgomery, SM1
Premji, Z1
Troye-Blomberg, M1
Björkman, A1
Fanello, CI1
Karema, C1
van Doren, W1
Van Overmeir, C1
Ngamije, D1
Malunga, F1
Thuma, PE1
Alloueche, A2
Greenwood, BM1
Shah, SN1
Obonyo, CO1
Kain, KC1
Slutsker, L1
Hamel, MJ1
Snyder, C1
Chollet, J1
Santo-Tomas, J1
Scheurer, C1
Wittlin, S1
Kofoed, PE1
Rodrigues, A1
Aaby, P1
Rombo, L1
Ibrahium, AM1
Kheir, MM1
Osman, ME1
Rouamba, N1
Dokomajilar, C2
Priotto, G1
Guthmann, JP1
Kiguli, J1
Adjuik, M1
Snounou, G1
Taylor, WR1
Staedke, S1
Njama-Meya, D1
Nzarubara, B1
Maiteki-Sebuguzi, C1
Mbonye, AK1
Bygbjerg, I1
Parise, M1
Traoré, B2
Tukur, IU1
Sagay, AS1
Yusuf, BO1
Fadero, FF1
Mokuolu, OA1
Hamer, DH3
Salako, LA1
Happi, CT1
Folarin, OA1
van Oosterhout, JJ1
Thesing, PC1
Dzinjalamala, FK1
Hsi, T1
Beraho, L1
Graham, SM1
Gill, CJ2
Macleod, WB2
Mwanakasale, V2
Chalwe, V2
Mwananyanda, L2
Champo, D2
Mukwamataba, D2
Chilengi, R2
Thea, DM2
Mubikayi, L1
Mulele, CK1
Lell, B2
Schwarz, NG1
Gabor, J1
Dornemann, J1
Potschke, M1
Kiessling, GC1
Necek, M1
Langin, MU1
Klein Klouwenberg, P1
Klopfer, A1
Naumann, B1
Altun, H1
Agnandji, ST1
Goesch, J1
Decker, M1
Salazar, CL1
Supan, C1
Kombila, DU1
Borchert, L1
Koster, KB1
Pongratz, P1
Adegnika, AA1
Glasenapp, Iv1
Issifou, S1
Kremsner, PG3
Blanke, CH1
Naisabha, GB1
Balema, MB1
Mbaruku, GM1
Heide, L1
Müller, MS1
Little, F1
Mabuza, A1
Mngomezulu, N1
Govere, J1
Durrheim, D1
Roper, C1
Watkins, B1
Beadle, C1
McElroy, PD1
Oster, CN1
Onyango, FK1
Chumo, DK1
Bales, JD1
Sherwood, JA1
Hoffman, SL1
Djimde, A2
Bouare, M1
Wellems, TE1
Del Nero, L1
Lamizana, L1
Nebié, I1
Hogh, B1
Thompson, R1
Hetzel, C1
Fleck, SL1
Kruse, NA1
Jones, I1
Barreto, J1
Schultz, LJ1
Steketee, RW1
Macheso, A1
Kazembe, P3
Chitsulo, L1
Wirima, JJ1
Metzger, W1
Mordmüller, B1
Graninger, W1
Agrawal, A1
Tripathi, LM1
Puri, SK2
Pandey, VC1
Nwanyanwu, OC1
Ziba, C1
Gamadzi, G1
Gandwe, J1
Redd, SC1
Miédougé, M1
Bessières, MH1
Cassaing, S1
Swierczynski, B1
Séguéla, JP1
Okoyeh, JN1
Lege-Oguntoye, L1
Ugbode, RO1
Ogunrinde, GO1
Verhoeff, FH2
Masache, P1
Kachale, B1
Van der Kaay, HJ1
Ménard, R1
Janse, C1
Puta, C1
Manyando, C1
Chimsuku, L1
Russell, WB1
Broadhead, RL1
Collins, WE1
Warren, M1
Barat, LM2
Himonga, B2
Nkunika, S1
Ettling, M1
Ruebush, TK2
Kapelwa, W1
Shulman, CE1
Dorman, EK1
Cutts, F1
Kawuondo, K1
Bulmer, JN1
Peshu, N1
Marsh, K1
Fryauff, DJ1
Sumawinata, I1
Richie, TL1
Tjitra, E2
Kadir, A1
Ingkokusumo, G1
Caraballo, A1
Rodriguez-Acosta, A1
Kocken, CH1
van der Wel, A1
Thomas, AW1
Diourté, Y1
Coulibaly, Y1
Diallo, M1
Diakité, M1
Jelinek, T1
Kilian, AH1
Westermeier, A1
Pröll, S1
Kabagambe, G1
Nothdurft, HD1
von Sonnenburg, F1
Löscher, T1
Kun, JF1
Klabunde, J1
Luckner, D1
Alpers, M1
May, J1
Meyer, C1
Singh, N1
Pinder, M1
Bojang, K1
Anyalebechi, C1
Coleman, R2
Ude, JI1
Sadiq, A1
Duraisingh, M1
Warhurst, D1
Targett, G2
McAdam, K1
Doherty, T2
Wilairatana, P1
Silachamroon, U1
Krudsood, S1
Singhasivanon, P1
Treeprasertsuk, S1
Bussaratid, V1
Phumratanaprapin, W1
Srivilirit, S1
Looareesuwan, S1
Parola, P1
Ali, I1
Djermakoye, F1
Crassard, N1
Bendavid, C1
Faugère, B1
Condomines, P1
Babiker, HA1
Abdel-Muhsin, AA1
Hamad, A1
Mackinnon, MJ1
Hill, WG1
Walliker, D1
Awono-Ambene, HP1
Le Hesran, JY1
Trape, JF1
Falade, AG2
Akinyinka, OO1
Gorissen, E1
Ashruf, G1
Lamboo, M1
Bennebroek, J1
Gikunda, S1
Mbaruku, G1
Sowunmi, CO1
Sijuade, AO1
Figueroa, MS1
Bou, G1
Marti-Belda, P1
Lopez-Velez, R1
Guerrero, A1
Jawara, M1
Suprianto, S1
Currie, BJ1
Morris, PS1
Saunders, JR1
Anstey, NM1
Okafor, HU1
Nwaiwu, O1
Barro-Kiki, PC1
Nigué, L1
Konan, YJ1
Tarimo, DS1
Minjas, JN1
Bustos, DG1
Lazaro, JE1
Gay, F1
Pottier, A1
Laracas, CJ1
Diquet, B1

Clinical Trials (32)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Prospective Randomized Open-Label Study on the Efficacy and Safety of Intermittent Preventive Treatment in Pregnancy (IPTp) With Dihydroartemisinin-Piperaquine (DP) Versus IPTp With Sulfadoxine-Pyrimethamine (SP) in Malawi[NCT03009526]Phase 3602 participants (Actual)Interventional2017-01-17Completed
Effect of Single-course Malaria Chemoprevention on Clearance of and Protection From Plasmodium Falciparum Infection in the Presence of Resistance-associated Genotypes in Cameroon[NCT06173206]Phase 3900 participants (Anticipated)Interventional2024-03-15Not yet recruiting
A Comparative Study of Mefloquine and Sulphadoxine-pyrimethamine as Prophylaxis Against Malaria in Pregnant Human Immunodeficiency Virus Positive Patients[NCT02524444]Phase 1142 participants (Actual)Interventional2015-09-30Completed
Comparison of IST Using Ultra-sensitive Malaria Rapid Diagnostic Test and Pyronaridine - Artesunate - PYRAMAX®) to Standard IPT Sulfadoxine-pyrimethamine to Prevent Malaria in Pregnant Women Living in Endemic Areas[NCT04783051]Phase 3250 participants (Actual)Interventional2021-05-06Completed
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise[NCT00121641]Phase 31,035 participants (Actual)Interventional2005-07-31Completed
A Trial of Seasonal Malaria Chemoprevention Plus Azithromycin in African Children[NCT02211729]Phase 322,090 participants (Actual)Interventional2014-05-31Completed
Assessment of the Efficacy and Effectiveness of Sulphadoxine-pyrimethamine for Intermittent Preventive Treatment of Malaria in Pregnancy in Malawi[NCT01120145]1,410 participants (Actual)Observational2010-03-31Completed
A Proof-of-concept Study to Assess the Effect of ACT-451840 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Subjects[NCT02223871]Phase 18 participants (Actual)Interventional2014-06-30Completed
Improving Neonatal Health Through Rapid Malaria Testing in Early Pregnancy With High-Sensitivity[NCT05757167]Phase 42,500 participants (Anticipated)Interventional2023-11-06Recruiting
Operational Feasibility, Impact of Additional Screening Using Highly-sensitives RDTs Combined With High Coverage of IPTp on Placental Malaria and Low Birth Weight[NCT04147546]Phase 3340 participants (Actual)Interventional2020-08-31Completed
Reducing the Burden of Malaria in HIV-uninfected Pregnant Women and Infants (PROMOTE Birth Cohort 1)[NCT02163447]Phase 3300 participants (Actual)Interventional2014-06-23Completed
[NCT01075945]Phase 4140 participants (Anticipated)Interventional2010-02-28Recruiting
Efficacy of Sulphadoxine-pyrimethamine and Amodiaquine Alone or in Combination as Intermittent Preventive Treatment in Pregnancy in the Kassena-Nankana District of Ghana: a Randomized Controlled Trial[NCT00146783]Phase 2/Phase 33,642 participants (Actual)Interventional2004-06-30Completed
Assessment of Antimalaria Drugs Susceptibility Testing for an Effective Management of Infected Patients in Sub-Sahara Africa[NCT02974348]Phase 3300 participants (Actual)Interventional2013-01-31Completed
Assessing the Effectiveness of Community Delivery of Intermittent Preventive Treatment in Pregnancy (IPTp) in Malawi[NCT03376217]1,447 participants (Actual)Interventional2017-12-01Completed
Determining the Impact of Scaling up Mass Testing, Treatment and Tracking on Malaria Prevalence Among Children in the Pakro Sub District of Ghana[NCT04301531]5,861 participants (Actual)Interventional2020-03-01Completed
Exploring the Impact of Scaling up Mass Testing, Treatment and Tracking on Malaria Prevalence Among Children in the Pakro Sub District of Ghana[NCT04167566]5,000 participants (Actual)Interventional2017-07-01Completed
Dihydroartemisinin-Piperaquine or Sulphadoxine-Pyrimethamine for the Chemoprevention of Malaria in Children With Sickle Cell Anaemia in Eastern and Southern Africa: a Double Blind Randomised Trial (CHEMCHA)[NCT04844099]Phase 3723 participants (Actual)Interventional2021-04-09Completed
Efficacy of Intrarectal Versus Intravenous Quinine for the Treatment of Childhood Cerebral Malaria: a Randomized Clinical Trial[NCT00124267]Phase 3108 participants Interventional2003-09-30Active, not recruiting
Evaluation of the Efficacy and Safety of Primaquine for Clearance of Gametocytes in Uncomplicated Falciparum Malaria in Uganda[NCT01365598]Phase 3468 participants (Actual)Interventional2011-12-31Completed
A Trial of the Combined Impact of Intermittent Preventive Treatment and Insecticide Treated Bednets in Reducing Morbidity From Malaria in African Children[NCT00738946]6,000 participants (Anticipated)Interventional2008-08-31Completed
Impact of Mass Screening and Selective Treatment With Dihydroartemisinin-piperaquine Plus Primaquine on Malaria Transmission in High Endemic Area, Belu Regency, Nusa Tenggara Timur Province, Indonesia: a Randomized Cluster Trial[NCT01878357]Phase 41,488 participants (Actual)Interventional2013-06-30Completed
Mass-Drug Administration With a Gametocytocidal Drug Combination, a Model for a Transmission Blocking Vaccine[NCT00509015]6,000 participants (Anticipated)Interventional2008-02-29Completed
Short Course of Quinine Plus a Single Dose of Sulphadoxine-Pyrimethamine for Plasmodium Falciparum Malaria[NCT00167739]Phase 450 participants Interventional2003-04-30Completed
Effect of Single-course Malaria Chemoprevention on Clearance of and Protection From Plasmodium Falciparum Infection in the Presence of Resistance-associated Genotypes in Zambia[NCT06166498]Phase 3600 participants (Anticipated)Interventional2024-02-15Not yet recruiting
Evaluation of the Safety and Effectiveness of EPI-linked Malaria Intermittent Chemotherapy and Iron Supplementation[NCT00857077]2,485 participants (Actual)Interventional2000-09-30Completed
Longitudinal Comparison of Combination Antimalarial Therapies in Ugandan Children: Evaluation of Safety, Tolerability, and Efficacy[NCT00123552]Phase 3601 participants (Actual)Interventional2004-11-30Completed
Intermittent Preventive Treatment of Malaria With Sulfadoxine-Pyrimethamine in HIV-Seropositive and HIV-Seronegative Pregnant Women in Zambia[NCT00270530]Phase 4454 participants Interventional2002-11-30Completed
A Longitudinal Study Assessing the Infectious Status and Immunity of Mothers and Their Children in Lambaréné, Including Intermittent Treatment of Children With Sulfadoxine-pyrimethamine for Malaria Control and Its Impact on Long-term Health[NCT00167843]Phase 41,189 participants Interventional2002-12-31Completed
A Phase IIIB Comparative Trial of Seasonal Vaccination With the Malaria Vaccine RTS,S/AS01, Seasonal Malaria Chemoprevention and of the Two Interventions Combined[NCT03143218]Phase 35,920 participants (Actual)Interventional2017-04-17Completed
Intermittent Preventive Treatment With Azithromycin-containing Regimens for the Prevention of Malarial Infections and Anaemia and the Control of Sexually Transmitted Infections in Pregnant Women in Papua New Guinea[NCT01136850]Phase 32,793 participants (Actual)Interventional2009-11-30Completed
A Comparative Assessment of the Efficacy of Fosmidomycin-Clindamycin Versus Sulfadoxine-Pyrimethamine for the Treatment of Children With Uncomplicated Plasmodium Falciparum Malaria[NCT00214643]Phase 3160 participants Interventional2005-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

All Reported Hypoglycemic Adverse Events During ST + LT Treatment Period

Hypoglycemic Events are based upon the Saxagliptin Predefined List of Events, which included hypoglycemia, blood glucose decreased, and hypoglycemic unconsciousness. (NCT00121641)
Timeframe: AEs: up to last treatment day + 1 day or last visit; SAEs: up to last treatment day + 30 days or last visit + 30 days. Mean duration of exposure was 109 weeks in 10 mg arm, 94.7 weeks in 2.5 mg arm, 103 weeks in 5 mg arm, and 98.4 weeks in placebo arm.

Interventionparticipants (Number)
Saxagliptin 2.5 mg9
Saxagliptin 5 mg11
Saxagliptin 10 mg10
Placebo9

All Reported Hypoglycemic Adverse Events During ST + LT Treatment Period - Open-Label Cohort

Hypoglycemic Events are based upon the Saxagliptin Predefined List of Events, which included hypoglycemia, blood glucose decreased, and hypoglycemic unconsciousness. (NCT00121641)
Timeframe: AEs: up to last treatment day + 1 day or last visit; SAEs: up to last treatment day + 30 days or last visit + 30 days. Mean duration of exposure was 34 weeks.

Interventionparticipants (Number)
Open-Label Treatment Cohort (Direct Enrollees)2

Baseline Demographic Characteristic (Age, Continuous) - Summary for ST + LT Treatment Period - Open-Label Cohort

This cohort represents a different population (screening A1C > 10.0% and ≤ 12.0%) than the double-blind cohort, and was presented separately in the study report. (NCT00121641)
Timeframe: Baseline

Interventionyears (Mean)
Open-Label Treatment Cohort (Direct Enrollees)49.09

Baseline Demographic Characteristic (Body Mass Index) - Summary for ST + LT Treatment Period - Open-Label Cohort

This cohort represents a different population (screening A1C > 10.0% and ≤ 12.0%) than the double-blind cohort, and was presented separately in the study report. (NCT00121641)
Timeframe: Baseline

Interventionkg/m^2 (Mean)
Open-Label Treatment Cohort (Direct Enrollees)31.73

Baseline Demographic Characteristic (Weight) - Summary for ST + LT Treatment Period - Open-Label Cohort

This cohort represents a different population (screening A1C > 10.0% and ≤ 12.0%) than the double-blind cohort, and was presented separately in the study report. (NCT00121641)
Timeframe: Baseline

Interventionkg (Mean)
Open-Label Treatment Cohort (Direct Enrollees)91.41

Confirmed Hypoglycemia During ST + LT Treatment Period

'Confirmed' = recorded on the hypoglycemia AE case report form page with a fingerstick glucose <= 50 mg/dL and associated symptoms (NCT00121641)
Timeframe: AEs: up to last treatment day + 1 day or last visit; SAEs: up to last treatment day + 30 days or last visit + 30 days. Mean duration of exposure was 109 weeks in 10 mg arm, 94.7 weeks in 2.5 mg arm, 103 weeks in 5 mg arm, and 98.4 weeks in placebo arm.

Interventionparticipants (Number)
Saxagliptin 2.5 mg1
Saxagliptin 5 mg1
Saxagliptin 10 mg0
Placebo0

Confirmed Hypoglycemia During ST + LT Treatment Period - Open-Label Cohort

'Confirmed' = recorded on the hypoglycemia AE case report form page with a fingerstick glucose <= 50 mg/dL and associated symptoms (NCT00121641)
Timeframe: AEs: up to last treatment day + 1 day or last visit; SAEs: up to last treatment day + 30 days or last visit + 30 days. Mean duration of exposure was 34 weeks.

Interventionparticipants (Number)
Open-Label Treatment Cohort (Direct Enrollees)0

Percentage of Participants Achieving Therapeutic Glycemic Response (A1C < 7.0%) at Week 24

(NCT00121641)
Timeframe: Week 24

Interventionpercentage of participants (Number)
Saxagliptin 2.5 mg35.0
Saxagliptin 5 mg37.9
Saxagliptin 10 mg41.1
Placebo23.9

Percentage of Participants Achieving Therapeutic Glycemic Response (A1C < 7.0%) at Week 24 - Open Label Cohort

(NCT00121641)
Timeframe: Week 24

Interventionpercentage of participants (Number)
Open Label Cohort (Direct Enrollees)14.1

A1C Changes From Baseline at Week 24 - Open Label Cohort

To compare the change from baseline in HbA1c achieved with each dose of saxagliptin versus placebo in treatment naive subjects with type 2 diabetes who have inadequate glycemic control defined as A1C ≥7.0% and ≤10.0%. (NCT00121641)
Timeframe: Baseline, Week 24

InterventionPercentage of glycosylated hemoglobins (Mean)
Baseline MeanMean Change from Baseline
Open Label Cohort (Direct Enrollees)10.70-1.87

Baseline and Change From Baseline at Week 24 in Fasting Plasma Glucose (FPG)

(NCT00121641)
Timeframe: Baseline, Week 24

,,,
Interventionmg/dL (Mean)
BaselineAdjusted Change from Baseline
Placebo171.856.06
Saxagliptin 10 mg176.51-16.75
Saxagliptin 2.5 mg177.72-14.53
Saxagliptin 5 mg171.31-8.67

Baseline and Change From Baseline at Week 24 in Fasting Plasma Glucose (FPG) - Open Label Cohort

(NCT00121641)
Timeframe: Baseline, Week 24

Interventionmg/dL (Mean)
BaselineChange from Baseline
Open-Label Cohort (Direct Enrollees)241.08-33.42

Baseline and Change From Baseline at Week 24 in Postprandial Glucose (PPG) Area Under the Curve (AUC)

(NCT00121641)
Timeframe: Baseline, Week 24

,,,
Interventionmg*min/dL (Mean)
BaselineAdjusted Change from Baseline
Placebo46030-646.6
Saxagliptin 10 mg44614-8084
Saxagliptin 2.5 mg45030-6868
Saxagliptin 5 mg45691-6896

Baseline and Change From Baseline at Week 24 in Postprandial Glucose (PPG) Area Under the Curve (AUC) - Open Label Cohort

(NCT00121641)
Timeframe: Baseline, Week 24

Interventionmg*min/dL (Mean)
BaselineChange from Baseline
Open Label Cohort (Direct Enrollees)60687-11078

Baseline and Changes From Baseline in Absolute Basophil Counts (x 10^3 c/µL) During the ST + LT Period

(NCT00121641)
Timeframe: Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 30, 37, 50, 63, 76, 89, 102, 115, 128, 141, 154, 167, 180, 193, 206

,,,
Interventionx 10^3 c/µL (Mean)
Baseline (BL) (Week 0) (n=102, 106, 98, 94)Change from BL at Week 2 (n=95, 99, 92, 86)Change from BL at Week 4 (n=91, 99, 90, 90)Change from BL at Week 6 (n=89, 95, 87, 82)Change from BL at Week 8 (n=91, 88, 90, 79)Change from BL at Week 10 (n=68, 76, 69, 63)Change from BL at Week 12 (n=83, 88, 87, 82)Change from BL at Week 14 (n=76, 77, 80, 75)Change from BL at Week 16 (n=90, 91, 83, 71)Change from BL at Week 18 (n=78, 75, 82, 71)Change from BL at Week 20 (n=83, 79, 78, 72)Change from BL at Week 22 (n=77, 74, 75, 65)Change from BL at Week 24 (n=83, 81, 78, 74)Change from BL at Week 30 (n=76, 78, 79, 67)Change from BL at Week 37 (n=74, 72, 70, 60)Change from BL at Week 50 (n=67, 69, 71, 61)Change from BL at Week 63 (n=60, 66, 67, 55)Change from BL at Week 76 (n=51, 58, 63, 49)Change from BL at Week 89 (n=48, 58, 56, 42)Change from BL at Week 102 (n=39, 47, 50, 40)Change from BL at Week 115 (n=34, 43, 42, 34)Change from BL at Week 128 (n=30, 40, 40, 29)Change from BL at Week 141 (n=28, 38, 34, 28)Change from BL at Week 154 (n=26, 33, 31, 24)Change from BL at Week 167 (n=24, 33, 30, 25)Change from BL at Week 180 (n=21, 28, 28, 26)Change from BL at Week 193 (n=19, 25, 26, 23)Change from BL at Week 206 (n=17, 22, 23, 21)
Placebo0.020.00-0.00-0.01-0.01-0.01-0.00-0.00-0.01-0.01-0.00-0.00-0.010.010.000.020.020.010.020.020.030.030.020.010.020.020.020.01
Saxagliptin 10 mg0.02-0.01-0.01-0.01-0.01-0.01-0.00-0.01-0.01-0.00-0.010.00-0.01-0.010.000.010.020.020.020.020.010.010.010.020.010.000.010.01
Saxagliptin 2.5 mg0.010.000.000.010.000.00-0.000.000.000.000.010.010.000.000.000.020.020.020.020.020.020.030.020.030.020.010.010.00
Saxagliptin 5 mg0.02-0.01-0.01-0.01-0.00-0.01-0.010.00-0.000.00-0.01-0.00-0.010.010.010.010.010.010.020.020.030.030.020.020.010.020.010.02

Baseline and Changes From Baseline in Absolute Eosinophil Counts (x 10^3 c/µL) During the ST + LT Period

(NCT00121641)
Timeframe: Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 30, 37, 50, 63, 76, 89, 102, 115, 128, 141, 154, 167, 180, 193, 206

,,,
Interventionx 10^3 c/µL (Mean)
Baseline (BL) (Week 0) (n=102, 106, 98, 94)Change from BL at Week 2 (n=95, 99, 92, 86)Change from BL at Week 4 (n=91, 99, 90, 90)Change from BL at Week 6 (n=89, 95, 87, 82)Change from BL at Week 8 (n=91, 88, 90, 79)Change from BL at Week 10 (n=68, 76, 69, 63)Change from BL at Week 12 (n=83, 88, 87, 82)Change from BL at Week 14 (n=76, 77, 80, 75)Change from BL at Week 16 (n=90, 91, 83, 71)Change from BL at Week 18 (n=78, 75, 82, 71)Change from BL at Week 20 (n=83, 79, 78, 72)Change from BL at Week 22 (n=77, 74, 75, 65)Change from BL at Week 24 (n=83, 81, 78, 74)Change from BL at Week 30 (n=76, 78, 79, 67)Change from BL at Week 37 (n=74, 72, 70, 60)Change from BL at Week 50 (n=67, 69, 71, 61)Change from BL at Week 63 (n=60, 66, 67, 55)Change from BL at Week 76 (n=51, 58, 63, 49)Change from BL at Week 89 (n=48, 58, 56, 42)Change from BL at Week 102 (n=39, 47, 50, 40)Change from BL at Week 115 (n=34, 43, 42, 34)Change from BL at Week 128 (n=30, 40, 40, 29)Change from BL at Week 141 (n=28, 38, 34, 28)Change from BL at Week 154 (n=26, 33, 31, 24)Change from BL at Week 167 (n=24, 33, 30, 25)Change from BL at Week 180 (n=21, 28, 28, 26)Change from BL at Week 193 (n=19, 25, 26, 23)Change from BL at Week 206 (n=17, 22, 23, 21)
Placebo0.20-0.02-0.02-0.02-0.010.01-0.02-0.01-0.000.00-0.03-0.02-0.04-0.03-0.02-0.01-0.02-0.03-0.02-0.01-0.00-0.010.010.030.060.070.050.06
Saxagliptin 10 mg0.20-0.02-0.01-0.02-0.02-0.02-0.01-0.01-0.03-0.03-0.04-0.04-0.03-0.02-0.04-0.02-0.00-0.02-0.020.02-0.01-0.03-0.00-0.010.01-0.000.000.03
Saxagliptin 2.5 mg0.18-0.01-0.020.010.00-0.010.00-0.01-0.02-0.02-0.02-0.00-0.02-0.03-0.03-0.03-0.00-0.03-0.030.02-0.00-0.02-0.010.00-0.02-0.02-0.010.00
Saxagliptin 5 mg0.200.01-0.01-0.01-0.01-0.02-0.02-0.01-0.02-0.02-0.03-0.03-0.03-0.03-0.01-0.010.00-0.04-0.020.010.070.02-0.00-0.00-0.02-0.01-0.01-0.00

Baseline and Changes From Baseline in Absolute Lymphocyte Counts (x 10^3 c/µL) During the ST + LT Period

(NCT00121641)
Timeframe: Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 30, 37, 50, 63, 76, 89, 102, 115, 128, 141, 154, 167, 180, 193, 206

,,,
Interventionx 10^3 c/µL (Mean)
Baseline (BL) (Week 0) (n=102, 106, 98, 94)Change from BL at Week 2 (n=95, 99, 92, 86)Change from BL at Week 4 (n=91, 99, 90, 90)Change from BL at Week 6 (n=89, 95, 87, 82)Change from BL at Week 8 (n=91, 88, 90, 79)Change from BL at Week 10 (n=68, 76, 69, 63)Change from BL at Week 12 (n=83, 88, 87, 82)Change from BL at Week 14 (n=76, 77, 80, 75)Change from BL at Week 16 (n=90, 91, 83, 71)Change from BL at Week 18 (n=78, 75, 82, 71)Change from BL at Week 20 (n=83, 79, 78, 72)Change from BL at Week 22 (n=77, 74, 75, 65)Change from BL at Week 24 (n=83, 81, 78, 74)Change from BL at Week 30 (n=76, 78, 79, 67)Change from BL at Week 37 (n=74, 72, 70, 60)Change from BL at Week 50 (n=67, 69, 71, 61)Change from BL at Week 63 (n=60, 66, 67, 55)Change from BL at Week 76 (n=51, 58, 63, 49)Change from BL at Week 89 (n=49, 58, 56, 42)Change from BL at Week 102 (n=39, 48, 51, 40)Change from BL at Week 115 (n=34, 43, 43, 35)Change from BL at Week 128 (n=30, 40, 40, 30)Change from BL at Week 141 (n=28, 38, 34, 28)Change from BL at Week 154 (n=26, 33, 31, 24)Change from BL at Week 167 (n=24, 33, 30, 25)Change from BL at Week 180 (n=21, 28, 28, 26)Change from BL at Week 193 (n=19, 25, 26, 23)Change from BL at Week 206 (n=17, 22, 23, 21)
Placebo2.22-0.13-0.04-0.09-0.000.05-0.020.060.010.08-0.110.09-0.01-0.03-0.08-0.03-0.16-0.20-0.23-0.16-0.10-0.060.00-0.14-0.16-0.050.01-0.08
Saxagliptin 10 mg2.14-0.11-0.18-0.23-0.20-0.10-0.16-0.01-0.110.01-0.10-0.07-0.13-0.09-0.17-0.25-0.19-0.18-0.19-0.23-0.21-0.16-0.10-0.23-0.11-0.06-0.04-0.05
Saxagliptin 2.5 mg2.16-0.04-0.03-0.04-0.070.07-0.060.200.030.110.080.16-0.000.080.05-0.06-0.06-0.10-0.12-0.17-0.15-0.12-0.13-0.23-0.23-0.15-0.06-0.17
Saxagliptin 5 mg2.21-0.10-0.12-0.09-0.110.02-0.120.080.010.13-0.020.13-0.07-0.000.02-0.09-0.10-0.09-0.02-0.07-0.00-0.00-0.030.04-0.13-0.22-0.09-0.14

Baseline and Changes From Baseline in Absolute Monocyte Counts (x 10^3 c/µL) During the ST + LT Period

(NCT00121641)
Timeframe: Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 30, 37, 50, 63, 76, 89, 102, 115, 128, 141, 154, 167, 180, 193, 206

,,,
Interventionx 10^3 c/µL (Mean)
Baseline (BL) (Week 0) (n=102, 106, 98, 94)Change from BL at Week 2 (n=95, 99, 92, 86)Change from BL at Week 4 (n=91, 99, 90, 90)Change from BL at Week 6 (n=89, 95, 87, 82)Change from BL at Week 8 (n=91, 88, 90, 79)Change from BL at Week 10 (n=68, 76, 69, 63)Change from BL at Week 12 (n=83, 88, 87, 82)Change from BL at Week 14 (n=76, 77, 80, 75)Change from BL at Week 16 (n=90, 91, 83, 71)Change from BL at Week 18 (n=78, 75, 82, 71)Change from BL at Week 20 (n=83, 79, 78, 72)Change from BL at Week 22 (n=77, 74, 75, 65)Change from BL at Week 24 (n=83, 81, 78, 74)Change from BL at Week 30 (n=76, 78, 79, 67)Change from BL at Week 37 (n=74, 72, 70, 60)Change from BL at Week 50 (n=67, 69, 71, 61)Change from BL at Week 63 (n=60, 66, 67, 55)Change from BL at Week 76 (n=51, 58, 63, 49)Change from BL at Week 89 (n=48, 58, 56, 42)Change from BL at Week 102 (n=39, 47, 50, 40)Change from BL at Week 115 (n=34, 43, 42, 34)Change from BL at Week 128 (n=30, 40, 40, 29)Change from BL at Week 141 (n=28, 38, 34, 28)Change from BL at Week 154 (n=26, 33, 31, 24)Change from BL at Week 167 (n=24, 33, 30, 25)Change from BL at Week 180 (n=21, 28, 28, 26)Change from BL at Week 193 (n=19, 25, 26, 23)Change from BL at Week 206 (n=17, 22, 23, 21)
Placebo0.32-0.010.010.02-0.020.030.010.040.010.040.010.050.030.030.000.060.070.050.050.070.130.070.100.080.110.110.130.09
Saxagliptin 10 mg0.32-0.05-0.01-0.01-0.010.040.000.030.040.060.040.060.030.040.040.050.070.060.080.090.060.070.100.060.100.110.110.13
Saxagliptin 2.5 mg0.310.010.050.050.030.080.050.090.060.060.040.080.040.050.060.070.080.120.110.140.120.120.080.100.070.080.090.05
Saxagliptin 5 mg0.340.010.00-0.010.030.040.000.060.040.050.020.050.010.030.020.030.050.040.030.040.050.040.020.050.040.040.040.05

Baseline and Changes From Baseline in Absolute Neutrophil Counts (x 10^3 c/µL) During the ST + LT Period

(NCT00121641)
Timeframe: Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 30, 37, 50, 63, 76, 89, 102, 115, 128, 141, 154, 167, 180, 193, 206

,,,
Interventionx 10^3 c/µL (Mean)
Baseline (BL) (Week 0) (n=102, 106, 98, 94)Change from BL at Week 2 (n=95, 99, 92, 86)Change from BL at Week 4 (n=91, 99, 90, 90)Change from BL at Week 6 (n=89, 95, 87, 82)Change from BL at Week 8 (n=91, 88, 90, 79)Change from BL at Week 10 (n=68, 76, 69, 63)Change from BL at Week 12 (n=83, 88, 87, 82)Change from BL at Week 14 (n=76, 77, 80, 75)Change from BL at Week 16 (n=90, 91, 83, 71)Change from BL at Week 18 (n=78, 75, 82, 71)Change from BL at Week 20 (n=83, 79, 78, 72)Change from BL at Week 22 (n=77, 74, 75, 65)Change from BL at Week 24 (n=83, 81, 78, 74)Change from BL at Week 30 (n=76, 78, 79, 67)Change from BL at Week 37 (n=74, 72, 70, 60)Change from BL at Week 50 (n=67, 69, 71, 61)Change from BL at Week 63 (n=60, 66, 67, 55)Change from BL at Week 76 (n=51, 58, 63, 49)Change from BL at Week 89 (n=48, 58, 56, 42)Change from BL at Week 102 (n=39, 47, 50, 40)Change from BL at Week 115 (n=34, 43, 42, 34)Change from BL at Week 128 (n=30, 40, 40, 29)Change from BL at Week 141 (n=28, 38, 34, 28)Change from BL at Week 154 (n=26, 33, 31, 24)Change from BL at Week 167 (n=24, 33, 30, 25)Change from BL at Week 180 (n=21, 28, 28, 26)Change from BL at Week 193 (n=19, 25, 26, 23)Change from BL at Week 206 (n=17, 22, 23, 21)
Placebo4.01-0.070.230.170.190.450.300.460.180.210.150.32-0.030.000.200.270.16-0.010.010.010.420.220.400.410.330.51-0.010.31
Saxagliptin 10 mg4.160.000.050.040.030.170.180.170.160.320.070.440.160.320.240.190.080.080.050.240.290.560.450.470.270.550.510.90
Saxagliptin 2.5 mg4.00-0.060.090.010.020.180.010.070.170.230.190.440.090.040.130.030.110.050.580.190.280.610.410.25-0.040.230.340.15
Saxagliptin 5 mg3.980.110.160.190.270.480.210.640.490.670.320.580.570.290.420.400.250.330.180.430.810.590.800.390.560.500.080.63

Baseline and Changes From Baseline in Hematocrit During the ST + LT Period

(NCT00121641)
Timeframe: Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 30, 37, 50, 63, 76, 89, 102, 115, 128, 141, 154, 167, 180, 193, 206

,,,
Interventionpercentage red blood cells (Mean)
Baseline (BL) (Week 0) (n=102, 106, 98, 94)Change from BL at Week 2 (n=95,100, 93, 87)Change from BL at Week 4 (n=92, 99, 91, 91)Change from BL at Week 6 (n=91, 96, 87, 82)Change from BL at Week 8 (n=92, 90, 91, 79)Change from BL at Week 10 (n=70, 76, 69, 63)Change from BL at Week 12 (n=85, 88, 87, 82)Change from BL at Week 14 (n=76, 80, 81, 75)Change from BL at Week 16 (n=90. 91, 83, 71)Change from BL at Week 18 (n=78, 75, 82, 71)Change from BL at Week 20 (n=83, 80, 78, 72)Change from BL at Week 22 (n=78, 74, 76, 65)Change from BL at Week 24 (n=83, 82, 78, 74)Change from BL at Week 30 (n=77, 78, 79, 67)Change from BL at Week 37 (n=75, 73, 70, 62)Change from BL at Week 50 (n=67, 71, 71, 61)Change from BL at Week 63 (n=61, 66, 67, 55)Change from BL at Week 76 (n=51, 59, 63, 49)Change from BL at Week 89 (n=49, 58, 56, 42)Change from BL at Week 102 (n=40, 49, 51, 40)Change from BL at Week 115 (n=34, 43, 43, 35)Change from BL at Week 128 (n=30, 40, 40, 30)Change from BL at Week 141 (n=28, 39, 34, 28)Change from BL at Week 154 (n=26, 34, 31, 24)Change from BL at Week 167 (n=24, 33, 30, 26)Change from BL at Week 180 (n=21, 28, 28, 26)Change from BL at Week 193 (n=19, 26, 26, 23)Change from BL at Week 206 (n=17, 22, 24, 21)
Placebo42.8-0.40.30.30.50.50.70.20.30.40.20.50.50.4-0.40.20.70.80.4-0.70.2-0.1-0.2-0.3-0.4-0.5-0.0-0.5
Saxagliptin 10 mg42.7-0.7-0.10.00.2-0.20.60.20.60.30.1-0.3-0.10.20.40.10.60.71.2-0.00.20.00.2-1.00.21.00.50.2
Saxagliptin 2.5 mg42.5-0.4-0.20.10.50.60.60.60.50.20.70.30.00.50.00.10.30.70.9-0.2-0.00.2-0.1-0.8-0.11.10.6-0.4
Saxagliptin 5 mg42.8-0.2-0.20.30.4-0.00.40.60.70.40.40.20.2-0.1-0.10.30.10.50.90.50.60.3-0.1-0.80.20.61.10.2

Baseline and Changes From Baseline in Hemoglobin During the ST + LT Period

(NCT00121641)
Timeframe: Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 30, 37, 50, 63, 76, 89, 102, 115, 128, 141, 154, 167, 180, 193, 206

,,,
Interventiong/dL (Mean)
Baseline (BL) (Week 0) (n=102, 106, 98, 94)Change from BL at Week 2 (n=95,100, 93, 87)Change from BL at Week 4 (n=92, 99, 91, 91)Change from BL at Week 6 (n=91, 96, 87, 82)Change from BL at Week 8 (n=92, 90, 91, 79)Change from BL at Week 10 (n=70, 76, 69, 63)Change from BL at Week 12 (n=85, 88, 87, 82)Change from BL at Week 14 (n=76, 80, 81, 75)Change from BL at Week 16 (n=90, 91, 83, 71)Change from BL at Week 18 (n=78, 75, 82, 71)Change from BL at Week 20 (n=83, 80, 78, 72)Change from BL at Week 22 (n=78, 74, 76, 65)Change from BL at Week 24 (n=83, 82, 78, 74)Change from BL at Week 30 (n=77, 78, 79, 67)Change from BL at Week 37 (n=75, 73, 70, 62)Change from BL at Week 50 (n=67, 71, 71, 61)Change from BL at Week 63 (n=61, 66, 67, 55)Change from BL at Week 76 (n=51, 59, 63, 49)Change from BL at Week 89 (n=49, 58, 56, 42)Change from BL at Week 102 (n=40, 49, 51, 40)Change from BL at Week 115 (n=34, 43, 43, 35)Change from BL at Week 128 (n=30, 40, 40, 30)Change from BL at Week 141 (n=28, 39, 34, 28)Change from BL at Week 154 (n=26, 34, 31, 24)Change from BL at Week 167 (n=24, 33, 30, 26)Change from BL at Week 180 (n=21, 28, 28, 26)Change from BL at Week 193 (n=19, 26, 26, 23)Change from BL at Week 206 (n=17, 22, 24, 21)
Placebo14.50-0.090.100.040.090.040.16-0.030.04-0.03-0.19-0.18-0.14-0.18-0.33-0.010.08-0.10-0.10-0.29-0.19-0.33-0.36-0.25-0.24-0.61-0.39-0.32
Saxagliptin 10 mg14.47-0.22-0.09-0.07-0.02-0.13-0.07-0.120.00-0.07-0.25-0.36-0.32-0.19-0.06-0.020.07-0.07-0.04-0.07-0.18-0.25-0.15-0.24-0.03-0.08-0.160.10
Saxagliptin 2.5 mg14.49-0.21-0.16-0.12-0.000.01-0.04-0.09-0.10-0.26-0.16-0.35-0.37-0.25-0.31-0.17-0.18-0.27-0.18-0.32-0.41-0.38-0.40-0.45-0.51-0.38-0.45-0.51
Saxagliptin 5 mg14.45-0.13-0.15-0.000.04-0.20-0.07-0.050.01-0.10-0.14-0.23-0.25-0.29-0.220.06-0.11-0.19-0.09-0.00-0.07-0.17-0.35-0.37-0.05-0.08-0.03-0.07

Baseline and Changes From Baseline in Platelet Counts (x 10^9 c/L) During the ST + LT Period

(NCT00121641)
Timeframe: Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 30, 37, 50, 63, 76, 89, 102, 115, 128, 141, 154, 167, 180, 193, 206

,,,
Interventionx 10^9 c/L (Mean)
Baseline (BL) (Week 0) (n=101, 106, 96, 94)Change from BL at Week 2 (n=92, 96, 85, 82)Change from BL at Week 4 (n=88, 97, 90, 90)Change from BL at Week 6 (n=88, 93, 84, 81)Change from BL at Week 8 (n=86, 85, 86, 77)Change from BL at Week 10 (n=68, 75, 67, 62)Change from BL at Week 12 (n=83, 84, 85, 82)Change from BL at Week 14 (n=72, 79, 77, 74)Change from BL at Week 16 (n=86, 88, 81, 69)Change from BL at Week 18 (n=77, 71, 79, 70)Change from BL at Week 20 (n=78, 78, 72, 70)Change from BL at Week 22 (n=74, 72, 73, 62)Change from BL at Week 24 (n=80, 76, 73, 72)Change from BL at Week 30 (n=73, 74, 74, 67)Change from BL at Week 37 (n=70, 68, 66, 59)Change from BL at Week 50 (n=66, 67, 66, 59)Change from BL at Week 63 (n=59, 64, 65, 54)Change from BL at Week 76 (n=50, 58, 61, 49)Change from BL at Week 89 (n=47, 56, 54, 42)Change from BL at Week 102 (n=39, 47, 49, 39)Change from BL at Week 115 (n=33, 41, 41, 34)Change from BL at Week 128 (n=30, 38, 39, 30)Change from BL at Week 141 (n=27, 39, 33, 27)Change from BL at Week 154 (n=25, 35, 31, 23)Change from BL at Week 167 (n=22, 32, 28, 26)Change from BL at Week 180 (n=20, 27, 27, 25)Change from BL at Week 193 (n=17, 25, 25, 22)Change from BL at Week 206 (n=15, 21, 23, 21)
Placebo259.89.511.39.54.07.14.05.23.25.8-1.35.0-3.04.50.16.610.21.22.79.79.22.6-1.38.84.34.0-12.0-6.1
Saxagliptin 10 mg261.62.25.6-0.2-4.3-4.4-4.8-3.7-6.0-2.7-8.3-5.4-15.5-9.9-15.6-11.5-6.3-6.0-6.7-4.8-12.0-2.6-0.3-2.9-14.6-17.3-13.46.2
Saxagliptin 2.5 mg251.11.811.24.30.4-0.8-6.31.2-2.3-1.1-1.90.3-7.1-2.0-14.3-2.5-3.1-2.03.53.25.03.8-1.15.0-18.0-11.1-13.6-2.6
Saxagliptin 5 mg253.14.48.64.31.03.0-1.33.21.12.0-4.8-2.5-6.0-3.3-8.1-5.6-3.4-1.51.9-2.3-8.8-2.1-4.65.8-0.1-24.0-13.4-18.7

Baseline and Changes From Baseline in Red Blood Cell Counts (x 10^6 c/µL) During the ST + LT Period

(NCT00121641)
Timeframe: Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 30, 37, 50, 63, 76, 89, 102, 115, 128, 141, 154, 167, 180, 193, 206

,,,
Interventionx 10^6 c/µL (Mean)
Baseline (BL) (Week 0) (n=102, 106, 98, 94)Change from BL at Week 2 (n=95,100, 93, 87Change from BL at Week 4 (n=92, 99, 91, 91)Change from BL at Week 6 (n=91, 96, 87, 82)Change from BL at Week 8 (n=92, 90, 91, 79)Change from BL at Week 10 (n=70, 76, 69, 63)Change from BL at Week 12 (n=85, 88, 87, 82)Change from BL at Week 14 (n=76, 80, 81, 75)Change from BL at Week 16 (n=90, 91, 83, 71)Change from BL at Week 18 (n=78, 75, 82, 71)Change from BL at Week 20 (n=83, 80, 78, 72)Change from BL at Week 22 (n=78, 74, 76, 65)Change from BL at Week 24 (n=83, 82, 78, 74)Change from BL at Week 30 (n=77, 78, 79, 67)Change from BL at Week 37 (n=75, 73, 70, 62)Change from BL at Week 50 (n=67, 71, 71, 61)Change from BL at Week 63 (n=61, 66, 67, 55)Change from BL at Week 76 (n=51, 59, 63, 49)Change from BL at Week 89 (n=49, 58, 56, 42)Change from BL at Week 102 (n=40, 49, 51, 40)Change from BL at Week 115 (n=34, 43, 43, 35)Change from BL at Week 128 (n=30, 40, 40, 30)Change from BL at Week 141 (n=28, 39, 34, 28)Change from BL at Week 154 (n=26, 35, 31, 24)Change from BL at Week 167 (n=24, 33, 30, 26)Change from BL at Week 180 (n=21, 28, 28, 26)Change from BL at Week 193 (n=19, 26, 26, 23)Change from BL at Week 206 (n=17, 22, 24, 21)
Placebo4.82-0.050.040.020.050.070.080.040.060.04-0.01-0.01-0.01-0.03-0.090.010.05-0.03-0.07-0.13-0.06-0.10-0.11-0.09-0.10-0.17-0.10-0.08
Saxagliptin 10 mg4.82-0.08-0.020.000.03-0.020.070.040.080.050.01-0.05-0.03-0.010.040.020.080.00-0.01-0.03-0.02-0.04-0.02-0.08-0.01-0.01-0.020.06
Saxagliptin 2.5 mg4.80-0.06-0.010.000.050.050.050.050.060.010.03-0.01-0.040.00-0.04-0.020.00-0.07-0.04-0.10-0.04-0.05-0.10-0.13-0.11-0.05-0.05-0.03
Saxagliptin 5 mg4.80-0.04-0.040.020.03-0.030.030.030.080.040.02-0.01-0.04-0.07-0.040.04-0.01-0.07-0.06-0.03-0.01-0.07-0.13-0.13-0.04-0.08-0.06-0.06

Baseline and Changes From Baseline in White Blood Cell Counts (x 10^3 c/µL) During the ST + LT Period

(NCT00121641)
Timeframe: Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 30, 37, 50, 63, 76, 89, 102, 115, 128, 141, 154, 167, 180, 193, 206

,,,
Interventionx 10^3 c/µL (Mean)
Baseline (BL) (Week 0) (n=102, 106, 98, 94)Change from BL at Week 2 (n=95, 99, 92, 86)Change from BL at Week 4 (n=92, 99, 90, 90)Change from BL at Week 6 (n=89, 95, 87, 82)Change from BL at Week 8 (n=91, 89, 90, 79)Change from BL at Week 10 (n=68, 76, 69, 63)Change from BL at Week 12 (n=83, 88, 87, 82)Change from BL at Week 14 (n=76, 78, 80, 75)Change from BL at Week 16 (n=90, 91, 83, 71)Change from BL at Week 18 (n=78, 75, 82, 71)Change from BL at Week 20 (n=83, 79, 78, 72)Change from BL at Week 22 (n=77, 74, 76, 65)Change from BL at Week 24 (n=83, 82, 78, 74)Change from BL at Week 30 (n=77, 78, 79, 67)Change from BL at Week 37 (n=74, 73, 70, 62)Change from BL at Week 50 (n=67, 69, 71, 61)Change from BL at Week 63 (n=60, 66, 67, 55)Change from BL at Week 76 (n=51, 58, 63, 49)Change from BL at Week 89 (n=48, 58, 56, 42)Change from BL at Week 102 (n=39, 47, 51, 40)Change from BL at Week 115 (n=34, 43, 42, 34)Change from BL at Week 128 (n=30, 40, 40, 29)Change from BL at Week 141 (n=28, 39, 34, 28)Change from BL at Week 154 (n=26, 34, 31, 24)Change from BL at Week 167 (n=24, 33, 30, 25)Change from BL at Week 180 (n=21, 28, 28, 26)Change from BL at Week 193 (n=19, 26, 26, 23)Change from BL at Week 206 (n=17, 22, 23, 21)
Placebo6.79-0.230.170.090.160.530.260.560.190.320.020.45-0.06-0.030.140.290.06-0.20-0.18-0.090.440.220.510.380.350.650.190.38
Saxagliptin 10 mg6.82-0.14-0.16-0.18-0.170.120.050.220.040.420.010.440.080.280.12-0.03-0.04-0.07-0.100.100.110.440.440.300.270.590.601.01
Saxagliptin 2.5 mg6.71-0.110.060.01-0.020.32-0.000.330.240.370.290.660.100.150.210.010.120.030.510.160.240.580.350.12-0.220.130.340.01
Saxagliptin 5 mg6.750.050.050.100.180.550.090.710.540.820.290.720.470.330.420.330.200.230.170.440.930.660.780.440.440.300.020.55

Baseline Demographic Characteristics - Summary for ST + LT Treatment Period - Open-Label Cohort

This cohort represents a different population (screening A1C > 10.0% and ≤ 12.0%) than the double-blind cohort, and was presented separately in the study report. (NCT00121641)
Timeframe: Baseline

Interventionparticipants (Number)
Age <65 yearsAge >=65 yearsAge >=75 yearsGender, MaleGender, FemaleAge =<50 years, females onlyAge >50 years, females onlyRace, WhiteRace, Black/African AmericanRace, AsianRace, OtherEthnicity, Hispanic/LatinoEthnicity, Not Hispanic/LatinoEthnicity, Not ReportedBody Mass Index <30%Body Mass Index >=30%
Open-Label Treatment Cohort (Direct Enrollees)642032341915613111337162244

Changes From Baseline in Diastolic Blood Pressure During the ST + LT Period

(NCT00121641)
Timeframe: Baseline, Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 30, 37, 50, 63, 76, 89, 102, 115, 128, 141, 154, 167, 180, 193, 206

,,,
InterventionmmHg (Mean)
Change from BL at Week 2 (n=96, 100, 94, 89)Change from BL at Week 4 (n=96, 100, 92, 91)Change from BL at Week 6 (n=91, 98, 88, 84)Change from BL at Week 8 (n=94, 91, 91, 80)Change from BL at Week 10 (n=51, 66, 51, 50)Change from BL at Week 12 (n=82, 83, 87, 79)Change from BL at Week 14 (n=65, 72, 66, 62)Change from BL at Week 16 (n=87, 87, 81, 72)Change from BL at Week 18 (n=73, 69, 76, 66)Change from BL at Week 20 (n=84, 80, 76, 73)Change from BL at Week 22 (n=78, 73, 76, 64)Change from BL at Week 24 (n=84, 83, 77, 75)Change from BL at Week 30 (n=79, 78, 79, 66)Change from BL at Week 37 (n=77, 74, 71, 66)Change from BL at Week 50 (n=70, 73, 73, 62)Change from BL at Week 63 (n=61, 66, 69, 56)Change from BL at Week 76 (n=53, 59, 64, 50)Change from BL at Week 89 (n=49, 58, 56, 44)Change from BL at Week 102 (n=42, 51, 51, 42)Change from BL at Week 115 (n=34, 43, 43, 37)Change from BL at Week 128 (n=31, 40, 41, 31)Change from BL at Week 141 (n=29, 40, 35, 29)Change from BL at Week 154 (n=27, 36, 33, 27)Change from BL at Week 167 (n=24, 33, 30, 27)Change from BL at Week 180 (n=21, 28, 28, 27)Change from BL at Week 193 (n=19, 26, 27, 24)Change from BL at Week 206 (n=17, 24, 24, 23)
Placebo-1.5-1.8-1.9-2.4-3.4-1.8-2.7-2.1-2.1-2.2-1.7-3.4-2.8-2.0-0.6-0.5-0.3-0.1-1.2-1.01.01.31.3-1.1-0.8-0.2-0.2
Saxagliptin 10 mg-0.50.3-0.8-0.7-1.3-0.7-2.4-0.1-1.9-1.9-2.5-2.3-0.3-0.6-0.3-0.00.1-1.6-0.4-1.11.11.12.52.40.50.51.9
Saxagliptin 2.5 mg-0.0-1.4-1.5-1.4-0.8-1.3-2.5-1.5-2.3-2.2-3.0-1.5-1.4-0.4-1.7-0.1-1.60.4-1.1-0.9-1.80.91.20.81.40.80.3
Saxagliptin 5 mg-1.2-1.1-0.9-0.9-1.1-2.0-2.4-0.5-1.6-1.8-2.0-1.7-2.2-1.70.3-0.4-2.0-2.1-2.0-2.7-3.7-2.0-0.80.3-2.0-1.6-0.6

Changes From Baseline in Diastolic Blood Pressure During the ST + LT Period - Open Label Cohort

(NCT00121641)
Timeframe: Baseline, Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 30, 37, 50, 63, 76, 89, 102, 115, 128, 141, 154, 167

InterventionmmHg (Mean)
Change from BL at Week 2 (n=62)Change from BL at Week 4 (n=59)Change from BL at Week 6 (n=60)Change from BL at Week 8 (n=49)Change from BL at Week 10 (n=24)Change from BL at Week 12 (n=47)Change from BL at Week 14 (n=35)Change from BL at Week 16 (n=46)Change from BL at Week 18 (n=42)Change from BL at Week 20 (n=45)Change from BL at Week 22 (n=44)Change from BL at Week 24 (n=44)Change from BL at Week 30 (n=40)Change from BL at Week 37 (n=35)Change from BL at Week 50 (n=36)Change from BL at Week 63 (n=26)Change from BL at Week 76 (n=24)Change from BL at Week 89 (n=23)Change from BL at Week 102 (n=15)Change from BL at Week 115 (n=13)Change from BL at Week 128 (n=11)Change from BL at Week 141 (n=10)Change from BL at Week 154 (n=10)Change from BL at Week 167 (n=10)
Open-Label Treatment Cohort (Direct Enrollees)-3.7-1.7-2.8-2.0-1.0-3.7-4.5-2.8-3.3-2.1-2.8-3.4-3.8-2.0-1.3-0.9-1.0-2.61.0-4.1-3.7-6.0-0.5-2.5

Changes From Baseline in Heart Rate During the ST + LT Period

(NCT00121641)
Timeframe: Baseline, Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 30, 37, 50, 63, 76, 89, 102, 115, 128, 141, 154, 167, 180, 193, 206

,,,
Interventionbeats per minute (Mean)
Change from BL at Week 2 (n=96, 100, 94, 89)Change from BL at Week 4 (n=96, 100, 92, 91)Change from BL at Week 6 (n=91, 98, 88, 84)Change from BL at Week 8 (n=94, 91, 91, 80)Change from BL at Week 10 (n=51, 66, 51, 49)Change from BL at Week 12 (n=82, 83, 87, 79)Change from BL at Week 14 (n=65, 72, 65, 62)Change from BL at Week 16 (n=87, 87, 81, 72)Change from BL at Week 18 (n=73, 69, 76, 66)Change from BL at Week 20 (n=84, 80, 76, 73)Change from BL at Week 22 (n=78, 73, 76, 64)Change from BL at Week 24 (n=84, 83, 77, 75)Change from BL at Week 30 (n=79, 78, 79, 66)Change from BL at Week 37 (n=77, 74, 71, 66)Change from BL at Week 50 (n=70, 73, 73, 62)Change from BL at Week 63 (n=62, 66, 69, 56)Change from BL at Week 76 (n=53, 59, 64, 50)Change from BL at Week 89 (n=49, 58, 56, 44)Change from BL at Week 102 (n=42, 51, 51, 42)Change from BL at Week 115 (n=34, 43, 43, 37)Change from BL at Week 128 (n=31, 40, 41, 31)Change from BL at Week 141 (n=29, 40, 35, 29)Change from BL at Week 154 (n=27, 36, 33, 27)Change from BL at Week 167 (n=24, 33, 30, 27)Change from BL at Week 180 (n=21, 28, 28, 27)Change from BL at Week 193 (n=19, 26, 27, 24)Change from BL at Week 206 (n=17, 24, 24, 23)
Placebo0.3-0.11.4-0.20.10.81.9-0.12.60.81.5-0.4-1.2-0.9-0.20.60.2-0.3-0.00.81.70.9-0.60.5-1.21.1-0.8
Saxagliptin 10 mg0.20.7-0.60.2-1.00.50.6-0.11.51.30.9-0.7-0.70.5-0.20.90.4-0.9-0.11.0-0.7-0.6-1.3-2.1-2.0-2.40.0
Saxagliptin 2.5 mg-0.10.2-1.5-0.5-0.20.30.1-0.8-0.01.30.1-0.3-0.1-0.4-0.1-0.4-0.3-0.5-2.8-3.2-2.1-2.8-2.0-5.1-3.1-4.6-5.3
Saxagliptin 5 mg-0.5-1.1-0.6-0.9-1.5-1.2-0.5-1.5-0.8-1.5-0.30.1-1.2-1.4-0.7-2.5-3.3-1.5-1.5-2.3-4.5-3.5-2.6-0.8-5.3-4.2-2.6

Changes From Baseline in Heart Rate During the ST + LT Period - Open Label Cohort

(NCT00121641)
Timeframe: Baseline, Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 30, 37, 50, 63, 76, 89, 102, 115, 128, 141, 154, 167

Interventionbeats per minute (Mean)
Change from BL at Week 2 (n=62)Change from BL at Week 4 (n=59)Change from BL at Week 6 (n=60)Change from BL at Week 8 (n=49)Change from BL at Week 10 (n=23)Change from BL at Week 12 (n=47)Change from BL at Week 14 (n=34)Change from BL at Week 16 (n=46)Change from BL at Week 18 (n=42)Change from BL at Week 20 (n=45)Change from BL at Week 22 (n=43)Change from BL at Week 24 (n=44)Change from BL at Week 30 (n=40)Change from BL at Week 37 (n=35)Change from BL at Week 50 (n=36)Change from BL at Week 63 (n=26)Change from BL at Week 76 (n=24)Change from BL at Week 89 (n=23)Change from BL at Week 102 (n=15)Change from BL at Week 115 (n=13)Change from BL at Week 128 (n=11)Change from BL at Week 141 (n=10)Change from BL at Week 154 (n=10)Change from BL at Week 167 (n=10)
Open-Label Treatment Cohort (Direct Enrollees)-0.8-0.4-0.3-0.7-1.8-3.0-2.0-0.7-2.01.6-0.4-0.40.6-1.6-2.9-3.0-0.4-1.3-0.31.7-1.6-3.4-1.5-1.9

Changes From Baseline in Systolic Blood Pressure During the ST + LT Period

(NCT00121641)
Timeframe: Baseline, Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 30, 37, 50, 63, 76, 89, 102, 115, 128, 141, 154, 167, 180, 193, 206

,,,
InterventionmmHg (Mean)
Change from BL at Week 2 (n=96, 100, 94, 89)Change from BL at Week 4 (n=96, 100, 92, 91)Change from BL at Week 6 (n=91, 98, 88, 84)Change from BL at Week 8 (n=94, 91, 91, 80)Change from BL at Week 10 (n=51, 66, 51, 50)Change from BL at Week 12 (n=82, 83, 87, 79)Change from BL at Week 14 (n=65, 72, 66, 62)Change from BL at Week 16 (n=87, 87, 81, 72)Change from BL at Week 18 (n=73, 69, 76, 66)Change from BL at Week 20 (n=84, 80, 76, 73)Change from BL at Week 22 (n=78, 73, 76, 64)Change from BL at Week 24 (n=84, 83, 77, 75)Change from BL at Week 30 (n=79, 78, 79, 66)Change from BL at Week 37 (n=77, 74, 71, 66)Change from BL at Week 50 (n=70, 73, 73, 62)Change from BL at Week 63 (n=62, 66, 69, 56)Change from BL at Week 76 (n=53, 59, 64, 50)Change from BL at Week 89 (n=49, 58, 56, 44)Change from BL at Week 102 (n=42, 47, 50, 40)Change from BL at Week 115 (n=34, 43, 43, 37)Change from BL at Week 128 (n=31, 40, 41, 31)Change from BL at Week 141 (n=29, 40, 35, 29)Change from BL at Week 154 (n=27, 36, 33, 27)Change from BL at Week 167 (n=24, 33, 30, 27)Change from BL at Week 180 (n=21, 28, 28, 27)Change from BL at Week 193 (n=19, 26, 27, 24)Change from BL at Week 206 (n=17, 24, 24, 23)
Placebo-3.1-4.3-4.5-5.5-6.1-3.2-1.9-2.1-4.7-4.9-3.9-6.3-5.4-3.6-0.4-2.4-0.9-2.2-1.00.91.1-1.42.3-0.6-0.8-2.60.7
Saxagliptin 10 mg-2.3-2.3-3.5-4.0-5.0-2.8-6.0-3.8-4.3-3.3-5.9-6.2-3.9-5.2-3.3-1.1-3.1-5.4-2.9-1.60.00.33.54.00.90.02.3
Saxagliptin 2.5 mg-1.0-1.9-1.5-3.0-3.6-3.3-4.9-3.2-5.1-5.0-6.1-2.8-3.6-3.0-2.5-1.2-2.9-2.8-0.6-2.6-5.1-1.8-0.80.70.93.44.8
Saxagliptin 5 mg-2.0-1.2-2.1-1.8-2.9-2.9-2.0-2.1-0.9-3.2-4.5-4.1-3.8-3.50.1-0.3-2.6-3.4-1.1-2.6-5.5-5.2-0.5-1.8-5.4-7.5-2.8

Changes From Baseline in Systolic Blood Pressure During the ST + LT Period - Open Label Cohort

(NCT00121641)
Timeframe: Baseline, Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 30, 37, 50, 63, 76, 89, 102, 115, 128, 141, 154, 167

InterventionmmHg (Mean)
Change from BL at Week 2 (n=62)Change from BL at Week 4 (n=59)Change from BL at Week 6 (n=60)Change from BL at Week 8 (n=49)Change from BL at Week 10 (n=24)Change from BL at Week 12 (n=47)Change from BL at Week 14 (n=35)Change from BL at Week 16 (n=46)Change from BL at Week 18 (n=42)Change from BL at Week 20 (n=45)Change from BL at Week 22 (n=44)Change from BL at Week 24 (n=44)Change from BL at Week 30 (n=40)Change from BL at Week 37 (n=35)Change from BL at Week 50 (n=36)Change from BL at Week 63 (n=26)Change from BL at Week 76 (n=24)Change from BL at Week 89 (n=23)Change from BL at Week 102 (n=15)Change from BL at Week 115 (n=13)Change from BL at Week 128 (n=11)Change from BL at Week 141 (n=10)Change from BL at Week 154 (n=10)Change from BL at Week 167 (n=10)
Open-Label Treatment Cohort (Direct Enrollees)-4.4-3.8-2.7-5.1-4.2-4.9-5.1-1.9-5.8-3.6-4.0-4.3-4.8-4.7-1.6-0.7-1.9-4.00.9-6.6-5.6-7.25.7-2.2

Electrocardiogram (ECG) Tracings - Shift Table From Baseline (BL) to Selected Visits During ST + LT Treatment Period

The normality/abnormality of the ECG tracing was determined by the investigator. (NCT00121641)
Timeframe: Baseline, Weeks 12, 24, 76, 102, 154, 206

,,,
Interventionparticipants (Number)
Normal BL, Normal Week 12 (BL n=65, 66, 67, 47)Normal BL, Abnormal Week 12 (BL n=65, 66, 67, 47)Abnormal BL, Normal Week 12 (BL n=27, 32, 26, 43)Abnormal BL, Abnormal Week 12(BL n=27, 32, 26, 43)Normal BL, Normal Week 24 (BL n=53, 52, 47, 33)Normal BL, Abnormal Week 24 (BL n=53, 52, 47, 33)Abnormal BL, Normal Week 24 (BL n=19, 24, 21, 25)Abnormal BL, Abnormal Week 24(BL n=19, 24, 21, 25)Normal BL, Normal Week 76 (BL n=48, 49, 48, 36)Normal BL, Abnormal Week 76 (BL n=48, 49, 48, 36)Abnormal BL, Normal Week 76 (BL n=19, 23, 21, 27)Abnormal BL, Abnormal Week 76(BL n=19, 23, 21, 27)Normal BL, Normal Week 102 (BL n=32, 32, 36, 22)Normal BL, Abnormal Week 102 (BL n=32, 32, 36, 22)Abnormal BL, Normal Week 102 (BL n=12, 18, 17, 20)Abnormal BL,Abnormal Week 102(BL n=12, 18, 17, 20)Normal BL, Normal Week 154 (BL n=20, 21, 26, 15)Normal BL, Abnormal Week 154 (BL n=20, 21, 26, 15)Abnormal BL, Normal Week 154 (BL n=7, 16, 11, 13)Abnormal BL, Abnormal Week 154(BL n=7, 16, 11, 13)Normal BL, Normal Week 206 (BL n=15, 13, 20, 14)Normal BL, Abnormal Week 206 (BL n=15, 13, 20, 14)Abnormal BL, Normal Week 206 (BL n=4, 13, 8, 11)Abnormal BL, Abnormal Week 206 (BL n=4, 13, 8, 11)
Placebo434152831281730613141841191417611347
Saxagliptin 10 mg5989174349124086153151252335618244
Saxagliptin 2.5 mg57862143105143711811257481644315022
Saxagliptin 5 mg5610626448816445815266513174412121310

Electrocardiogram (ECG) Tracings - Shift Table From Baseline (BL) to Selected Visits During ST + LT Treatment Period - Open Label Cohort

The normality/abnormality of the ECG tracing was determined by the investigator. (NCT00121641)
Timeframe: Baseline, Weeks 12, 24, 76, 102, 154, 206

Interventionparticipants (Number)
Normal BL, Normal Week 12 (BL n=23)Normal BL, Abnormal Week 12 (BL n=23)Abnormal BL, Normal Week 12 (BL n=18)Abnormal BL, Abnormal Week 12 (BL n=18)Normal BL, Normal Week 24 (BL n=10)Normal BL, Abnormal Week 24 (BL n=10)Abnormal BL, Normal Week 24 (BL n=6)Abnormal BL, Abnormal Week 24(BL n=6)Normal BL, Normal Week 76 (BL n=17)Normal BL, Abnormal Week 76 (BL n=17)Abnormal BL, Normal Week 76 (BL n=13)Abnormal BL, Abnormal Week 76 (BL n=13)Normal BL, Normal Week 102 (BL n=8)Normal BL, Abnormal Week 102 (BL n=8)Abnormal BL, Normal Week 102 (BL n=4)Abnormal BL, Abnormal Week 102 (BL n=4)Normal BL, Normal Week 154 (BL n=4)Normal BL, Abnormal Week 154 (BL n=4)Abnormal BL, Normal Week 154 (BL n=2)Abnormal BL, Abnormal Week 154 (BL n=2)Normal BL, Normal Week 206 (BL n=3)Normal BL, Abnormal Week 206 (BL n=3)Abnormal BL, Normal Week 206 (BL n=1)Abnormal BL, Abnormal Week 206 (BL n=1)
Open-Label Treatment Cohort (Direct Enrollees)194513822413449621331022101

Hemoglobin A1c (A1C) Changes From Baseline at Week 24

To compare the change from baseline in HbA1c achieved with each dose of saxagliptin versus placebo in treatment naive subjects with type 2 diabetes who have inadequate glycemic control defined as A1C ≥7.0% and ≤10.0%. (NCT00121641)
Timeframe: Baseline, Week 24

,,,
InterventionPercentage of glycosylated hemoglobins (Mean)
Baseline MeanAdjusted Mean Change from Baseline
Placebo7.880.19
Saxagliptin 10 mg7.85-0.54
Saxagliptin 2.5 mg7.91-0.43
Saxagliptin 5 mg7.98-0.46

Marked Laboratory Abnormalities - During ST + LT Treatment Period

A laboratory value was considered a marked abnormality if it is outside the pre-defined criteria for marked abnormality and the on-treatment value was more extreme (farther from the limit) than the baseline value. Pre-Rx=pretreatment; ULN=upper limit of normal; ALP=alkaline phosphatase; AST=aspartate aminotransferase; ALT=alanine aminotransferase; unspec=unspecified; sodium serum low: <0.9 x Pre-Rx & <=130mEq/L / high: >1.1 x Pre-Rx & >=150mEq/L; potassium, serum low: <=0.8 x Pre-Rx & >=6.0mEq/L / high: 1.2 x Pre-Rx & >=6.0mEq/L; LLN=lower limit of normal. (NCT00121641)
Timeframe: Lab assessments taken during and up to 14 days after the last dose of study drug during the ST + LT Treatment Period. Mean duration of exposure was 109 weeks in 10 mg arm, 94.7 weeks in 2.5 mg arm, 103 weeks in 5 mg arm, and 98.4 weeks in placebo arm.

,,,
Interventionparticipants (Number)
Hemoglobin < 8 g/dL (n=101, 105, 97, 93)Hematocrit < 0.75 x pre-Rx (n=101, 105, 97, 93)Platelets < 50 x 10^9 c/L (n=100, 104, 94, 93)Platelets > 1.5 x ULN (n=100,104, 94, 93)Leukocytes < 2 x 1000 c/µL (n=101, 105, 97, 93)Neutrophils+Bands <1x1000 c/µL(n=101, 105, 97, 93)Eosinophils >0.9x1000 c/µL (n=101, 105, 97, 93)Lymphocytes <=0.75x1000 c/µL (n=101, 105, 97, 93)ALP >3 x pre-Rx and >ULN (n=101,105, 97, 94)ALP >1.5 x ULN (n=101, 105, 97, 94)AST >3 x ULN (n=101, 105, 97, 94)AST >5 x ULN (n=101, 105, 97, 94)AST >10 x ULN (n=101, 105, 97, 94)AST >20 x ULN (n=101, 105, 97, 94)ALT >3 x ULN (n=101, 105, 97, 94)ALT >5 x ULN (n=101, 105, 97, 94)ALT >10 x ULN (n=101, 105, 97, 94)ALT >20 x ULN (n=101, 105, 97, 94)Bilirubin Total >2mg/dL (n=101, 105, 97, 94)Bilirubin Total >1.5xULN (n=101, 105, 97, 94)Bilirubin Total >2xULN (n=101, 105, 97, 94)BUN >2 x pre-Rx and >ULN (n=101, 105, 97, 94)Creatinine >2.5 mg/dL (n=101, 105, 97, 94)Glucose, Serum Fasting < 50 mg/dL (n=0, 0, 0, 0)Glucose, Serum Fasting > 500 mg/dL (n=0, 0, 0, 0)Glucose, Serum Unspec. < 50 mg/dL (n=0,0,0,0)Glucose, Serum Unspec. > 500 mg/dL (n=0,0,0,0)Glucose, Plasma Fasting<50mg/dL(n=101, 104, 96,94)Glucose,Plasma Fasting>500mg/dL(n=101, 104, 96,94)Glucose, Plasma Unspec.<50mg/dL(n=102, 105, 98,95)Glucose,Plasma Unspec.>500mg/dL(n=102, 105, 98,95)Sodium,Serum Low (see above) (n=101, 105, 97, 94)Sodium,Serum High(see above) (n=101, 105, 97, 94)Potassium,Serum Low(see above)(n=101, 105, 97, 94)Potassium, Serum High(see above)(n=101,105,97,94)Chloride < 90 mEq/L (n=101, 105, 97, 94)Chloride > 120 mEq/L (n=101, 105, 97, 94)Albumin < 0.9 LLN (n=101, 105, 97, 94)Creatine Kinase > 5 x ULN (n=101, 105, 97, 94)Uric Acid > 1.5 x ULN (n=0, 0, 0, 0)Protein Urine, >=2-4 (n=99, 103, 94, 92)Blood Urine, >=2-4 (n=99, 103, 94, 92)Red Blood Cells Urine >=2-4 (n=95, 97, 89, 88)White Blood Cells Urine >=2-4 (n=95, 97, 89, 88)
Placebo00010041010000100000000000020321003100403161412
Saxagliptin 10 mg010001320110000000331100000104001010001048815
Saxagliptin 2.5 mg000100140232103110111110000107001030002085613
Saxagliptin 5 mg0000005201210021000003000000041000300040911819

Marked Laboratory Abnormalities During ST + LT Treatment Period - Open-Label Cohort

A laboratory value was considered a marked abnormality if it is outside the pre-defined criteria for marked abnormality and the on-treatment value was more extreme (farther from the limit) than the baseline value. Pre-Rx=pretreatment; ULN=upper limit of normal; ALP=alkaline phosphatase; AST=aspartate aminotransferase; ALT=alanine aminotransferase; unspec=unspecified; sodium serum low: <0.9 x Pre-Rx & <=130mEq/L / high: >1.1 x Pre-Rx & >=150mEq/L; potassium, serum low: <=0.8 x Pre-Rx & >=6.0mEq/L / high: 1.2 x Pre-Rx & >=6.0mEq/L; LLN=lower limit of normal. (NCT00121641)
Timeframe: Lab assessments taken during and up to 14 days after the last dose of study drug during the ST + LT Treatment Period. Mean duration of exposure was 34 weeks.

Interventionparticipants (Number)
Hemoglobin < 8 g/dL (n=64)Hematocrit < 0.75 x pre-Rx (n=64)Platelets < 50 x 10^9 c/L (n=64)Platelets > 1.5 x ULN (n=64)Leukocytes < 2 x 1000 c/µL (n=64)Neutrophils+Bands <1x1000 c/uL (n=64)Eosinophils >0.9x1000 c/µL (n=64)Lymphocytes <=0.75x1000 c/uL (n=64)ALP >3 x pre-Rx and >ULN (n=64)ALP >1.5 x ULN (n=64)AST >3 x ULN (n=64)AST >5 x ULN (n=64)AST >10 x ULN (n=64)AST >20 x ULN (n=64)ALT >3 x ULN (n=64)ALT >5 x ULN (n=64)ALT >10 x ULN (n=64)ALT >20 x ULN (n=64)Bilirubin Total >2mg/dL (n=64)Bilirubin Total >1.5xULN (n=64)Bilirubin Total >2xULN (n=64)BUN >2 x pre-Rx and >ULN (n=64)Creatinine >2.5 mg/dL (n=64)Glucose, Serum Fasting < 50 mg/dL (n=1)Glucose, Serum Fasting > 500 mg/dL (n=1)Glucose, Serum Unspec. < 50 mg/dL (n=1)Glucose, Serum Unspec. > 500 mg/dL (n=1)Glucose, Plasma Fasting <50 mg/dL (n=64)Glucose,Plasma Fasting >500 mg/dL (n=64)Glucose, Plasma Unspec. <50 mg/dL (n=65)Glucose,Plasma Unspec. >500 mg/dL (n=65)Sodium,Serum Low (see above) (n=65)Sodium,Serum High (see above) (n=65)Potassium,Serum Low (see above) (n=65)Potassium, Serum High (see above) (n=65)Chloride < 90 mEq/L (n=65)Chloride > 120 mEq/L (n=65)Albumin < 0.9 LLN (n=64)Creatine Kinase > 5 x ULN (n=64)Uric Acid > 1.5 x ULN (n=0)Protein Urine, >=2-4 (n=64)Blood Urine, >=2-4 (n=64)Red Blood Cells Urine >=2-4 (n=58)White Blood Cells Urine >=2-4 (n=58)
Open-Label Treatment Cohort (Direct Enrollees)00000120001000100011020000000210202100002476

Overall Summary of Adverse Events During ST+LT Treatment Period

AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event. Related events=relationship of certain, probable, possible, or missing. (NCT00121641)
Timeframe: AEs: up to last treatment day + 1 day or last visit; SAEs: up to last treatment day + 30 days or last visit + 30 days. Mean duration of exposure was 109 weeks in 10 mg arm, 94.7 weeks in 2.5 mg arm, 103 weeks in 5 mg arm, and 98.4 weeks in placebo arm.

,,,
Interventionparticipants (Number)
At Least 1 AEAt Least 1 Related AEDeathsAt Least 1 SAEAt Least 1 Related SAEDiscontinuations Due to SAEsDiscontinuations Due to AEs
Placebo7725111015
Saxagliptin 10 mg8725090310
Saxagliptin 2.5 mg8925011069
Saxagliptin 5 mg94230181210

Overall Summary of Adverse Events During ST+LT Treatment Period - Open-Label Cohort

AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event. Related events=relationship of certain, probable, possible, or missing. (NCT00121641)
Timeframe: AEs: up to last treatment day + 1 day or last visit; SAEs: up to last treatment day + 30 days or last visit + 30 days. Mean duration of exposure was 34 weeks.

Interventionparticipants (Number)
At Least 1 AEAt Least 1 Related AEDeathsAt Least 1 SAEAt Least 1 Related SAEDiscontinuations Due to SAEsDiscontinuations Due to AEs
Open-Label Treatment Cohort (Direct Enrollees)49906025

Drug-specific Parasite Reduction Ratio (PRR48) of ACT-451840 Over 48 Hours Using a New Approach

"After the blood stage Plasmodium falciparum challenge (BSPC), malaria parasitemia was measured by polymerase chain reaction (PCR) in regularly collected blood samples.~The subject-specific and drug-specific parasite reduction rates over a 48 h period (PRR48) were calculated following the data-driven method by Marquart et al. (2015), removing potential lag and tail phases prior to log-linear regression modeling." (NCT02223871)
Timeframe: 48 hours after study drug administration

InterventionRatio (Mean)
ACT-451840 500 mg73.6

Drug-specific Parasite Reduction Ratio (PRR48) of ACT-451840 Over 48 Hours Using a Standardized Approach

"After the blood stage Plasmodium falciparum challenge (BSPC), malaria parasitemia was measured by polymerase chain reaction (PCR) in regularly collected blood samples.~The subject-specific and drug-specific parasite reduction rates over a 48 h period (PRR48) were calculated using an objective standardized approach (observed data over 48 h)" (NCT02223871)
Timeframe: 48 hours after study drug administration

InterventionRatio (Mean)
ACT-451840 500 mg234.5

Maximum Plasma Concentration (Cmax) of ACT-451840

Cmax was directly derived from the plasma concentrations-time curves of ACT-451840. Blood samples for pharmacokinetic characterization were drawn at pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 20, 24, 48, 72, 96, and 144 hours post-dose. (NCT02223871)
Timeframe: From pre-dose to 144 hours after study drug adminsitration

Interventionng/mL (Geometric Mean)
ACT-451840 500 mg121.7

Terminal Half-life [t(1/2)]

Blood samples for pharmacokinetic characterization were drawn at pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 20, 24, 48, 72, 96, and 144 hours post-dose (NCT02223871)
Timeframe: From pre-dose to144 hours after study drug adminsitration

InterventionHours (Geometric Mean)
ACT-451840 500 mg36.4

Time to Reach Maximum Plasma Concentration (Tmax) of ACT-451840

tmax was directly derived from the plasma concentration-time curves of ACT-451840. Blood samples for pharmacokinetic characterization were drawn at pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 20, 24, 48, 72, 96, and 144 hours post-dose. (NCT02223871)
Timeframe: From pre-dose to144 hours after study drug administration

InterventionHours (Median)
ACT-451840 500 mg4.0

Areas Under the Plasma Concentration-time Curve of ACT-451840

"Two AUCs were calculated using non-compartmental analysis: AUC(0-t) from pre-dose to last time-point of measure and AUC(0-inf) from pre-dose and extrapolated to infinity.~Blood samples for pharmacokinetic characterization were drawn at pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 20, 24, 48, 72, 96, and 144 hours post-dose" (NCT02223871)
Timeframe: From pre-dose to144 hours after study drug administration

Interventionng*h/mL (Geometric Mean)
AUC(0-t)AUC(0-inf)
ACT-451840 500 mg1254.81284.4

Change From Baseline in Blood Pressure to End of Study (EOS)

Vital signs, including diastolic and systolic blood pressure (DBP/SBP), were measured at each outpatient visit up to 7 days after ACT-451840 administration, every day during confinement or when malaria symptoms were presented and at the end of study visit (EOS). Other measures were performed if required. (NCT02223871)
Timeframe: Day 28 (EOS)

InterventionmmHg (Median)
SBP at baseline (Day 0)SBP at EOS (Day 28)Change from Day 0 to Day 28 in SBPDBP at baseline (Day 0)DBP at EOS (Day 28)Change from Day 0 to Day 28 in DBP
ACT-451840 500 mg121.0125.52.566.070.50.5

Change From Baseline in Body Temperature up to End of Study (EOS)

Body temperature was measured orally (NCT02223871)
Timeframe: Day 28 (EOS)

InterventionDegree Celsius (Median)
Temperature at baseline (Day 0)Temperature at EOS (Day 28)Change from Day 0 to Day 28 in temperature
ACT-451840 500 mg36.335.9-0.2

Change From Baseline in Respiratory Rate to End of Study (EOS)

(NCT02223871)
Timeframe: Day 28 (EOS)

InterventionBreaths/min (Median)
Respiratory rate at baseline (Day 0)Respiratory rate at EOS (Day 28)Change from Day 0 to Day 28 in respiratory rate
ACT-451840 500 mg14161.5

Incidence of Complicated Malaria in Infants

Any treatment for malaria meeting criteria for severe malaria or danger signs (NCT02163447)
Timeframe: Birth up to 24 months of age or early study termination

InterventionEvents per person years (Number)
3 Dose SP Pregnancy / 3 Monthly DP Infancy0.022
3 Dose DP Pregnancy / 3 Monthly DP Infancy0.024
3 Dose DP Pregnancy / Monthly DP Infancy0.000
Monthly DP Pregnancy / 3 Monthly DP Infancy0.035
Monthly DP Pregnancy / Monthly DP Infancy0.000

Incidence of Hospital Admissions in Infants

Admission to a hospital for pediatric inpatient care for any reason (NCT02163447)
Timeframe: Birth up to 24 months of age or early study termination

InterventionEvents per person years (Number)
3 Dose SP Pregnancy / 3 Monthly DP Infancy0.043
3 Dose DP Pregnancy / 3 Monthly DP Infancy0.036
3 Dose DP Pregnancy / Monthly DP Infancy0.089
Monthly DP Pregnancy / 3 Monthly DP Infancy0.082
Monthly DP Pregnancy / Monthly DP Infancy0.043

Incidence of Malaria in Infants

Incident cases will include all treatments for malaria not proceeded by another treatment in the previous 14 days. The study investigators will test the hypotheses that A) infants born to mothers randomized to receive IPTp with 3 dose DP or monthly DP will have a lower incidence of malaria during the first 24 months of life compared to infants born to mothers who were randomized to receive IPTp with 3 doses of SP, and, B) infants randomized to receive monthly DP between 2-24 months of age will have a lower incidence of malaria between 24-36 months of age after the intervention is stopped compared to infants randomized q 3 monthly DP between 2-24 months of age. (NCT02163447)
Timeframe: Time at risk will begin at 24 months of age and will end when study participants reaches 36 months of age or termination

InterventionEvents per person years (Number)
3 Dose SP Pregnancy / 3 Monthly DP Infancy0.87
3 Dose DP Pregnancy / 3 Monthly DP Infancy0.88
3 Dose DP Pregnancy / Monthly DP Infancy0.83
Monthly DP Pregnancy / 3 Monthly DP Infancy1.24
Monthly DP Pregnancy / Monthly DP Infancy0.64

Incidence of Malaria in Infants

Incident cases will include all treatments for malaria not proceeded by another treatment in the previous 14 days. The study investigators will test the hypotheses that A) infants born to mothers randomized to receive IPTp with 3 dose DP or monthly DP will have a lower incidence of malaria during the first 24 months of life compared to infants born to mothers who were randomized to receive IPTp with 3 doses of SP, and, B) infants randomized to receive monthly DP between 2-24 months of age will have a lower incidence of malaria between 24-36 months of age after the intervention is stopped compared to infants randomized q 3 monthly DP between 2-24 months of age. (NCT02163447)
Timeframe: Time at risk will begin at birth and will end when study participants reaches 24 months of age or early study termination (if prior to 24 months of age)

InterventionEvents per person years (Number)
3 Dose SP Pregnancy / 3 Monthly DP Infancy0.26
3 Dose DP Pregnancy / 3 Monthly DP Infancy0.30
3 Dose DP Pregnancy / Monthly DP Infancy0.00
Monthly DP Pregnancy / 3 Monthly DP Infancy0.43
Monthly DP Pregnancy / Monthly DP Infancy0.03

Incidence of Malaria in Pregnant Women

Incidence of malaria, defined as the number of incident episodes per time at risk. Incident cases will include all treatments for malaria not proceeded by another treatment in the previous 14 days. (NCT02163447)
Timeframe: Time at risk will begin after first dose of study drug and will end when study participants deliver or early study termination

Interventionevents per person years (Number)
Mothers - 3 Dose SP0.95
Mothers - 3 Dose DP0.31
Mothers - Monthly DP0

Number of Participants With One or More Birth Outcomes: Congenital Malformations, Spontaneous Abortion, LBW (<2500g), Still Birth, Pre-term Delivery

Congenital malformations, spontaneous abortion, LBW (<2500g), still birth, pre-term delivery (NCT02163447)
Timeframe: Delivery

InterventionParticipants (Count of Participants)
Mothers - 3 Dose SP19
Mothers - 3 Dose DP19
Mothers - Monthly DP9

Prevalence of Anemia in Pregnant Women

Prevalence of routine hemoglobin measurements < 11 g/dL (NCT02163447)
Timeframe: After first dose of study drugs up to delivery or early termination

Interventionhemoglobin measurements taken every 12wk (Number)
Mothers - 3 Dose SP94
Mothers - 3 Dose DP72
Mothers - Monthly DP61

Prevalence of Gametocytemia in Infants

Proportion of routine blood smears positive for gametocytes (NCT02163447)
Timeframe: Birth up to 24 months of age or early study termination

InterventionPositive blood smears (Number)
3 Dose SP Pregnancy / 3 Monthly DP Infancy7
3 Dose DP Pregnancy / 3 Monthly DP Infancy1
3 Dose DP Pregnancy / Monthly DP Infancy0
Monthly DP Pregnancy / 3 Monthly DP Infancy4
Monthly DP Pregnancy / Monthly DP Infancy0

Prevalence of Gametocytemia in Pregnant Women

Proportion of urgent blood smears positive for gametocytes (NCT02163447)
Timeframe: Gestational age between 12-20 weeks (at study entry) up to delivery

InterventionPositive blood smears (Number)
Mothers - 3 Dose SP4
Mothers - 3 Dose DP1
Mothers - Monthly DP3

Prevalence of Parasitemia at the Time of Monthly Routine Visits During Pregnancy

Detection of malaria parasites by LAMP during pregnancy (NCT02163447)
Timeframe: After first dose of study drug through delivery or early termination

InterventionPositive specimens (Number)
Mothers - 3 Dose SP206
Mothers - 3 Dose DP74
Mothers - Monthly DP26

Prevalence of Parasitemia in Infants

Proportion of routine monthly samples positive for parasites by LAMP. Proportion of routine samples (LAMP or blood smears) positive for asexual parasites. (NCT02163447)
Timeframe: Birth up to 24 months of age or early study termination

InterventionPositive blood smears (Number)
3 Dose SP Pregnancy / 3 Monthly DP Infancy59
3 Dose DP Pregnancy / 3 Monthly DP Infancy25
3 Dose DP Pregnancy / Monthly DP Infancy7
Monthly DP Pregnancy / 3 Monthly DP Infancy52
Monthly DP Pregnancy / Monthly DP Infancy4

Prevalence of Placental Malaria

Prevalence of placental malaria based on placental histopathology dichotomized into any evidence of placental infection (parasites or pigment) vs. no evidence and by histopathology as a categorical variable based on Rogerson et al criteria. (NCT02163447)
Timeframe: Delivery

InterventionParticipants (Count of Participants)
Mothers - 3 Dose SP49
Mothers - 3 Dose DP30
Mothers - Monthly DP26

Number of Participants With Blood Samples Positive for Parasites by Microscopy or LAMP

Prevalence of placental blood samples positive for parasites by microscopy or LAMP (NCT02163447)
Timeframe: Delivery

,,
InterventionParticipants (Count of Participants)
Micropscopic assessment of placental bloodLAMP assessment of placental blood
Mothers - 3 Dose DP33
Mothers - 3 Dose SP519
Mothers - Monthly DP02

Number of Participants With Maternal Blood Samples Positive for Parasites by Microscopy and LAMP at Delivery

Prevalence of maternal parasitemia at delivery by microscopy and LAMP (NCT02163447)
Timeframe: At delivery

,,
Interventionparticipants (Number)
MicroscopyLAMP
Mothers - 3 Dose DP13
Mothers - 3 Dose SP525
Mothers - Monthly DP01

Incidence of Clinical Episodes of Malaria

Passive surveillance to detect episode of fever (temperature > 37.5 C), or a history of fever within the past 48 hours, that is severe enough to require treatment at a health centre and which is accompanied by a positive blood film with a parasite density of 5,000 per µl or more (NCT03143218)
Timeframe: Passive surveillance of clinical episodes of malaria within the study area starting from the date of the first dose of study vaccines (April/May 2017) until 31st March 2020- a total of 36 months.

InterventionNo. of events/1000 person years at risk (Number)
SMC With SP+AQ304.8
RTS,S/AS01278.2
RTS,S/AS01 PLUS SMC With SP+AQ113.3

Reviews

9 reviews available for pyrimethamine and Parasitemia

ArticleYear
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    The Cochrane database of systematic reviews, 2022, 02-01, Volume: 2, Issue:2022

    Topics: Anemia; Antimalarials; Birth Weight; Child; Child, Preschool; Dietary Supplements; Female; Folic Aci

2022
Drug treatment and prevention of malaria in pregnancy: a critical review of the guidelines.
    Malaria journal, 2021, Jan-23, Volume: 20, Issue:1

    Topics: Adult; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artesunate; Chloroquine

2021
Intermittent preventive treatment for malaria in infants.
    The Cochrane database of systematic reviews, 2021, 07-17, Volume: 7

    Topics: Africa South of the Sahara; Amodiaquine; Antimalarials; Artemisinins; Bias; Confidence Intervals; Di

2021
Mefloquine for preventing malaria in pregnant women.
    The Cochrane database of systematic reviews, 2018, 03-21, Volume: 3

    Topics: Abortion, Spontaneous; Africa South of the Sahara; Antimalarials; Dizziness; Drug Combinations; Drug

2018
Mefloquine for preventing malaria in pregnant women.
    The Cochrane database of systematic reviews, 2018, 11-14, Volume: 11

    Topics: Anemia; Antimalarials; Drug Combinations; Drug Therapy, Combination; Female; HIV Seronegativity; Hum

2018
A systematic review and meta-analysis of dihydroartemisinin-piperaquine versus sulphadoxine-pyrimethamine for malaria prevention in pregnancy.
    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2019, Volume: 146, Issue:1

    Topics: Adult; Antimalarials; Artemisinins; Drug Combinations; Drug Therapy, Combination; Female; Humans; Ma

2019
Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria.
    The Cochrane database of systematic reviews, 2013, Oct-25, Issue:10

    Topics: Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Drug Combinations; Drug Resi

2013
Pregnancy-associated malaria and malaria in infants: an old problem with present consequences.
    Malaria journal, 2014, Jul-11, Volume: 13

    Topics: Adult; Africa South of the Sahara; Antimalarials; Comorbidity; Complement Activation; Developmental

2014
Artemisinin-based combination therapy for treating uncomplicated malaria.
    The Cochrane database of systematic reviews, 2009, Jul-08, Issue:3

    Topics: Antimalarials; Artemisinins; Artesunate; Drug Combinations; Drug Therapy, Combination; Ethanolamines

2009
Artemisinin-based combination therapy for treating uncomplicated malaria.
    The Cochrane database of systematic reviews, 2009, Jul-08, Issue:3

    Topics: Antimalarials; Artemisinins; Artesunate; Drug Combinations; Drug Therapy, Combination; Ethanolamines

2009
Artemisinin-based combination therapy for treating uncomplicated malaria.
    The Cochrane database of systematic reviews, 2009, Jul-08, Issue:3

    Topics: Antimalarials; Artemisinins; Artesunate; Drug Combinations; Drug Therapy, Combination; Ethanolamines

2009
Artemisinin-based combination therapy for treating uncomplicated malaria.
    The Cochrane database of systematic reviews, 2009, Jul-08, Issue:3

    Topics: Antimalarials; Artemisinins; Artesunate; Drug Combinations; Drug Therapy, Combination; Ethanolamines

2009
Artemisinin-based combination therapy for treating uncomplicated malaria.
    The Cochrane database of systematic reviews, 2009, Jul-08, Issue:3

    Topics: Antimalarials; Artemisinins; Artesunate; Drug Combinations; Drug Therapy, Combination; Ethanolamines

2009
Artemisinin-based combination therapy for treating uncomplicated malaria.
    The Cochrane database of systematic reviews, 2009, Jul-08, Issue:3

    Topics: Antimalarials; Artemisinins; Artesunate; Drug Combinations; Drug Therapy, Combination; Ethanolamines

2009
Artemisinin-based combination therapy for treating uncomplicated malaria.
    The Cochrane database of systematic reviews, 2009, Jul-08, Issue:3

    Topics: Antimalarials; Artemisinins; Artesunate; Drug Combinations; Drug Therapy, Combination; Ethanolamines

2009
Artemisinin-based combination therapy for treating uncomplicated malaria.
    The Cochrane database of systematic reviews, 2009, Jul-08, Issue:3

    Topics: Antimalarials; Artemisinins; Artesunate; Drug Combinations; Drug Therapy, Combination; Ethanolamines

2009
Artemisinin-based combination therapy for treating uncomplicated malaria.
    The Cochrane database of systematic reviews, 2009, Jul-08, Issue:3

    Topics: Antimalarials; Artemisinins; Artesunate; Drug Combinations; Drug Therapy, Combination; Ethanolamines

2009

Trials

78 trials available for pyrimethamine and Parasitemia

ArticleYear
The Impact of Antenatal Azithromycin and Monthly Sulfadoxine-Pyrimethamine on Maternal Malaria during Pregnancy and Fetal Growth: A Randomized Controlled Trial.
    The American journal of tropical medicine and hygiene, 2023, 04-05, Volume: 108, Issue:4

    Topics: Antimalarials; Azithromycin; Drug Combinations; Female; Fetal Development; Humans; Malaria; Parasite

2023
A Randomized Open-Label Evaluation of the Antimalarial Prophylactic Efficacy of Azithromycin-Piperaquine versus Sulfadoxine-Pyrimethamine in Pregnant Papua New Guinean Women.
    Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:10

    Topics: Adult; Antimalarials; Asymptomatic Diseases; Azithromycin; Chemoprevention; Drug Combinations; Eryth

2019
The Effect of Intermittent Preventive Treatment of Malaria During Pregnancy and Placental Malaria on Infant Risk of Malaria.
    The Journal of infectious diseases, 2022, 01-18, Volume: 225, Issue:2

    Topics: Adult; Antimalarials; Artemisinins; Drug Combinations; Female; Humans; Infant; Malaria; Malawi; Para

2022
Efficacies of DHA-PPQ and AS/SP in patients with uncomplicated Plasmodium falciparum malaria in an area of an unstable seasonal transmission in Sudan.
    Malaria journal, 2017, 04-20, Volume: 16, Issue:1

    Topics: Adolescent; Antimalarials; Artemisinins; Child; Child, Preschool; Drug Therapy, Combination; Female;

2017
Comparative study of mefloquine and sulphadoxine-pyrimethamine for malaria prevention among pregnant women with HIV in southwest Nigeria.
    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2018, Volume: 142, Issue:2

    Topics: Adult; Antimalarials; Drug Combinations; Female; HIV Infections; Humans; Malaria; Mefloquine; Nigeri

2018
Intermittent screening and treatment with artemether-lumefantrine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in pregnancy: a facility-based, open-label, non-inferiority trial in Nigeria.
    Malaria journal, 2018, Jul-06, Volume: 17, Issue:1

    Topics: Adolescent; Adult; Antimalarials; Artemether, Lumefantrine Drug Combination; Chemoprevention; Drug C

2018
Intermittent screening and treatment with artemether-lumefantrine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in pregnancy: a facility-based, open-label, non-inferiority trial in Nigeria.
    Malaria journal, 2018, Jul-06, Volume: 17, Issue:1

    Topics: Adolescent; Adult; Antimalarials; Artemether, Lumefantrine Drug Combination; Chemoprevention; Drug C

2018
Intermittent screening and treatment with artemether-lumefantrine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in pregnancy: a facility-based, open-label, non-inferiority trial in Nigeria.
    Malaria journal, 2018, Jul-06, Volume: 17, Issue:1

    Topics: Adolescent; Adult; Antimalarials; Artemether, Lumefantrine Drug Combination; Chemoprevention; Drug C

2018
Intermittent screening and treatment with artemether-lumefantrine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in pregnancy: a facility-based, open-label, non-inferiority trial in Nigeria.
    Malaria journal, 2018, Jul-06, Volume: 17, Issue:1

    Topics: Adolescent; Adult; Antimalarials; Artemether, Lumefantrine Drug Combination; Chemoprevention; Drug C

2018
A randomized controlled trial of azithromycin and sulphadoxine-pyrimethamine as prophylaxis against malaria in pregnancy among human immunodeficiency virus-positive women.
    Transactions of the Royal Society of Tropical Medicine and Hygiene, 2019, 08-01, Volume: 113, Issue:8

    Topics: Adult; Anti-Bacterial Agents; Antimalarials; Azithromycin; Drug Combinations; Drug Therapy, Combinat

2019
Nonrandomized controlled trial of artesunate plus sulfadoxine-pyrimethamine with or without primaquine for preventing posttreatment circulation of Plasmodium falciparum gametocytes.
    Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:7

    Topics: Adolescent; Adult; Antimalarials; Artemisinins; Child; Child, Preschool; Drug Combinations; Drug The

2013
Intermittent preventive treatment of malaria with sulphadoxine-pyrimethamine during pregnancy in Burkina Faso: effect of adding a third dose to the standard two-dose regimen on low birth weight, anaemia and pregnancy outcomes.
    Malaria journal, 2010, Nov-12, Volume: 9

    Topics: Adolescent; Adult; Anemia; Antimalarials; Burkina Faso; Drug Combinations; Female; Humans; Infant, L

2010
In vivo efficacy of sulphadoxine-pyrimethamine for the treatment of asymptomatic parasitaemia in pregnant women in Machinga District, Malawi.
    Malaria journal, 2015, May-13, Volume: 14

    Topics: Adolescent; Adult; Antimalarials; Asymptomatic Infections; Dihydropteroate Synthase; Drug Combinatio

2015
Evaluating the pharmacodynamic effect of antimalarial drugs in clinical trials by quantitative PCR.
    Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:7

    Topics: Adolescent; Adult; Algorithms; Antimalarials; Area Under Curve; Drug Combinations; Female; Half-Life

2015
Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy.
    The New England journal of medicine, 2016, Mar-10, Volume: 374, Issue:10

    Topics: Adolescent; Adult; Antimalarials; Artemisinins; Double-Blind Method; Drug Administration Schedule; D

2016
Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy.
    The New England journal of medicine, 2016, Mar-10, Volume: 374, Issue:10

    Topics: Adolescent; Adult; Antimalarials; Artemisinins; Double-Blind Method; Drug Administration Schedule; D

2016
Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy.
    The New England journal of medicine, 2016, Mar-10, Volume: 374, Issue:10

    Topics: Adolescent; Adult; Antimalarials; Artemisinins; Double-Blind Method; Drug Administration Schedule; D

2016
Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy.
    The New England journal of medicine, 2016, Mar-10, Volume: 374, Issue:10

    Topics: Adolescent; Adult; Antimalarials; Artemisinins; Double-Blind Method; Drug Administration Schedule; D

2016
Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy.
    The New England journal of medicine, 2016, Mar-10, Volume: 374, Issue:10

    Topics: Adolescent; Adult; Antimalarials; Artemisinins; Double-Blind Method; Drug Administration Schedule; D

2016
Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy.
    The New England journal of medicine, 2016, Mar-10, Volume: 374, Issue:10

    Topics: Adolescent; Adult; Antimalarials; Artemisinins; Double-Blind Method; Drug Administration Schedule; D

2016
Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy.
    The New England journal of medicine, 2016, Mar-10, Volume: 374, Issue:10

    Topics: Adolescent; Adult; Antimalarials; Artemisinins; Double-Blind Method; Drug Administration Schedule; D

2016
Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy.
    The New England journal of medicine, 2016, Mar-10, Volume: 374, Issue:10

    Topics: Adolescent; Adult; Antimalarials; Artemisinins; Double-Blind Method; Drug Administration Schedule; D

2016
Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy.
    The New England journal of medicine, 2016, Mar-10, Volume: 374, Issue:10

    Topics: Adolescent; Adult; Antimalarials; Artemisinins; Double-Blind Method; Drug Administration Schedule; D

2016
Efficacy and safety of intermittent preventive treatment in schoolchildren with sulfadoxine/pyrimethamine (SP) and SP plus piperaquine in Democratic Republic of the Congo: a randomised controlled trial.
    International journal of antimicrobial agents, 2017, Volume: 49, Issue:3

    Topics: Adolescent; Anemia; Antimalarials; Chemoprevention; Child; Child, Preschool; Democratic Republic of

2017
[Gametocytemia in falciparum malaria treated with amodiaquine or artesunate].
    Biomedica : revista del Instituto Nacional de Salud, 2008, Volume: 28, Issue:2

    Topics: Adolescent; Adult; Amodiaquine; Animals; Antimalarials; Artemisinins; Artesunate; Child, Preschool;

2008
A randomized, controlled trial of intermittent preventive treatment with sulfadoxine-pyrimethamine, amodiaquine, or the combination in pregnant women in Ghana.
    The Journal of infectious diseases, 2008, Oct-15, Volume: 198, Issue:8

    Topics: Amodiaquine; Anemia; Animals; Antimalarials; Child, Preschool; Drug Combinations; Drug Therapy, Comb

2008
Individual efficacy of intermittent preventive treatment with sulfadoxine-pyrimethamine in primi- and secundigravidae in rural Burkina Faso: impact on parasitaemia, anaemia and birth weight.
    Tropical medicine & international health : TM & IH, 2009, Volume: 14, Issue:2

    Topics: Adult; Anemia; Animals; Antimalarials; Birth Weight; Burkina Faso; Drug Combinations; Female; Humans

2009
Short report: comparison of chlorproguanil-dapsone with a combination of sulfadoxine-pyrimethamine and chloroquine in children with malaria in northcentral Nigeria.
    The American journal of tropical medicine and hygiene, 2009, Volume: 80, Issue:2

    Topics: Animals; Antimalarials; Child, Preschool; Chloroquine; Dapsone; Drug Combinations; Drug Therapy, Com

2009
Submicroscopic gametocytes and the transmission of antifolate-resistant Plasmodium falciparum in Western Kenya.
    PloS one, 2009, Volume: 4, Issue:2

    Topics: Animals; Artemisinins; Artesunate; Carrier State; Child, Preschool; Drug Combinations; Drug Resistan

2009
Intermittent preventive treatment using artemisinin-based combination therapy reduces malaria morbidity among school-aged children in Mali.
    Tropical medicine & international health : TM & IH, 2009, Volume: 14, Issue:7

    Topics: Adolescent; Anemia; Artemisinins; Artesunate; Child; Drug Combinations; Drug Therapy, Combination; F

2009
Artemisinin-naphthoquine combination (ARCO) therapy for uncomplicated falciparum malaria in adults of Papua New Guinea: a preliminary report on safety and efficacy.
    Malaria journal, 2009, Aug-12, Volume: 8

    Topics: Adolescent; Adult; Animals; Antimalarials; Artemisinins; Blood; Chloroquine; Drug Combinations; Huma

2009
Presumptive treatment with sulphadoxine-pyrimethamine versus weekly chloroquine for malaria prophylaxis in children with sickle cell anaemia in Uganda: a randomized controlled trial.
    Malaria journal, 2009, Oct-24, Volume: 8

    Topics: Anemia, Sickle Cell; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Administration Schedu

2009
Presumptive treatment with sulphadoxine-pyrimethamine versus weekly chloroquine for malaria prophylaxis in children with sickle cell anaemia in Uganda: a randomized controlled trial.
    Malaria journal, 2009, Oct-24, Volume: 8

    Topics: Anemia, Sickle Cell; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Administration Schedu

2009
Presumptive treatment with sulphadoxine-pyrimethamine versus weekly chloroquine for malaria prophylaxis in children with sickle cell anaemia in Uganda: a randomized controlled trial.
    Malaria journal, 2009, Oct-24, Volume: 8

    Topics: Anemia, Sickle Cell; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Administration Schedu

2009
Presumptive treatment with sulphadoxine-pyrimethamine versus weekly chloroquine for malaria prophylaxis in children with sickle cell anaemia in Uganda: a randomized controlled trial.
    Malaria journal, 2009, Oct-24, Volume: 8

    Topics: Anemia, Sickle Cell; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Administration Schedu

2009
Efficacy of non-artemisinin- and artemisinin-based combination therapies for uncomplicated falciparum malaria in Cameroon.
    Malaria journal, 2010, Feb-19, Volume: 9

    Topics: Administration, Oral; Amodiaquine; Antimalarials; Artemisinins; Cameroon; Child, Preschool; Drug Adm

2010
The effects of a pre-season treatment with effective antimalarials on subsequent malaria morbidity in under five-year-old children living in high and seasonal malaria transmission area of Burkina Faso.
    Tropical medicine & international health : TM & IH, 2010, Volume: 15, Issue:11

    Topics: Age Distribution; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Burkina Fa

2010
Malaria morbidity in children in the year after they had received intermittent preventive treatment of malaria in Mali: a randomized control trial.
    PloS one, 2011, Volume: 6, Issue:8

    Topics: Amodiaquine; Anemia; Antimalarials; Body Weight; Child, Preschool; Drug Administration Schedule; Dru

2011
A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania.
    Malaria journal, 2011, Aug-24, Volume: 10

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Artesunate; Child; Child, P

2011
A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania.
    Malaria journal, 2011, Aug-24, Volume: 10

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Artesunate; Child; Child, P

2011
A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania.
    Malaria journal, 2011, Aug-24, Volume: 10

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Artesunate; Child; Child, P

2011
A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania.
    Malaria journal, 2011, Aug-24, Volume: 10

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Artesunate; Child; Child, P

2011
Impact of combining intermittent preventive treatment with home management of malaria in children less than 10 years in a rural area of Senegal: a cluster randomized trial.
    Malaria journal, 2011, Dec-13, Volume: 10

    Topics: Amodiaquine; Anemia; Animals; Artemether, Lumefantrine Drug Combination; Artemisinins; Artesunate; C

2011
Efficacy of different primaquine-based antimalarial regimens against Plasmodium falciparum gametocytemia.
    Acta tropica, 2012, Volume: 122, Issue:2

    Topics: Adolescent; Adult; Aged; Amodiaquine; Antimalarials; Artemisinins; Artesunate; Child; Child, Prescho

2012
Treatment failure of pyrimethamine-sulphadoxine and induction of Plasmodium falciparum gametocytaemia in children in western Kenya.
    Tropical medicine & international health : TM & IH, 2003, Volume: 8, Issue:5

    Topics: Adolescent; Animals; Antimalarials; Child; Child, Preschool; Cohort Studies; Drug Combinations; Drug

2003
Plasmodium falciparum gametocytaemia in Nigerian children: before, during and after treatment with antimalarial drugs.
    Tropical medicine & international health : TM & IH, 2003, Volume: 8, Issue:9

    Topics: Age Factors; Amodiaquine; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combina

2003
The efficacy of chloroquine, sulfadoxine-pyrimethamine and a combination of both for the treatment of uncomplicated Plasmodium falciparum malaria in an area of low transmission in western Uganda.
    Tropical medicine & international health : TM & IH, 2004, Volume: 9, Issue:1

    Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combinations; Drug Resi

2004
Open randomized study of pyrimethamine-sulphadoxine vs. pyrimethamine-sulphadoxine plus probenecid for the treatment of uncomplicated Plasmodium falciparum malaria in children.
    Tropical medicine & international health : TM & IH, 2004, Volume: 9, Issue:5

    Topics: Acute Disease; Antimalarials; Child; Child, Preschool; Drug Combinations; Drug Interactions; Drug Re

2004
Efficacy of pyrimethamine-sulfadoxine in young children with uncomplicated falciparum malaria in rural Burkina Faso.
    Malaria journal, 2004, May-11, Volume: 3

    Topics: Antimalarials; Burkina Faso; Child, Preschool; Cohort Studies; Drug Combinations; Female; Humans; In

2004
Risk factors for gametocyte carriage in uncomplicated falciparum malaria in children.
    Parasitology, 2004, Volume: 129, Issue:Pt 3

    Topics: Amodiaquine; Animals; Antimalarials; Carrier State; Child; Child, Preschool; Chloroquine; Chlorpheni

2004
Impact of a double dose of sulphadoxine-pyrimethamine to reduce prevalence of pregnancy malaria in southern Mozambique.
    Tropical medicine & international health : TM & IH, 2004, Volume: 9, Issue:10

    Topics: Adolescent; Adult; Antimalarials; Birth Weight; Double-Blind Method; Drug Administration Schedule; D

2004
Plasmodium falciparum hyperparasitaemia in children. Risk factors, treatment outcomes, and gametocytaemia following treatment.
    Parasite (Paris, France), 2004, Volume: 11, Issue:3

    Topics: Age Factors; Amodiaquine; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combina

2004
Comparison of intermittent preventive treatment with chemoprophylaxis for the prevention of malaria during pregnancy in Mali.
    The Journal of infectious diseases, 2005, Jan-01, Volume: 191, Issue:1

    Topics: Abortion, Spontaneous; Adolescent; Adult; Anemia; Birth Weight; Chemoprevention; Chloroquine; Drug A

2005
A randomized comparative study of chloroquine, amodiaquine and sulphadoxine-pyrimethamine for the treatment of uncomplicated malaria in Ghana.
    Tropical medicine & international health : TM & IH, 2005, Volume: 10, Issue:3

    Topics: Amodiaquine; Antimalarials; Child, Preschool; Chloroquine; Drug Combinations; Female; Fever; Ghana;

2005
Comparison of sulfadoxine-pyrimethamine with and without chloroquine for uncomplicated malaria in Nigeria.
    The American journal of tropical medicine and hygiene, 2005, Volume: 72, Issue:3

    Topics: Adolescent; Adult; Antimalarials; Body Weight; Child; Chloroquine; Drug Therapy, Combination; Female

2005
Efficacy comparison between anti-malarial drugs in Africans presenting with mild malaria in the Central Republic of Africa: a preliminary study.
    Parasite (Paris, France), 2005, Volume: 12, Issue:1

    Topics: Adolescent; Adult; Animals; Antimalarials; Artemisinins; Central African Republic; Drug Combinations

2005
A comparison of the efficacy of artesunate plus sulfadoxine-pyrimethamine with that of sulfadoxine-pyrimethamine alone, in the treatment of uncomplicated, Plasmodium falciparum malaria in eastern Sudan.
    Annals of tropical medicine and parasitology, 2005, Volume: 99, Issue:5

    Topics: Adolescent; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Drug Combinations; Dru

2005
Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana.
    BMJ (Clinical research ed.), 2005, Oct-01, Volume: 331, Issue:7519

    Topics: Anemia; Antimalarials; Cluster Analysis; Drug Combinations; Ghana; Hospitalization; Humans; Incidenc

2005
Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana.
    BMJ (Clinical research ed.), 2005, Oct-01, Volume: 331, Issue:7519

    Topics: Anemia; Antimalarials; Cluster Analysis; Drug Combinations; Ghana; Hospitalization; Humans; Incidenc

2005
Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana.
    BMJ (Clinical research ed.), 2005, Oct-01, Volume: 331, Issue:7519

    Topics: Anemia; Antimalarials; Cluster Analysis; Drug Combinations; Ghana; Hospitalization; Humans; Incidenc

2005
Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana.
    BMJ (Clinical research ed.), 2005, Oct-01, Volume: 331, Issue:7519

    Topics: Anemia; Antimalarials; Cluster Analysis; Drug Combinations; Ghana; Hospitalization; Humans; Incidenc

2005
Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana.
    BMJ (Clinical research ed.), 2005, Oct-01, Volume: 331, Issue:7519

    Topics: Anemia; Antimalarials; Cluster Analysis; Drug Combinations; Ghana; Hospitalization; Humans; Incidenc

2005
Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana.
    BMJ (Clinical research ed.), 2005, Oct-01, Volume: 331, Issue:7519

    Topics: Anemia; Antimalarials; Cluster Analysis; Drug Combinations; Ghana; Hospitalization; Humans; Incidenc

2005
Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana.
    BMJ (Clinical research ed.), 2005, Oct-01, Volume: 331, Issue:7519

    Topics: Anemia; Antimalarials; Cluster Analysis; Drug Combinations; Ghana; Hospitalization; Humans; Incidenc

2005
Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana.
    BMJ (Clinical research ed.), 2005, Oct-01, Volume: 331, Issue:7519

    Topics: Anemia; Antimalarials; Cluster Analysis; Drug Combinations; Ghana; Hospitalization; Humans; Incidenc

2005
Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana.
    BMJ (Clinical research ed.), 2005, Oct-01, Volume: 331, Issue:7519

    Topics: Anemia; Antimalarials; Cluster Analysis; Drug Combinations; Ghana; Hospitalization; Humans; Incidenc

2005
Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana.
    BMJ (Clinical research ed.), 2005, Oct-01, Volume: 331, Issue:7519

    Topics: Anemia; Antimalarials; Cluster Analysis; Drug Combinations; Ghana; Hospitalization; Humans; Incidenc

2005
Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana.
    BMJ (Clinical research ed.), 2005, Oct-01, Volume: 331, Issue:7519

    Topics: Anemia; Antimalarials; Cluster Analysis; Drug Combinations; Ghana; Hospitalization; Humans; Incidenc

2005
Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana.
    BMJ (Clinical research ed.), 2005, Oct-01, Volume: 331, Issue:7519

    Topics: Anemia; Antimalarials; Cluster Analysis; Drug Combinations; Ghana; Hospitalization; Humans; Incidenc

2005
Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana.
    BMJ (Clinical research ed.), 2005, Oct-01, Volume: 331, Issue:7519

    Topics: Anemia; Antimalarials; Cluster Analysis; Drug Combinations; Ghana; Hospitalization; Humans; Incidenc

2005
Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana.
    BMJ (Clinical research ed.), 2005, Oct-01, Volume: 331, Issue:7519

    Topics: Anemia; Antimalarials; Cluster Analysis; Drug Combinations; Ghana; Hospitalization; Humans; Incidenc

2005
Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana.
    BMJ (Clinical research ed.), 2005, Oct-01, Volume: 331, Issue:7519

    Topics: Anemia; Antimalarials; Cluster Analysis; Drug Combinations; Ghana; Hospitalization; Humans; Incidenc

2005
Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana.
    BMJ (Clinical research ed.), 2005, Oct-01, Volume: 331, Issue:7519

    Topics: Anemia; Antimalarials; Cluster Analysis; Drug Combinations; Ghana; Hospitalization; Humans; Incidenc

2005
Open randomized study of artesunate-amodiaquine vs. chloroquine-pyrimethamine-sulfadoxine for the treatment of uncomplicated Plasmodium falciparum malaria in Nigerian children.
    Tropical medicine & international health : TM & IH, 2005, Volume: 10, Issue:11

    Topics: Amodiaquine; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Chloroquine; Drug Com

2005
[Evaluation of the therapeutic efficacy of amodiaquine versus chloroquine in the treatment of uncomplicated malaria in Abie, Côte-d'Ivoire].
    Bulletin de la Societe de pathologie exotique (1990), 2005, Volume: 98, Issue:3

    Topics: Amodiaquine; Animals; Antimalarials; Child, Preschool; Chloroquine; Cote d'Ivoire; Drug Combinations

2005
(Sub)microscopic Plasmodium falciparum gametocytaemia in Kenyan children after treatment with sulphadoxine-pyrimethamine monotherapy or in combination with artesunate.
    International journal for parasitology, 2006, Volume: 36, Issue:4

    Topics: Animals; Antimalarials; Artemisinins; Artesunate; Carrier State; Child; Child, Preschool; Drug Combi

2006
Lack of inhibition of the anti-malarial action of sulfadoxine-pyrimethamine by folic acid supplementation when used for intermittent preventive treatment in Gambian primigravidae.
    The American journal of tropical medicine and hygiene, 2006, Volume: 74, Issue:6

    Topics: Adolescent; Adult; Anemia; Animals; Antimalarials; Dietary Supplements; Drug Combinations; Female; F

2006
Folic acid treatment of Zambian children with moderate to severe malaria anemia.
    The American journal of tropical medicine and hygiene, 2006, Volume: 74, Issue:6

    Topics: Anemia; Animals; Antimalarials; Atovaquone; Child; Child, Preschool; Drug Combinations; Folic Acid;

2006
A randomized, placebo-controlled trial of intermittent preventive treatment with sulphadoxine-pyrimethamine in Gambian multigravidae.
    Tropical medicine & international health : TM & IH, 2006, Volume: 11, Issue:7

    Topics: Adolescent; Adult; Anemia; Antimalarials; Bedding and Linens; Drug Combinations; Female; Gambia; Gra

2006
A randomised trial to assess the safety and efficacy of artemether-lumefantrine (Coartem) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwanda.
    Transactions of the Royal Society of Tropical Medicine and Hygiene, 2007, Volume: 101, Issue:4

    Topics: Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child, Preschoo

2007
A randomised, double-blind, placebo-controlled trial of atovaquone-proguanil vs. sulphadoxine-pyrimethamine in the treatment of malarial anaemia in Zambian children.
    Tropical medicine & international health : TM & IH, 2006, Volume: 11, Issue:11

    Topics: Anemia; Antimalarials; Atovaquone; Child; Child, Preschool; Double-Blind Method; Drug Combinations;

2006
Continued efficacy of sulfadoxine-pyrimethamine as second line treatment for malaria in children in Guinea-Bissau.
    Acta tropica, 2006, Volume: 100, Issue:3

    Topics: Adolescent; Animals; Antimalarials; Child; Child, Preschool; Drug Combinations; Female; Guinea-Bissa

2006
Efficacies of artesunate plus either sulfadoxine-pyrimethamine or amodiaquine, for the treatment of uncomplicated, Plasmodium falciparum malaria in eastern Sudan.
    Annals of tropical medicine and parasitology, 2007, Volume: 101, Issue:1

    Topics: Adolescent; Amodiaquine; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Drug Comb

2007
Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial.
    Lancet (London, England), 2007, Feb-10, Volume: 369, Issue:9560

    Topics: Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Burkina Faso; C

2007
Molecular genotyping in a malaria treatment trial in Uganda - unexpected high rate of new infections within 2 weeks after treatment.
    Tropical medicine & international health : TM & IH, 2007, Volume: 12, Issue:2

    Topics: Animals; Antimalarials; Artemisinins; Artesunate; Child; Drug Combinations; Drug Therapy, Combinatio

2007
Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial.
    JAMA, 2007, May-23, Volume: 297, Issue:20

    Topics: Amodiaquine; Animals; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Artesu

2007
Intermittent preventive treatment of malaria in pregnancy: a community-based delivery system and its effect on parasitemia, anemia and low birth weight in Uganda.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2008, Volume: 12, Issue:1

    Topics: Adolescent; Adult; Anemia; Antimalarials; Case-Control Studies; Community Health Workers; Drug Admin

2008
A comparison of sulfadoxine-pyrimethamine with chloroquine and pyrimethamine for prevention of malaria in pregnant Nigerian women.
    The American journal of tropical medicine and hygiene, 2007, Volume: 76, Issue:6

    Topics: Adult; Animals; Antimalarials; Birth Weight; Chloroquine; Drug Combinations; Female; Hematocrit; Hum

2007
Intermittent preventive treatment with sulphadoxine-pyrimethamine is effective in preventing maternal and placental malaria in Ibadan, south-western Nigeria.
    Malaria journal, 2007, Jul-06, Volume: 6

    Topics: Adolescent; Adult; Antimalarials; Birth Weight; Dizziness; Drug Combinations; Female; Humans; Malari

2007
Therapeutic efficacy and effects of artemether-lumefantrine and amodiaquine-sulfalene-pyrimethamine on gametocyte carriage in children with uncomplicated Plasmodium falciparum malaria in southwestern Nigeria.
    The American journal of tropical medicine and hygiene, 2007, Volume: 77, Issue:2

    Topics: Amodiaquine; Animals; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child;

2007
Inferiority of single-dose sulfadoxine-pyrimethamine intermittent preventive therapy for malaria during pregnancy among HIV-positive Zambian women.
    The Journal of infectious diseases, 2007, Dec-01, Volume: 196, Issue:11

    Topics: Adult; AIDS-Related Opportunistic Infections; Anemia; Antimalarials; Birth Weight; Double-Blind Meth

2007
Two-dose versus monthly intermittent preventive treatment of malaria with sulfadoxine-pyrimethamine in HIV-seropositive pregnant Zambian women.
    The Journal of infectious diseases, 2007, Dec-01, Volume: 196, Issue:11

    Topics: Adult; AIDS-Related Opportunistic Infections; Anemia; Antimalarials; Birth Weight; Double-Blind Meth

2007
Intermittent preventive treatment against malaria in infants in Gabon--a randomized, double-blind, placebo-controlled trial.
    The Journal of infectious diseases, 2007, Dec-01, Volume: 196, Issue:11

    Topics: Anemia; Antimalarials; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female;

2007
Intermittent preventive treatment against malaria in infants in Gabon--a randomized, double-blind, placebo-controlled trial.
    The Journal of infectious diseases, 2007, Dec-01, Volume: 196, Issue:11

    Topics: Anemia; Antimalarials; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female;

2007
Intermittent preventive treatment against malaria in infants in Gabon--a randomized, double-blind, placebo-controlled trial.
    The Journal of infectious diseases, 2007, Dec-01, Volume: 196, Issue:11

    Topics: Anemia; Antimalarials; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female;

2007
Intermittent preventive treatment against malaria in infants in Gabon--a randomized, double-blind, placebo-controlled trial.
    The Journal of infectious diseases, 2007, Dec-01, Volume: 196, Issue:11

    Topics: Anemia; Antimalarials; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female;

2007
Intermittent preventive treatment against malaria in infants in Gabon--a randomized, double-blind, placebo-controlled trial.
    The Journal of infectious diseases, 2007, Dec-01, Volume: 196, Issue:11

    Topics: Anemia; Antimalarials; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female;

2007
Intermittent preventive treatment against malaria in infants in Gabon--a randomized, double-blind, placebo-controlled trial.
    The Journal of infectious diseases, 2007, Dec-01, Volume: 196, Issue:11

    Topics: Anemia; Antimalarials; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female;

2007
Intermittent preventive treatment against malaria in infants in Gabon--a randomized, double-blind, placebo-controlled trial.
    The Journal of infectious diseases, 2007, Dec-01, Volume: 196, Issue:11

    Topics: Anemia; Antimalarials; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female;

2007
Intermittent preventive treatment against malaria in infants in Gabon--a randomized, double-blind, placebo-controlled trial.
    The Journal of infectious diseases, 2007, Dec-01, Volume: 196, Issue:11

    Topics: Anemia; Antimalarials; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female;

2007
Intermittent preventive treatment against malaria in infants in Gabon--a randomized, double-blind, placebo-controlled trial.
    The Journal of infectious diseases, 2007, Dec-01, Volume: 196, Issue:11

    Topics: Anemia; Antimalarials; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female;

2007
Herba Artemisiae annuae tea preparation compared to sulfadoxine-pyrimethamine in the treatment of uncomplicated falciparum malaria in adults: a randomized double-blind clinical trial.
    Tropical doctor, 2008, Volume: 38, Issue:2

    Topics: Adult; Animals; Antimalarials; Artemisia annua; Double-Blind Method; Drug Combinations; Drugs, Chine

2008
Specific and nonspecific responses to Plasmodium falciparum blood-stage parasites and observations on the gametocytemia in schoolchildren living in a malaria-endemic area of Mozambique.
    The American journal of tropical medicine and hygiene, 1995, Volume: 52, Issue:1

    Topics: Adolescent; Animals; Antibodies, Protozoan; Antigens, Protozoan; Antimalarials; Blotting, Western; C

1995
The efficacy of antimalarial regimens containing sulfadoxine-pyrimethamine and/or chloroquine in preventing peripheral and placental Plasmodium falciparum infection among pregnant women in Malawi.
    The American journal of tropical medicine and hygiene, 1994, Volume: 51, Issue:5

    Topics: Analysis of Variance; Antimalarials; Chi-Square Distribution; Chloroquine; Drug Combinations; Drug T

1994
Sulfadoxine/pyrimethamine or chloroquine/clindamycin treatment of Gabonese school children infected with chloroquine resistant malaria.
    The Journal of antimicrobial chemotherapy, 1995, Volume: 36, Issue:4

    Topics: Adolescent; Animals; Anti-Bacterial Agents; Antimalarials; Child; Child, Preschool; Chloroquine; Cli

1995
The effect of oral iron therapy during treatment for Plasmodium falciparum malaria with sulphadoxine-pyrimethamine on Malawian children under 5 years of age.
    Annals of tropical medicine and parasitology, 1996, Volume: 90, Issue:6

    Topics: Antimalarials; Child, Preschool; Drug Combinations; Drug Therapy, Combination; Follow-Up Studies; He

1996
Responses of multidrug-resistant Plasmodium falciparum parasites to mefloquine in Nigerian children.
    Tropical medicine & international health : TM & IH, 1997, Volume: 2, Issue:4

    Topics: Animals; Anti-Infective Agents; Antimalarials; Child; Child, Preschool; Drug Resistance, Microbial;

1997
Chloroquine in Africa: critical assessment and recommendations for monitoring and evaluating chloroquine therapy efficacy in sub-Saharan Africa.
    Tropical medicine & international health : TM & IH, 1998, Volume: 3, Issue:7

    Topics: Antimalarials; Child, Preschool; Chloroquine; Drug Combinations; Drug Monitoring; Drug Resistance; F

1998
Intermittent sulphadoxine-pyrimethamine to prevent severe anaemia secondary to malaria in pregnancy: a randomised placebo-controlled trial.
    Lancet (London, England), 1999, Feb-20, Volume: 353, Issue:9153

    Topics: Anemia; Antimalarials; Bedding and Linens; Double-Blind Method; Drug Administration Schedule; Drug C

1999
Intermittent sulphadoxine-pyrimethamine to prevent severe anaemia secondary to malaria in pregnancy: a randomised placebo-controlled trial.
    Lancet (London, England), 1999, Feb-20, Volume: 353, Issue:9153

    Topics: Anemia; Antimalarials; Bedding and Linens; Double-Blind Method; Drug Administration Schedule; Drug C

1999
Intermittent sulphadoxine-pyrimethamine to prevent severe anaemia secondary to malaria in pregnancy: a randomised placebo-controlled trial.
    Lancet (London, England), 1999, Feb-20, Volume: 353, Issue:9153

    Topics: Anemia; Antimalarials; Bedding and Linens; Double-Blind Method; Drug Administration Schedule; Drug C

1999
Intermittent sulphadoxine-pyrimethamine to prevent severe anaemia secondary to malaria in pregnancy: a randomised placebo-controlled trial.
    Lancet (London, England), 1999, Feb-20, Volume: 353, Issue:9153

    Topics: Anemia; Antimalarials; Bedding and Linens; Double-Blind Method; Drug Administration Schedule; Drug C

1999
Population structure of recrudescent Plasmodium falciparum isolates from western Uganda.
    Tropical medicine & international health : TM & IH, 1999, Volume: 4, Issue:7

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antigens, Protozoan; Antimalarials; Child; Chil

1999
Efficacy of artesunate plus pyrimethamine-sulphadoxine for uncomplicated malaria in Gambian children: a double-blind, randomised, controlled trial.
    Lancet (London, England), 2000, Jan-29, Volume: 355, Issue:9201

    Topics: Animals; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Double-Blind Method; Drug

2000
Efficacy of primaquine regimens for primaquine-resistant Plasmodium vivax malaria in Thailand.
    The American journal of tropical medicine and hygiene, 1999, Volume: 61, Issue:6

    Topics: Adolescent; Adult; Aged; Animals; Antimalarials; Artemisinins; Artesunate; Drug Combinations; Drug R

1999
Comparative efficacy of chloroquine plus chlorpheniramine alone and in a sequential combination with sulfadoxine-pyrimethamine, for the treatment of acute, uncomplicated, falciparum malaria in children.
    Annals of tropical medicine and parasitology, 2000, Volume: 94, Issue:3

    Topics: Animals; Antimalarials; Antipruritics; Child; Child, Preschool; Chloroquine; Chlorpheniramine; Drug

2000
In vivo efficacy study of amodiaquine and sulfadoxine/ pyrimethamine in Kibwezi, Kenya and Kigoma, Tanzania.
    Tropical medicine & international health : TM & IH, 2000, Volume: 5, Issue:6

    Topics: Amodiaquine; Animals; Antimalarials; Child; Child, Preschool; Drug Resistance, Microbial; Female; Fe

2000
Therapy of uncomplicated falciparum malaria: a randomized trial comparing artesunate plus sulfadoxine-pyrimethamine versus sulfadoxine-pyrimethamine alone in Irian Jaya, Indonesia.
    The American journal of tropical medicine and hygiene, 2001, Volume: 65, Issue:4

    Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antimalarials; Artemisini

2001
Anemia of persistent malarial parasitemia in Nigerian children.
    Journal of tropical pediatrics, 2001, Volume: 47, Issue:5

    Topics: Anemia; Antimalarials; Child, Preschool; Chloroquine; Drug Combinations; Drug Resistance; Female; Hu

2001
Sulfadoxine-pyrimethamine monotherapy in Tanzanian children gives rapid parasite clearance but slow fever clearance that is improved by chloroquine in combination therapy.
    Tropical medicine & international health : TM & IH, 2002, Volume: 7, Issue:7

    Topics: Acetaminophen; Antimalarials; Child, Preschool; Chloroquine; Drug Combinations; Drug Resistance; Dru

2002
Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines.
    Tropical medicine & international health : TM & IH, 2002, Volume: 7, Issue:7

    Topics: Acute Disease; Adolescent; Adult; Antimalarials; Area Under Curve; Child; Chloroquine; Drug Administ

2002

Other Studies

98 other studies available for pyrimethamine and Parasitemia

ArticleYear
Discovery of new thienopyrimidinone derivatives displaying antimalarial properties toward both erythrocytic and hepatic stages of Plasmodium.
    European journal of medicinal chemistry, 2015, May-05, Volume: 95

    Topics: Animals; Antimalarials; Cell Proliferation; CHO Cells; Cricetinae; Cricetulus; Drug Discovery; Eryth

2015
Development and Optimization of a Selective Whole-Genome Amplification To Study Plasmodium ovale Spp.
    Microbiology spectrum, 2022, 10-26, Volume: 10, Issue:5

    Topics: Amino Acids; Endonucleases; Humans; Malaria; Parasitemia; Plasmodium ovale; Pyrimethamine; Recurrenc

2022
Intermittent preventive treatment with Sulphadoxine-Pyrimethamine (IPTp-SP) is associated with protection against sub-microscopic P. falciparum infection in pregnant women during the low transmission dry season in southwestern Cameroon: A Semi - longitudi
    PloS one, 2022, Volume: 17, Issue:9

    Topics: Antimalarials; Birth Weight; Cameroon; Drug Combinations; Female; Humans; Infant, Newborn; Insectici

2022
A new effective antiplasmodial compound: Nanoformulated pyrimethamine.
    Journal of global antimicrobial resistance, 2020, Volume: 20

    Topics: Animals; Antimalarials; Disease Models, Animal; Drug Compounding; Liver; Malaria; Male; Mice; Micell

2020
The efficacy of intermittent preventive therapy in the eradication of peripheral and placental parasitemia in a malaria-endemic environment, as seen in a tertiary hospital in Abuja, Nigeria.
    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2020, Volume: 148, Issue:3

    Topics: Adolescent; Adult; Antimalarials; Birth Weight; Cross-Sectional Studies; Drug Combinations; Female;

2020
Sulfadoxine-pyrimethamine parasitological efficacy against Plasmodium falciparum among pregnant women and molecular markers of resistance in Zambia: an observational cohort study.
    Malaria journal, 2021, Jan-22, Volume: 20, Issue:1

    Topics: Adult; Antimalarials; Cohort Studies; Drug Combinations; Female; Genetic Markers; Humans; Malaria, F

2021
Intermittent preventive treatment comparing two versus three doses of sulphadoxine pyrimethamine (IPTp-SP) in the prevention of anaemia in pregnancy in Ghana: A cross-sectional study.
    PloS one, 2021, Volume: 16, Issue:4

    Topics: Adult; Anemia; Antimalarials; Cross-Sectional Studies; Drug Combinations; Educational Status; Female

2021
In vivo antimalarial activity of a probiotic bacterium Lactobacillus sakei isolated from traditionally fermented milk in BALB/c mice infected with Plasmodium berghei ANKA.
    Journal of ethnopharmacology, 2021, Nov-15, Volume: 280

    Topics: Animals; Antimalarials; Cameroon; Chloroquine; Disease Models, Animal; Drug Combinations; Fermented

2021
The Discovery of Novel Antimalarial Aminoxadiazoles as a Promising Nonendoperoxide Scaffold.
    Journal of medicinal chemistry, 2017, 08-24, Volume: 60, Issue:16

    Topics: 2,2'-Dipyridyl; Animals; Antimalarials; Atovaquone; Chloroquine; Drug Design; Female; Humans; Hydraz

2017
Effect of Adding Azithromycin to Seasonal Malaria Chemoprevention.
    The New England journal of medicine, 2019, Jun-06, Volume: 380, Issue:23

    Topics: Amodiaquine; Anti-Bacterial Agents; Antimalarials; Azithromycin; Burkina Faso; Child Mortality; Chil

2019
What is the Link between Malaria Prevention in Pregnancy and Neonatal Survival in Nigeria?
    African journal of reproductive health, 2019, Volume: 23, Issue:1

    Topics: Adolescent; Adult; Antimalarials; Chemoprevention; Cross-Sectional Studies; Drug Combinations; Femal

2019
High rates of parasite recrudescence following intermittent preventive treatment with sulphadoxine-pyrimethamine during pregnancy in Benin.
    Malaria journal, 2013, Jun-10, Volume: 12

    Topics: Adolescent; Adult; Antimalarials; Benin; Dihydropteroate Synthase; Drug Combinations; Female; Haplot

2013
In vitro and in vivo antimalarial activity and cytotoxicity of extracts and fractions from the leaves, root-bark and stem-bark of Triclisia gilletii.
    Journal of ethnopharmacology, 2013, Sep-16, Volume: 149, Issue:2

    Topics: Animals; Antimalarials; Cell Line; Cell Survival; Chloroquine; Drug Resistance, Multiple; Humans; Ma

2013
Treatment of pregnant BALB/c mice with sulphadoxine pyrimethamine or chloroquine abrogates Plasmodium berghei induced placental pathology.
    Parasitology international, 2014, Volume: 63, Issue:1

    Topics: Animals; Antimalarials; Antioxidants; Chloroquine; DNA Fragmentation; Drug Combinations; Female; Lip

2014
Effectiveness of intermittent preventive treatment with sulfadoxine-pyrimethamine during pregnancy on placental malaria, maternal anaemia and birthweight in areas with high and low malaria transmission intensity in Tanzania.
    Tropical medicine & international health : TM & IH, 2014, Volume: 19, Issue:9

    Topics: Adult; Anemia; Antimalarials; Birth Weight; Drug Combinations; Female; Humans; Infant, Low Birth Wei

2014
Submicroscopic malaria infection during pregnancy and the impact of intermittent preventive treatment.
    Malaria journal, 2014, Jul-15, Volume: 13

    Topics: Adult; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Asymptomatic Diseases

2014
Uptake of intermittent preventive treatment with sulphadoxine-pyrimethamine for malaria during pregnancy and pregnancy outcomes: a cross-sectional study in Geita district, North-Western Tanzania.
    Malaria journal, 2014, Nov-24, Volume: 13

    Topics: Adolescent; Adult; Antimalarials; Cross-Sectional Studies; Drug Combinations; Drug Therapy, Combinat

2014
Comparative Study of Effectiveness and Resistance Profile of Chloroquine and Sulfadoxine-Pyrimethamine in Uncomplicated Plasmodium falciparum Malaria in Kolkata.
    The Journal of the Association of Physicians of India, 2015, Volume: 63, Issue:5

    Topics: Adolescent; Adult; Antimalarials; Child; Chloroquine; Drug Combinations; Drug Resistance; Female; Hu

2015
The risk of malaria in Ghanaian infants born to women managed in pregnancy with intermittent screening and treatment for malaria or intermittent preventive treatment with sulfadoxine/pyrimethamine.
    Malaria journal, 2016, Jan-28, Volume: 15

    Topics: Antimalarials; Drug Combinations; Female; Ghana; Humans; Infant; Infant, Newborn; Malaria; Male; Par

2016
Decrease of microscopic Plasmodium falciparum infection prevalence during pregnancy following IPTp-SP implementation in urban cities of Gabon.
    Transactions of the Royal Society of Tropical Medicine and Hygiene, 2016, Volume: 110, Issue:6

    Topics: Adult; Anemia; Antimalarials; Birth Weight; Cities; Cross-Sectional Studies; Drug Combinations; Fema

2016
Methylene blue inhibits lumefantrine-resistant Plasmodium berghei.
    Journal of infection in developing countries, 2016, Jun-30, Volume: 10, Issue:6

    Topics: Animals; Antimalarials; Disease Models, Animal; Drug Resistance; Drug-Related Side Effects and Adver

2016
Predictors of antimalarial treatment failure in an area of unstable malaria transmission in eastern Sudan.
    Transactions of the Royal Society of Tropical Medicine and Hygiene, 2009, Volume: 103, Issue:1

    Topics: Adolescent; Age Factors; Antimalarials; Child; Child, Preschool; Chloroquine; Cross-Sectional Studie

2009
Should countries implementing an artemisinin-based combination malaria treatment policy also introduce rapid diagnostic tests?
    Malaria journal, 2008, Sep-15, Volume: 7

    Topics: Adolescent; Animals; Artemisinins; Child; Child, Preschool; Cost-Benefit Analysis; Diagnostic Tests,

2008
Costs and cost-effectiveness of delivering intermittent preventive treatment through schools in western Kenya.
    Malaria journal, 2008, Sep-30, Volume: 7

    Topics: Anemia; Antimalarials; Chemoprevention; Communicable Disease Control; Cost-Benefit Analysis; Drug Co

2008
Implementation of intermittent preventive treatment in pregnancy with sulphadoxine/pyrimethamine (IPTp-SP) at a district health centre in rural Senegal.
    Malaria journal, 2008, Nov-07, Volume: 7

    Topics: Adolescent; Adult; Analysis of Variance; Antimalarials; Drug Combinations; Female; Humans; Infant, L

2008
Antiplasmodial activity of root extract and fractions of Croton zambesicus.
    Journal of ethnopharmacology, 2009, Jan-12, Volume: 121, Issue:1

    Topics: Animals; Antimalarials; Chloroquine; Croton; Female; Lethal Dose 50; Malaria; Male; Mice; Parasitemi

2009
Plasmodium falciparum gametocyte dynamics in areas of different malaria endemicity.
    Malaria journal, 2008, Dec-03, Volume: 7

    Topics: Adolescent; Animals; Antimalarials; Artemisinins; Carrier State; Child; Child, Preschool; Drug Combi

2008
Sub-microscopic infections and long-term recrudescence of Plasmodium falciparum in Mozambican pregnant women.
    Malaria journal, 2009, Jan-09, Volume: 8

    Topics: Adult; Animals; Antigens, Protozoan; Antimalarials; Chloroquine; Drug Combinations; Female; Genotype

2009
Community-based distribution of sulfadoxine-pyrimethamine for intermittent preventive treatment of malaria during pregnancy improved coverage but reduced antenatal attendance in southern Malawi.
    Tropical medicine & international health : TM & IH, 2009, Volume: 14, Issue:2

    Topics: Adolescent; Adult; Anemia; Antimalarials; Birth Weight; Community Health Services; Drug Combinations

2009
Plasmodium berghei: efficacy of 5-fluoroorotate in combination with commonly used antimalarial drugs in a mouse model.
    Experimental parasitology, 2009, Volume: 121, Issue:4

    Topics: Animals; Antimalarials; Artemisinins; Artesunate; Dapsone; Drug Synergism; Drug Therapy, Combination

2009
Active case detection, treatment of falciparum malaria with combined chloroquine and sulphadoxine/pyrimethamine and vivax malaria with chloroquine and molecular markers of anti-malarial resistance in the Republic of Vanuatu.
    Malaria journal, 2010, Apr-06, Volume: 9

    Topics: Adolescent; Adult; Antigens, Protozoan; Antimalarials; Case-Control Studies; Child; Child, Preschool

2010
Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs.
    Malaria journal, 2010, May-24, Volume: 9

    Topics: Adolescent; Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Art

2010
Efficacy of intermittent preventive treatment with sulfadoxine-pyrimethamine on placental parasitemia in pregnant women in midwestern Nigeria.
    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2011, Volume: 112, Issue:1

    Topics: Adult; Anemia; Antimalarials; Cohort Studies; Drug Combinations; Female; Humans; Infant, Low Birth W

2011
Marked reduction in prevalence of malaria parasitemia and anemia in HIV-infected pregnant women taking cotrimoxazole with or without sulfadoxine-pyrimethamine intermittent preventive therapy during pregnancy in Malawi.
    The Journal of infectious diseases, 2011, Feb-15, Volume: 203, Issue:4

    Topics: Adolescent; Adult; Anemia; Antimalarials; Chemoprevention; Cross-Sectional Studies; Drug Combination

2011
Artemether-Lumefantrin (Coartem) and artesunate with sulfadoxine-pyrimethamine therapeutic efficacy in the treatment of uncomplicated malaria at Gilgel Gibe II (GGII) South-Western Ethiopia.
    Ethiopian medical journal, 2010, Volume: 48, Issue:4

    Topics: Adolescent; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Artesunate; Chil

2010
Coverage of intermittent prevention treatment with sulphadoxine-pyrimethamine among pregnant women and congenital malaria in Côte d'Ivoire.
    Malaria journal, 2011, Apr-29, Volume: 10

    Topics: Adolescent; Adult; Chemoprevention; Cote d'Ivoire; Cross-Sectional Studies; Drug Combinations; Drug

2011
Selection of drug resistant mutants from random library of Plasmodium falciparum dihydrofolate reductase in Plasmodium berghei model.
    Malaria journal, 2011, May-10, Volume: 10

    Topics: Animals; Antimalarials; Drug Resistance; Female; Folic Acid Antagonists; Gene Expression Regulation,

2011
Prolonged elevation of viral loads in HIV-1-infected children in a region of intense malaria transmission in Northern Uganda: a prospective cohort study.
    The Pan African medical journal, 2010, Volume: 7

    Topics: Antimalarials; CD4 Lymphocyte Count; Child; Child, Preschool; Chloroquine; Disease Progression; Drug

2010
Quantification of the burden and consequences of pregnancy-associated malaria in the Democratic Republic of the Congo.
    The Journal of infectious diseases, 2011, Dec-01, Volume: 204, Issue:11

    Topics: Anemia; Antimalarials; Birth Weight; Cross-Sectional Studies; Democratic Republic of the Congo; Drug

2011
The effectiveness and perception of the use of sulphadoxine-pyrimethamine in intermittent preventive treatment of malaria in pregnancy programme in Offinso district of Ashanti region, Ghana.
    Malaria journal, 2011, Dec-29, Volume: 10

    Topics: Adult; Anemia; Antimalarials; Cross-Sectional Studies; Drug Administration Schedule; Drug Combinatio

2011
The impact of intermittent preventive treatment with sulfadoxine-pyrimethamine on the prevalence of malaria parasitaemia in pregnancy.
    Tropical doctor, 2012, Volume: 42, Issue:3

    Topics: Adult; Antimalarials; Drug Administration Schedule; Drug Combinations; Female; Humans; Malaria; Para

2012
Antenatal receipt of sulfadoxine-pyrimethamine does not exacerbate pregnancy-associated malaria despite the expansion of drug-resistant Plasmodium falciparum: clinical outcomes from the QuEERPAM study.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012, Volume: 55, Issue:1

    Topics: Adolescent; Adult; Antibiotic Prophylaxis; Antimalarials; Cross-Sectional Studies; Drug Combinations

2012
Routine delivery of artemisinin-based combination treatment at fixed health facilities reduces malaria prevalence in Tanzania: an observational study.
    Malaria journal, 2012, Apr-30, Volume: 11

    Topics: Adolescent; Adult; Antimalarials; Artemisinins; Child; Child, Preschool; Cross-Sectional Studies; Dr

2012
Using community-owned resource persons to provide early diagnosis and treatment and estimate malaria burden at community level in north-eastern Tanzania.
    Malaria journal, 2012, May-03, Volume: 11

    Topics: Adolescent; Adult; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Blood; Ch

2012
The effects of malaria and intermittent preventive treatment during pregnancy on fetal anemia in Malawi.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012, Volume: 55, Issue:8

    Topics: Anemia, Neonatal; Antimalarials; Cross-Sectional Studies; Drug Combinations; Female; Fetal Blood; Fe

2012
A high malaria reinfection rate in children and young adults living under a low entomological inoculation rate in a periurban area of Bamako, Mali.
    The American journal of tropical medicine and hygiene, 2002, Volume: 66, Issue:3

    Topics: Adolescent; Animals; Anopheles; Antimalarials; Child; Drug Combinations; Female; Humans; Insect Bite

2002
Determinants of treatment response to sulfadoxine-pyrimethamine and subsequent transmission potential in falciparum malaria.
    American journal of epidemiology, 2002, Aug-01, Volume: 156, Issue:3

    Topics: Adolescent; Adult; Aged; Animals; Antimalarials; Child; Child, Preschool; Dihydropteroate Synthase;

2002
Plasmodium berghei: routine production of pure gametocytes, extracellular gametes, zygotes, and ookinetes.
    Experimental parasitology, 2002, Volume: 101, Issue:1

    Topics: Animals; Antimalarials; Centrifugation; Erythrocytes; Female; Germ Cells; Malaria; Mice; Parasitemia

2002
Increased efficacy of sulfadoxine-pyrimethamine in the treatment of uncomplicated falciparum malaria among children with sickle cell trait in Western Kenya.
    The Journal of infectious diseases, 2002, Dec-01, Volume: 186, Issue:11

    Topics: Animals; Antimalarials; Child, Preschool; Drug Combinations; Female; Hemoglobin A; Hemoglobin, Sickl

2002
In vitro sensitivity of Plasmodium falciparum to amodiaquine compared with other major antimalarials in Madagascar.
    Parassitologia, 2002, Volume: 44, Issue:3-4

    Topics: Amodiaquine; Animals; Antimalarials; Chloroquine; Drug Resistance; Drug Resistance, Multiple; Humans

2002
Malaria treated with daraprim, including cerebral malaria and high parasitaemia.
    Transactions of the Royal Society of Tropical Medicine and Hygiene, 1952, Volume: 46, Issue:5

    Topics: Malaria; Malaria, Cerebral; Parasitemia; Pyrimethamine; Pyrimidines

1952
Therapeutic efficacies of antimalarial drugs in the treatment of uncomplicated, Plasmodium falciparum malaria in Assam, north-eastern India.
    Annals of tropical medicine and parasitology, 2003, Volume: 97, Issue:8

    Topics: Adolescent; Adult; Aged; Animals; Anti-Infective Agents; Antimalarials; Artemisinins; Child; Child,

2003
Drug resistance in Plasmodium falciparum from the Chittagong Hill Tracts, Bangladesh.
    Tropical medicine & international health : TM & IH, 2004, Volume: 9, Issue:6

    Topics: Adolescent; Adult; Animals; Antimalarials; ATP-Binding Cassette Transporters; Bangladesh; Child; Chi

2004
Early treatment during a primary malaria infection modifies the development of cross immunity.
    Parasite immunology, 2004, Volume: 26, Issue:1

    Topics: Animals; Antibodies, Protozoan; Body Weight; Cross Reactions; Gene Expression; Hemoglobins; Immunity

2004
Plasmodium falciparum gametocyte carriage in asymptomatic children in western Kenya.
    Malaria journal, 2004, Jun-17, Volume: 3

    Topics: Adolescent; Age Factors; Animals; Antimalarials; Carrier State; Child; Child, Preschool; Cohort Stud

2004
Malaria: use of restriction endonuclease digestion and mutation-specific PCR for antifolate resistance isolate detection.
    Parassitologia, 2003, Volume: 45, Issue:1

    Topics: Amino Acid Substitution; Animals; Antimalarials; DNA Mutational Analysis; DNA, Protozoan; Drug Resis

2003
Monitoring susceptibility to sulfadoxine-pyrimethamine among cases of uncomplicated, Plasmodium falciparum malaria in Saharevo, Madagascar.
    Annals of tropical medicine and parasitology, 2004, Volume: 98, Issue:6

    Topics: Animals; Antimalarials; Child; Child, Preschool; Drug Combinations; Female; Humans; Madagascar; Mala

2004
Comparative effects of pyrimethamine-sulfadoxine, with and without probenecid, on Plasmodium falciparum gametocytes in children with acute, uncomplicated malaria.
    Annals of tropical medicine and parasitology, 2004, Volume: 98, Issue:8

    Topics: Acute Disease; Animals; Antimalarials; Child; Drug Combinations; Drug Therapy, Combination; Endemic

2004
Efficacy of amodiaquine in uncomplicated falciparum malaria in Nigeria in an area with high-level resistance to chloroquine and sulphadoxine/pyrimethamine.
    Parasitology research, 2005, Volume: 96, Issue:3

    Topics: Amodiaquine; Animals; Antimalarials; Child, Preschool; Chloroquine; Drug Combinations; Drug Resistan

2005
Plasmodium falciparum dhfr but not dhps mutations associated with sulphadoxine-pyrimethamine treatment failure and gametocyte carriage in northern Ghana.
    Tropical medicine & international health : TM & IH, 2005, Volume: 10, Issue:9

    Topics: Animals; Antimalarials; Child, Preschool; Dihydropteroate Synthase; Drug Combinations; Drug Resistan

2005
Efficacy of sulfadoxine-pyrimethamine in Tanzania after two years as first-line drug for uncomplicated malaria: assessment protocol and implication for treatment policy strategies.
    Malaria journal, 2005, Nov-18, Volume: 4

    Topics: Animals; Antigens, Protozoan; Antimalarials; Body Temperature; Child, Preschool; Drug Combinations;

2005
CD4 T cell activation as a predictor for treatment failure in Ugandans with Plasmodium falciparum malaria.
    The American journal of tropical medicine and hygiene, 2006, Volume: 74, Issue:1

    Topics: Adolescent; Adult; Age Factors; Animals; Antimalarials; Body Temperature; CD4-Positive T-Lymphocytes

2006
Improved transfection and new selectable markers for the rodent malaria parasite Plasmodium yoelii.
    Molecular and biochemical parasitology, 2006, Volume: 146, Issue:2

    Topics: Animals; Antimalarials; Disease Models, Animal; Drug Resistance; Electroporation; Female; Green Fluo

2006
Prevalence of malaria parasitemia among clients seeking treatment for fever or malaria at drug stores in rural Tanzania 2004.
    Tropical medicine & international health : TM & IH, 2006, Volume: 11, Issue:4

    Topics: Adult; Amodiaquine; Analgesics, Non-Narcotic; Anemia; Antimalarials; Child, Preschool; Drug Combinat

2006
Microscopy and outpatient malaria case management among older children and adults in Kenya.
    Tropical medicine & international health : TM & IH, 2006, Volume: 11, Issue:4

    Topics: Adolescent; Adult; Ambulatory Care; Amodiaquine; Antimalarials; Case Management; Child; Cross-Sectio

2006
The efficacy of sulfadoxine-pyrimethamine alone and in combination with chloroquine for malaria treatment in rural Eastern Sudan: the interrelation between resistance, age and gametocytogenesis.
    Tropical medicine & international health : TM & IH, 2006, Volume: 11, Issue:5

    Topics: Adolescent; Adult; Age Distribution; Antimalarials; Child; Chloroquine; Cohort Studies; Drug Combina

2006
Malaria prevention during pregnancy: assessing the disease burden one year after implementing a program of intermittent preventive treatment in Koupela District, Burkina Faso.
    The American journal of tropical medicine and hygiene, 2006, Volume: 75, Issue:2

    Topics: Adolescent; Adult; Antimalarials; Bedding and Linens; Burkina Faso; Drug Combinations; Female; Human

2006
Relationship between antipyretic effects and cytokine levels in uncomplicated falciparum malaria during different treatment regimes.
    Acta tropica, 2006, Volume: 99, Issue:1

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Antimalarials; Child, Preschool; Chloroquine; Cyto

2006
HIV immunosuppression and antimalarial efficacy: sulfadoxine-pyrimethamine for the treatment of uncomplicated malaria in HIV-infected adults in Siaya, Kenya.
    The Journal of infectious diseases, 2006, Dec-01, Volume: 194, Issue:11

    Topics: Adult; Anemia; Antimalarials; CD4 Lymphocyte Count; Drug Combinations; Female; Fever; HIV Infections

2006
In vitro and in vivo interaction of synthetic peroxide RBx11160 (OZ277) with piperaquine in Plasmodium models.
    Experimental parasitology, 2007, Volume: 115, Issue:3

    Topics: Animals; Antimalarials; Artemether; Artemisinins; Atovaquone; Disease Models, Animal; Drug Interacti

2007
Assessing malaria burden during pregnancy in Mali.
    Acta tropica, 2007, Volume: 102, Issue:2

    Topics: Adult; Animals; Antimalarials; Chloroquine; Cross-Sectional Studies; Drug Combinations; Female; Huma

2007
Malaria treatment efficacy among people living with HIV: the role of host and parasite factors.
    The American journal of tropical medicine and hygiene, 2007, Volume: 77, Issue:4

    Topics: Adolescent; Adult; Antimalarials; CD4 Lymphocyte Count; Child; Child, Preschool; Cohort Studies; Dru

2007
Increased gametocytemia after treatment: an early parasitological indicator of emerging sulfadoxine-pyrimethamine resistance in falciparum malaria.
    The Journal of infectious diseases, 2008, Jun-01, Volume: 197, Issue:11

    Topics: Adolescent; Adult; Animals; Antimalarials; Area Under Curve; Child; Dihydropteroate Synthase; Drug C

2008
Impact of transmission intensity and age on Plasmodium falciparum density and associated fever: implications for malaria vaccine trial design.
    The Journal of infectious diseases, 1995, Volume: 172, Issue:4

    Topics: Age Factors; Animals; Anopheles; Antimalarials; Child; Child, Preschool; Clinical Trials as Topic; C

1995
Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa.
    The American journal of tropical medicine and hygiene, 1995, Volume: 52, Issue:6

    Topics: Animals; Base Sequence; Child; DNA Primers; DNA, Protozoan; Drug Resistance; Folic Acid Antagonists;

1995
Sensitivity to antimalarial drugs by Plasmodium falciparum in Goundry, Oubritenga province, Burkina Faso.
    Parassitologia, 1994, Volume: 36, Issue:3

    Topics: Amodiaquine; Animals; Antimalarials; Burkina Faso; Child; Child, Preschool; Chloroquine; Drug Resist

1994
Studies on ammonia-metabolizing enzymes during Plasmodium yoelii infection and pyrimethamine treatment in mice.
    International journal for parasitology, 1996, Volume: 26, Issue:4

    Topics: Alanine Transaminase; Ammonia; Animals; Antimalarials; Aspartate Aminotransferases; Biomarkers; Brai

1996
Parasitemia and parasitic loads in acute infection and after anti-gamma-interferon treatment in a toxoplasmic mouse model.
    Parasitology research, 1997, Volume: 83, Issue:4

    Topics: Acute Disease; Animals; Anti-Infective Agents; Antibodies; Brain; Chronic Disease; Drug Therapy, Com

1997
Parasitological and haematological responses to treatment of Plasmodium falciparum malaria with sulphadoxine-pyrimethamine in southern Malawi.
    Annals of tropical medicine and parasitology, 1997, Volume: 91, Issue:2

    Topics: Anemia; Antimalarials; Child, Preschool; Drug Combinations; Female; Follow-Up Studies; Hemoglobins;

1997
Gene targeting in malaria parasites.
    Methods (San Diego, Calif.), 1997, Volume: 13, Issue:2

    Topics: Animals; Anopheles; Genes, Reporter; Genetic Vectors; Humans; Malaria; Parasitemia; Plasmids; Plasmo

1997
Enhanced gametocyte production in Fansidar-treated Plasmodium falciparum malaria patients: implications for malaria transmission control programmes.
    Tropical medicine & international health : TM & IH, 1997, Volume: 2, Issue:3

    Topics: Adolescent; Adult; Animals; Antimalarials; Child; Culicidae; Drug Combinations; Female; Humans; Inse

1997
An evaluation of the effects of intermittent sulfadoxine-pyrimethamine treatment in pregnancy on parasite clearance and risk of low birthweight in rural Malawi.
    Annals of tropical medicine and parasitology, 1998, Volume: 92, Issue:2

    Topics: Adolescent; Adult; Antimalarials; Birth Weight; Drug Therapy, Combination; Female; Humans; Infant, L

1998
Studies on infections with two strains of Plasmodium inui from Taiwan in rhesus monkeys and different anopheline mosquitoes.
    The Journal of parasitology, 1998, Volume: 84, Issue:3

    Topics: Animals; Anopheles; Antimalarials; Disease Models, Animal; Host-Parasite Interactions; Insect Vector

1998
A systematic approach to the development of a rational malaria treatment policy in Zambia.
    Tropical medicine & international health : TM & IH, 1998, Volume: 3, Issue:7

    Topics: Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combinations; Drug Evaluation; Drug Resist

1998
In vivo responses to antimalarials by Plasmodium falciparum and Plasmodium vivax from isolated Gag Island off northwest Irian Jaya, Indonesia.
    The American journal of tropical medicine and hygiene, 1999, Volume: 60, Issue:4

    Topics: Adolescent; Adult; Age Distribution; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; D

1999
Chemotherapy of malaria and resistance to antimalarial drugs in Guayana area, Venezuela.
    The American journal of tropical medicine and hygiene, 1999, Volume: 61, Issue:1

    Topics: Adolescent; Adult; Aged; Animals; Antimalarials; Chloroquine; Dose-Response Relationship, Drug; Drug

1999
Plasmodium cynomolgi: transfection of blood-stage parasites using heterologous DNA constructs.
    Experimental parasitology, 1999, Volume: 93, Issue:1

    Topics: Animals; Antimalarials; Disease Models, Animal; DNA Primers; DNA, Protozoan; Drug Resistance; Electr

1999
Pyrimethamine-sulfadoxine efficacy and selection for mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase in Mali.
    The American journal of tropical medicine and hygiene, 1999, Volume: 60, Issue:3

    Topics: Animals; Antimalarials; Blood; Child; Dihydropteroate Synthase; DNA Restriction Enzymes; DNA, Protoz

1999
Association of the ICAM-1Kilifi mutation with protection against severe malaria in Lambaréné, Gabon.
    The American journal of tropical medicine and hygiene, 1999, Volume: 61, Issue:5

    Topics: Animals; Anti-Bacterial Agents; Antimalarials; Case-Control Studies; Child; Clindamycin; Deoxyribonu

1999
Azithromycin: antimalarial profile against blood- and sporozoite-induced infections in mice and monkeys.
    Experimental parasitology, 2000, Volume: 94, Issue:1

    Topics: Animals; Anti-Bacterial Agents; Antimalarials; Azithromycin; Chloroquine; Doxycycline; Erythromycin;

2000
[Chloroquine sensitivity of Plasmodium falciparum at the Gamkalley Clinic and the Nigerian armed forces PMI (Niamey, Niger)].
    Bulletin de la Societe de pathologie exotique (1990), 1999, Volume: 92, Issue:5

    Topics: Adolescent; Adult; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Resistance; Hu

1999
Population dynamics of Plasmodium falciparum in an unstable malaria area of eastern Sudan.
    Parasitology, 2000, Volume: 120 ( Pt 2)

    Topics: Alleles; Animals; Antigens, Protozoan; Antimalarials; Chloroquine; Cohort Studies; DNA Primers; DNA,

2000
Gametocytemia and infectivity to mosquitoes of patients with uncomplicated Plasmodium falciparum malaria attacks treated with chloroquine or sulfadoxine plus pyrimethamine.
    The American journal of tropical medicine and hygiene, 2000, Volume: 62, Issue:2

    Topics: Acetaminophen; Adolescent; Adult; Analgesics, Non-Narcotic; Animals; Anopheles; Antimalarials; Child

2000
In vivo sensitivity of Plasmodium falciparum to chloroquine and sulfadoxine-pyrimethamine among schoolchildren in rural Uganda: a comparison between 1995 and 1998.
    Acta tropica, 2000, Oct-02, Volume: 76, Issue:3

    Topics: Animals; Antimalarials; Child; Chloroquine; Drug Combinations; Humans; Malaria, Falciparum; Parasite

2000
Comparative clinical characteristics and response to oral antimalarial therapy of children with and without Plasmodium falciparum hyperparasitaemia in an endemic area.
    Annals of tropical medicine and parasitology, 2000, Volume: 94, Issue:6

    Topics: Adolescent; Age Factors; Analysis of Variance; Antimalarials; Child; Child, Preschool; Chloroquine;

2000
Diagnostic value of polymerase chain reaction in blood and aqueous humor in immunocompetent patients with ocular toxoplasmosis.
    Retina (Philadelphia, Pa.), 2000, Volume: 20, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Animals; Antiprotozoal Agents; Aqueous Humor; Blotting, Southern; DN

2000
Parasitaemia and gametocytaemia after treatment with chloroquine, pyrimethamine/sulfadoxine, and pyrimethamine/sulfadoxine combined with artesunate in young Gambians with uncomplicated malaria.
    Tropical medicine & international health : TM & IH, 2001, Volume: 6, Issue:2

    Topics: Animals; Antimalarials; Artemisinins; Artesunate; Child; Chloroquine; Cost-Benefit Analysis; Disease

2001
[In vivo sensitivity of Plasmodium falciparum to amino-4-quinolines and sulfadoxine pyrimethamine in Agou (Ivory Coast)].
    Pathologie-biologie, 2002, Volume: 50, Issue:3

    Topics: Adolescent; Aminoquinolines; Amodiaquine; Animals; Antimalarials; Child; Child, Preschool; Cote d'Iv

2002